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Liver surgery, be it for resection or transplantation, causes injury to the organ.
Pretreatment of the liver to protect it from injury would be of clinical interest as poor
liver function following surgery can be life threatening. Such "preconditioning"
treatments could be applied to both elective liver surgery and liver transplantation.
The aim of this project was to establish the ability of certain pharmacological agents
to induce the stress response in human hepatocytes, and to protect them from the type
of injury seen in surgical practice. Curcumin, an extract of the spice turmeric, was
found to induce the enzyme heme oxygenase-1. It preconditioned hepatocytes to
survive in models mimicking both ischaemia-reperfusion injury and the cold
preservation injury which occurs during transplantation. Cyclosporin A was also
studied as a putative preconditioning agent. However, although it did have some
effect on the stress response, it did not precondition human hepatocytes. As an
extension of the work on heme oxygenase 1, the effect of a promoter polymorphism
in the human HO-1 gene was studied. This work has demonstrated that curcumin
does pharmacologically precondition human hepatocytes in vitro. It has also
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Liver transplantation is dependent on successful function of the implanted allograft.
The process of organ harvesting, cold storage and reperfusion is damaging, and
causes significant injury which can result in primary non-function or prejudice long-
term graft survival. Primary non-function and initial poor function affects a large
number of liver transplants (6% and 15% respectively), causing significant morbidity
and mortality (Strasberg 1994). Pretreatment of the liver prior to its harvest to protect
it from injury would be of great clinical importance. It may be life-saving, and could
improve long-term graft survival. Similar damage occurs during elective liver
surgery, resulting in perioperative hepatic impairment, a major contributor to
morbidity and mortality following liver resection (Parks 2001). Pretreatment of the
liver prior to surgery could reduce postoperative hepatic impairment and may
improve clinical outcomes. Hence "preconditioning" treatments have a significant
clinical potential in the area of liver surgery and transplantation (Selzner 2003).
1.2 Ischaemia Reperfusion Injury
Injury to the liver during elective surgery and transplantation is due predominantly to
the attendant ischaemia-reperfusion injury which occurs as a result of the surgical
process. Ischaemia reperfusion injury is, as its name suggests, a two stage
phenomenon which comprises: damage sustained during an ischaemic, hypoxic
period where blood inflow to the tissue is halted; and the subsequent damaging
effects associated with restoration of blood flow. This is a significant problem in
2
clinical practice, accounting for up to 10% of early graft failures following liver
transplantation, and it predisposes to acute and chronic rejection (Howard 1990,
Fellstrom 1998).
During liver resection, it may be necessary to restrict hepatic inflow for a period of
time to minimise blood loss, and for technical reasons. The liver remains in situ and
therefore suffers "warm ischaemia", when the cellular metabolism attempts to
continue within the limits of the hypoxic environment. After the resection has been
performed, the hepatic vessels are undamped and blood flow recommences,
reperfusing the liver (figure 1.1). During harvesting of the liver for transplantation,
the liver is perfused with cold preservative solution, and then removed from the body
and stored on ice prior to its transplantation. This subjects the organ to "cold
ischaemia". After the ischaemic period, there is a short period of time when the liver
has been replaced in the abdominal cavity whilst vessel continuity is being restored,
where it undergoes warm ischaemia. After the hepatic inflow is undamped the organ
is implanted and the liver is reperfused (figure 1.1).
In the above situations, the ischaemia reperfusion injury is a planned surgical insult
to the liver and as such, treatments may be developed to help minimise any damage.
The development of such therapies requires an understanding of the complex series
of cellular events that occur during ischaemia and reperfusion.
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Cold ischaemia Warm Ischaemia Reperfusion
Time
Figure 1.1. Schematic representation of the different insults that occur during
liver resectional surgery and liver transplantation.
In elective liver surgery warm ischaemia occurs when the hepatic inflow is clamped.
Reperfusion occurs once the surgery has been performed and the clamp is removed. The
same process occurs during liver transplantation. However, the organ is cooled at the
time of harvest, resulting in a period of cold ischaemia. Once the organ is ready for re¬
implantation, it is placed within the abdomen whilst the blood vessels are being
anastamosed. This leads to a short period ofwarm ischaemia. Reperfusion occurs once




The various cell types of the liver are differentially affected by ischaemia and
reperfusion. Structural changes include cellular swelling, endothelial cell shrinkage,
neutrophil infiltration and cell loss. These changes are the result of intracellular
events (figure 1.2).
Hypoxia leads to depletion of cellular energy stores (namely ATP), inhibiting
homeostatic pump function and resulting in cellular sodium accumulation and
swelling (Lemasters 1997). Depending on the duration of ischaemia and degree of
ATP depletion, the mitochondrial membrane potential may be lost, which can lead to
cell death either by apoptosis or necrosis (Kim 2003). Formation of the
mitochondrial permeability transition pore (MPTP) is a critical component of this
process in ischaemia-reperfusion injury (Green 2004). Formation of this pore occurs
in response to hypoxia and oxidative stress, both ofwhich occur in ischaemia-
reperfusion injury (IRI). It requires the assembly ofmultiple proteins, including
cyclophilin D, Bclxi and adenine nucleotide translocases. The pore forms a junction
between the inner and outer membranes of the mitochondria, causing short circuiting
of the electron transport chain and cytochrome c release. Apoptosis is triggered by
cytochrome c release from the disrupted mitochondria, resulting in caspase activation
(Jaeschke 2003a). In hepatic IRI, both apoptosis and cell necrosis occur, dependent
on the degree of damage and cellular ATP levels, a process termed necrapoptosis
(Jaeschke 2003b).
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On reperfusion, endothelial cell injury results in activation of the endothelium,
upregulation of adhesion molecules and neutrophil recruitment. This is exacerbated
by areas of endothelial cell loss due to apoptosis (Kupiec-Weglinski 2005). These
recruited, activated neutrophils generate elastase, matrix metalloproteinases and
reactive oxygen species (ROS), resulting in localised tissue damage (Okajima 2004,
Sievert 2003). Kupffer cells are activated by ischaemia-reperfusion injury (IRI),
triggering production ofROS and proinflammatory cytokines such as TNFa, IL-1
and IFN-y (Menger 1999). These are damaging to surrounding cells, may trigger
apoptosis, and contribute to the activation of neutrophils and the endothelium,
aggravating tissue damage. Necrotic debris from dead cells also increases the
inflammatory state (Jaeschke 2003).
As a result of proteinase activity during ischaemia, xanthine oxidase is formed from
xanthine dehydrogenase. It uses hypoxanthine as a substrate to generate O2 and
H2O2. Hypoxanthine accumulates during ischaemia as a result ofATP catalysis. This
allows rapid generation of significant levels of ROS on reperfusion (Van Bilsen
1989). Endothelial cells and hepatocytes also contain an NADPH oxidase which
generates further ROS (Ray 2005). In addition, disruption of the sinusoidal epithelial
barrier and changes in the red blood cells results in extravasation of red blood cells
and the liberated free heme acts as a further source ofROS, exacerbating the extent
of the insult (Teoh 2003).
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Figure 1.2. Diagrammatic representation of some of the cellular events which
occur in the liver during reperfusion after an ischaemic period.
Endothelial cells are activated by the process of reperfusion, leading to expression of
cell surface adhesion molecules such as ICAMs. In conjunction with reduced nitric
oxide production causing vasospasm, and loss of endothelial continuity, this results
in neutrophil recruitment and activation, which then infiltrate the tissue. Some
hepatocytes undergo necrosis or apoptosis as an immediate result of the cell damage.
During ischaemia, there is formation of xanthine oxidase (see text), and an
accumulation of xanthine from ATP catalysis. On reperfusion, XO-mediated
degradation of xanthine generates superoxide radicals (02-~)- Activated Kupffer cells
also release ROS and inflammatory mediators. EC endothelial cell; HC hepatocyte;
KC Kupffer cell; XO xanthine oxidase; XDH xanthine dehydrogenase; MPTP
mitochondrial permeability transition pore opening; ROS reactive oxygen species.
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Nitric oxide (NO) is an important factor in maintaining the microcirculation of the
liver. It exerts its effect through activation of soluble guanylyl cyclase, increasing
production of cGMP. This intracellular second messenger system acts through cGMP
dependent kinases to cause protein phosphorylation, the effects ofwhich include
smooth muscle relaxation (Murad 2006). During normal physiological conditions,
the vasodilatory effects ofNO and the vasoconstrictor endothelin-1 achieve a
physiological balance, through which precise control of the hepatic microcirculation
is achieved (Paxian 2004). IRI increases the level of endothelin-1 in the circulation
and the liver, whilst NO levels are initially low during reperfusion (Kim 2004). This
imbalance results in sinusoidal constriction and reduced perfusion of the organ
during reperfusion, and the slow flow aids neutrophil recruitment into the damaged
organ (Uhlmann 2004).
Potentially, NO can react with ROS, resulting in the formation of nitrogen radicals
such as peroxynitrite, which could contribute to cellular damage in hepatic
ischaemia-reperfusion injury (IRI). Supporting this, inducible nitric oxide synthase
(iNOS) is increased following hepatic IRI, nitrotyrosine is detected in those areas of
the liver with histological damage and inhibition of iNOS attenuates hepatic damage
after experimental IRI in a rat model (Serracino-Inglott 2003, Takamatsu 2006).
However, a different group has demonstrated that exogenous administration of
peroxynitrite reduces leukocyte recruitment into the liver following IRI, and
inhibition ofNOS, whilst reducing peroxynitrite formation, leads to increased
neutrophil accumulation and an exacerbation of hepatic injury (Liu 1998, Liu 2000).
This apparent contradiction could be the result of the specificity of different NOS
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inhibitors used in the two studies as L-NAME (used by Liu) inhibits both endothelial
NOS (eNOS) and iNOS, whilst ONO-1714 is believed to be iNOS specific
(Takamatsu 2006). Hence it would appear that the production ofperoxynitrite from
endothelial cells limits neutrophil recruitment and acts to reduce hepatic injury,
whilst iNOS-derived peroxynitrite from either resident liver cells or recruited
leukocytes causes hepatic damage.
Other cells can contribute to the degree of injury seen in hepatic IRI. There is
evidence that the immune response is activated following IRI. This occurs through
multiple mechanisms, and involves activation of both the innate and adaptive
immune system. The innate immune system appears to be activated through Toll-
Like Receptors (TLRs) (Wu 2004). These receptors are involved in the recognition
and presentation ofmicrobial antigens, and are present on Kupffer cells, B cells and
dendritic cells. TLR activation leads to MAPK and NFkB activation, which results in
antigen specific production of cytokines and chemokines, complement activation and
neutrophil recruitment. There is increasing evidence that TLRs are activated
following IRI. TLRs are not only activated in response to bacterial components, and
endogenous ligands can also trigger activation. In particular, heat shock proteins
released from necrotic cells have been implicated in TLR activation (Vabulas 2002).
There is increased TLR4 present in Kupffer cells in rat liver transplantation, and
TLR4 deficiency reduces the severity of hepatic IRI in mice (Peng 2004, Wu 2004).
T cell activation can also contribute to ischaemia reperfusion injury. It was noted
many years ago that systemic immunosuppression with calcineurin inhibitors can
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reduce the severity of hepatic ischaemia reperfusion injury, implicating T cell
involvement (Suzuki 1993). This has been confirmed in a T cell knockout model of
renal IRI, where the severity of injury was reduced in the absence of T cells, and
adoptive transfer of T cells restored the severity to that seen in wild-type animals
(Ysebaert 2004). The role of the T cell is not entirely clear, but it appears to increase
neutrophil recruitment (Zwacka 1997). Furthermore, sinusoidal endothelial cells can
present antigens to T cells (Lohse 1996), and T cells are seen to adhere to sinusoidal
endothelial cells following cold ischaemia (Clavien 1993).
Ischaemia-reperfusion in the liver is different to that in other organs due to the
hepatic anatomy. The liver receives a proportion of its blood supply from the arterial
circulation, but in addition also receives de-oxygenated blood from the portal
circulation. During hepatic inflow clamping, the portal tract becomes congested,
resulting in increased ROS production and translocation of bacteria from the
intestine, leading to increased levels of endotoxin. This endotoxic load augments the
IRI in the liver and will contribute to TLR activation (Dai 1998).
Circulating factors also play a role in the pathophysiology of hepatic IRI. The
complement cascade is activated by the release of cellular debris. C5a increases
neutrophil recruitment and aids in activation ofKupffer and endothelial cells, and the
membrane attack complex causes direct cell injury (Arumugam 2004). Also,
reperfusion of the liver does not occur in isolation. Cytokines and vasoactive
mediators released during hepatic reperfusion can cause haemodynamic impairment
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and secondary insults to the organ due to underperfusion. This further exacerbates
the regional perfusion abnormalities within the liver (Chouker 2004).
1.2.2 Cellular Signalling Mechanisms
Ischaemia-reperfusion activates multiple intracellular signalling pathways, through
which some of the above changes are mediated, for example increased expression of
pro-inflammatory cytokines such as TNFa and IL-1. These pathways are complex
and cannot be seen in isolation, as there is cross-talk between them which helps to
integrate their signals. Most of these signals result in the activation or inhibition of
transcription factors, and hence alter gene expression. However, some kinases have
direct effects on existing aspects of the cell machinery.
Mitogen activated protein kinases (MAP Kinases, MAPKs) are a super-family of
serine/threonine kinases which form important signalling pathways transmitting
signals from the cell surface to the nucleus (Fang 2005). There are three main
families ofMAPK: c-Jun N-terminal kinases (JNK), extracellular-signal-regulated
kinases (ERK) and p38-MAPK. Each family is organised in functional modules,
which are composed of a series of upstream kinases which mediate signal
transduction. All three pathways are activated following hepatic ischaemia and
reperfusion (Bendinelli 1996, Zwacka 1998, Kobayashi 2002).
JNK activation is a key orchestrator of hepatocyte death from a wide variety of
stimuli (Czaja 2003). It contributes to cell death following liver ischaemia-
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reperfusion injury (Uehara 2005). The mechanism is not clear, but may result from
increased production of TNFa through activation of the transcription factor AP-1
(Becker 1999), or through phosphorylation and activation of the proapoptotic protein
Bad (Donovan 2002).
The NFkB (Nuclear Factor kB) transcription factor is also activated by hepatic
ischaemia-reperfusion (Zwacka 1998). The mammalian NFkB family contains five
subunits (p50,p52, p65, RelA and RelB), and requires a homodimer or heterodimer
of two subunits to form a transcriptionally active complex (Ghosh 1998). Their
transcriptional effect varies between the different types of dimer (Gerondakis 1999).
The prototypical NFkB dimer (p50/p65) exists as an inactive form in the cytoplasm,
complexed with an inhibitor protein called Inhibitor ofNFkB (IkB), ofwhich there
are also several different forms (for example IicBa and IkBP) (Luedde 2006). IkB
masks the nuclear localisation sequence and DNA binding sequence ofNFkB,
maintaining it in the inactive form. For NFkB to become activated, IkB must be
serine phosphorylated by IkB Kinase (IKK) (Karin 1999). Once phosphorylated, IkB
dissociates, is polyubiquitinylated and degraded. NFkB then migrates to the nucleus
and binds to the promoter of the target gene.
TNFa release from activated Kupffer cells activates NFkB through binding to the
TNF receptor (TNF-R1) and subsequent activation of IKK (Nakamitsu 2001, Luedde
2006). TNFa has been found to be a critical mediator of apoptosis in hepatic
ischaemia-reperfusion (Rudiger 2002). However, following ischaemia-reperfusion
injury, NFkB activation can also occur through tyrosine phosphorylation of IkB by
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the kinase c-Src (Fan 2004). Irrespective of the pathway through which it occurs,
NFkB activation contributes to the liver injury following ischaemia-reperfusion (Fan
2004, Luedde 2005).
1.3 Preconditioning in the Liver
Preconditioning has significant potential for clinical applications in the liver.
Surgical manipulation of the liver, either during resectional surgery or
transplantation, result in damage to the organ, which can lead to post operative
impairment or failure of the organ, and even death. Any treatment which improves
the tolerance of the liver to such insults would have clinical potential. It is for this
reason that there is interest in the development of preconditioning strategies for the
liver (Selzner 2003).
Broadly speaking, there are two types of preconditioning which have been attempted
- physical and pharmacological. Physical techniques include ischaemic pre¬
conditioning (Clavien 2003) and heat treatment (Redaelli 2001, Terajima 2000).
Pharmacological techniques include the administration of drugs, cytokines and gene
transfer techniques (Camargo 1997, He 2006).
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1.3.1 Ischaemic Preconditioning
The phenomenon of preconditioning was first identified in the setting of cardiac
ischaemia (Murray 1986). Ischaemic preconditioning has since been tried and found
to be protective in a wide variety ofmodels, including liver injury (Pang 1995,
Heurteaux 1995, Compagnon 2005). During ischaemic preconditioning, the liver is
deprived of oxygenated blood for a short period of time, typically 5 to 10 minutes,
blood flow is restored for a further period of time, again typically 5 to 10 minutes,
and then the surgical procedure or injurious process is commenced. Koti recently
reviewed the literature on ischaemic preconditioning in the liver, and the technique
has been found to be beneficial in models of total or partial hepatic ischaemia, and to
be effective in mice, rats and pigs. It can also protect the liver from both warm and
cold ischaemic injury. Ischaemic preconditioning results in reduced liver cell
damage, improved ATP levels, lower cytokine expression and reduced neutrophil
recruitment following ischaemia reperfusion injury (Koti 2003).
Ischaemic preconditioning (IP) studies have been performed in humans, both in
patients undergoing liver resection, and in patients having liver transplantation
(Clavien 2003, Azoulay 2005). Clavien's randomised controlled trial in 100 patients
undergoing hepatic resection found that IP was of greatest benefit in younger
patients, and in those with fatty infiltration of the liver (Clavien 2003). This study
demonstrated the proof of principle in humans. However, a trial in human hepatic
transplantation demonstrated that although ischaemic preconditioning improved the
tolerance of the graft to preservation and reperfusion, it resulted in impaired early
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function (Azoulay 2005). Thus, further study with larger numbers is required to
understand more fully how to select patients for this intervention, and who is likely
to benefit the most.
Ischaemic preconditioning provides two "windows" of protection: the first window is
effective immediately and lasts for several hours; the second window is only
effective after at least 12 hours and lasts for up to 72 hours (Pagliaro 2001). The
different timing of these two windows reflects the different mechanisms through
which they work. The first window is thought to be due to rapid changes in the
tissues such as: activation of kinase signalling pathways including MAP kinases;
generation of adenosine and nitric oxide; and mitochondrial changes. In contrast the
second window appears with the production of protective proteins which require time
to be synthesised by the cells. These proteins include heat shock proteins and heme
oxygenase 1.
1.3.1.1 First window of protection
Mitogen activated protein kinases are activated following hepatic ischaemia and
reperfusion (see section 1.2.2). However, ischaemic preconditioning does alter the
responsiveness of these pathways to IRI such as inhibiting JNK activation (Izuishi
2006). This change renders hepatocytes resistant to apoptosis (Marderstein 2003) and
may contribute to the first window of protection.
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NO also plays a role in hepatic preconditioning which appears to be mediated
through stimulation of p38 MAPK via cGMP dependent pathways, rather than
through modulation ofPKC (Carini 2003). This may be an effect of adenosine
release, which could stimulate nitric oxide synthase in endothelial cells (Serracino-
Inglott 2002).
Adenosine generated from ADP breakdown interacts with cell surface receptors, and
appears to be central to ischaemic preconditioning (IP), with exogenous delivery of
adenosine being able to mimic IP (Peralta 1997). Activation of the A\ or A3 receptor
is important in myocardial preconditioning (De Jonge 2002). However, in the liver,
preconditioning appears to be mediated through A2 receptors, as shown by inhibitor
studies (Peralta 1999, Nakayama 1999). Delineation of this pathway has shown that
adenosine receptors signal through PI3K or phospholipase C, activating PKC 5 and s,
the target ofwhich is stimulation of p38 MAPK (Carini 2004). PKC activity has been
shown to be essential for hepatic IP in a porcine cold ischaemia model (Ricciardi
2001).
Thus it appears that the first window of ischaemic preconditioning is effected
through, activation of p38 MAPK, which results in increased tolerance of the cells to
injury, and initiates cellular proliferation which is required as regenerative response.
The mechanism through which p38 works is unclear at present, although downstream
factors which may be involved include MAPKAPK2, and the transcription factors
ATF-2 and MEF2C (Nakano 2000).
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Improved preservation of cellular homeostasis also contributes, and IP improves the
maintenance of intracellular pH which may prevent ATP depletion (Carini 2000,
Peralta 2000). IP also reduces production of xanthine and xanthine oxidase, thus
reducing oxidative stress on reperfusion (Fernandez 2002).
1.3.1.2 Second window of protection
The second window of preconditioning is characterised by adaptations in the liver
which generally require the synthesis of new proteins, and it lasts longer than the first
window, being effective from approximately 12 hours up to 72 hours depending on
the model used. Many of the newly synthesised proteins are heat shock proteins,
including Hsp70 and heme oxygenase 1. Some researchers believe that these are only
markers of the second window, and that they do not provide the protective effect
seen (Pagliaro 2001), although this is debated. Hsps are numerous in class and
function, but generally help to maintain cellular homeostasis. Other synthesised
proteins include cyclin D, iNOS and MnSOD, which stimulate cell proliferation and
increase the defence against antioxidants (Eisen 2004).
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1.3.2 Other Physical Preconditioning Methods
Remote preconditioning is essentially a modification of ischaemic preconditioning,
whereby a site distant from that undergoing the injury, such as a limb, is subjected to
the preconditioning stimulus. This appears to have similar efficacy to that of
ischaemic preconditioning within the target organ itself (Kharbanda 2002). It may
rely on similar mechanisms to "normal" ischaemic preconditioning, and the release
of humoral factors is thought to play a significant role, although this has not yet been
fully elucidated (Dickson 1999).
Heat preconditioning involves subjecting the target organ to a period of elevated
temperature ("heat shock"), leading to the synthesis of proteins which protect the
tissue against further injury, and this has been shown to be protective in the liver in
both ischaemia-reperfusion injury and transplant-associated injury (Terajima 2000,
Mokuno 2004). These newly synthesised proteins are called heat shock proteins and
have several specialised functions. Many have chaperone properties and help to
maintain the functional integrity of cellular machinery. Of note, heat shock can also
inhibit NFkB, and this may account for some of its effects, in addition to the effect of
the heat shock protein production (DeMeester 2001, Chen 2005).
Whilst heat preconditioning has been used in animal and cell models, there are
practical difficulties in subjecting a human subject to whole body hyperthermia.
Induction of heat shock proteins can be achieved by individuals spending time in a
sauna or through incremental exercise (Currie 2004). However, it is likely to be
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unfeasible in routine clinical practice. Nonetheless a biological understanding of how
these proteins are induced and how they exert their cellular effects is of interest and
may aid the development of specific pharmacological agents which can induce these
proteins or target their processes.
1.3.3 Pharmacological Preconditioning
Pharmacological preconditioning encompasses a variety of techniques. This ranges
from commercially available drugs previously used in different fields, to genetic
techniques such as gene transfer. The agents used vary in their specificity and in their
functional target (Selzner 2003). As described in section 1.2, the pathophysiology of
ischaemia reperfusion injury is complex and multifactorial, thus providing numerous
possible avenues to explore for the development of therapeutic targets. Many of the
approaches attempted for pharmacological preconditioning have been addressed at
specific events that occur during hepatic IRI, whilst others have been identified from
studies on ischaemic preconditioning. All methods involve either inhibiting a
deleterious cellular process or upregulating a beneficial cell survival factor or
pathway. This is often achieved through induction of a degree of cellular stress,
which results in activation of the stress response (see section 1.4).
Ischaemia reperfusion injury is characterised by production of reactive oxygen
species from multiple cell types (see section 1.2.1), and several groups have used
anti-oxidant approaches to achieve preconditioning. Overexpression of superoxide
dismutase (which degrades superoxide radicals) reduces the severity of hepatic IRI
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(Zwacka 1998, Yabe 2001, Wheeler 2001). Reduction of hepatic IRI has also been
found with allopurinol, which inhibits xanthine oxidase (Karwinski 1997), and
catalase which degrades hydrogen peroxide (Tanaka 1990).
Mitochondrial dysfunction and disruption releases cytochrome C and leads to
caspase activation and apoptosis following hepatic IRI (Lemasters 1998, Cohen
1997). Caspase inhibitors reduce the severity of hepatic IRI however they do not
completely prevent it, suggesting that while they inhibit apoptosis, they have no
effect on necrosis (Cursio 1999 & 2000). Cyclosporin prevents the mitochondrial
permeability transition (Pastorino 1993) and also reduces liver IRI (Kurokawa 1992).
In addition to caspases, other degradative enzymes are activated by hepatic IRI,
including calpains and matrix metalloproteinases. Calpains are calcium dependent
cysteine proteases which degrade membrane proteins, and contribute to apoptosis
and necrosis and hepatic IRI (Squier 1994, Arora 1996, Kohli 1997), and their
inhibition reduces the degree of hepatocyte and endothelial cell death (Kohli 1997,
Sindram 1999). Methylprednisolone has been known for many years to protect the
liver from IRI (Fornander 1984), and it can be as effective as IP (Glanemann 2004).
Prednisolone reduces calpain activation, and this may contribute to its effects (Wang
2001).
Matrix metalloproteinases (MMPs) are important in the degradation and turnover of
extracellular matrix. They are induced following ischaemia reperfusion in the liver,
and the inhibitor RXP03 reduces hepatic damage following IRI (Cursio 2002). The
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inhibition ofMMPs may contribute to the preservative effects of University of
Wisconsin solution, which is currently the standard preservative for cold preservation
of human liver transplants (Upadhya 2000).
Hepatic nitric oxide levels are low following reperfusion (Kim 2004), and this may
contribute to regional perfusion abnormalities. Adenosine has preconditioning
properties, and may work through increasing nitric oxide production. It increases
nitric oxide production in the ischaemic liver (Peralta 1999), which prevents damage
to hepatocytes and endothelial cells (Cottart 1999). Adenosine was initially identified
as an important mediator of ischaemic preconditioning in the heart (Heidland 2000).
Whilst the A1 receptor is important in cardiac preconditioning, the A2A receptor
appears to be central to hepatic preconditioning. A selective agonist of the A2A
receptor exists - ATL146e. In a mouse model of hepatic ischaemia, it reduces
hepatocyte necrosis and leucocyte infiltration (Day 2004). Importantly, treatment
with ATL146e is still effective when administered at the time of reperfusion, of even
up to 1 hour after, presenting an attractive profile for the drug in clinical use. In the
above study, ATL146e reduced the level of pro-inflammatory cytokines produced
following IRI, including IL-la, IL-6, RANTES and IFN-y (Day 2004), which may
also contribute to its effects.
Nitric oxide itself exerts many of its effects through activation of soluble guanylyl
cyclase and increased production of cGMP. Through its effect on smooth muscle
relaxation and inhibition of platelets (Murad 2006), increasing cGMP may ameliorate
regional perfusion abnormalities in hepatic IRI, and nitric oxide donors induce
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protection against hepatic IRI (Dhar 1998, Cottart 1999). Infusion of atrial natriuretic
peptide (ANP) reproduces the effects of IP, reducing hepatic IRI and improving graft
survival after liver transplantation in a cyclic GMP (cGMP) dependent process
(Bilzer 1994 and 1999).
As described above, there are innumerable strategies through which to attempt
pharmacological preconditioning. Many of the pharmacological agents described
above have no established safety profile in humans, and have limited applicability to
clinical practice. They may also have unforeseen adverse effects, either through non¬
specific inhibition of a vital system, or through specific inhibition of the targeted
process which impairs the function of other organs. This is the main reason that few
of these pharmacological strategies have yet made the transition to clinical trials.
Matrix metalloproteinase inhibitors have been trialled in chronic diseases, but have
had significant side effects (Brown 2000).
This thesis examines the potential of two agents, which are suitable for
administration to patients, to induce a preconditioned phenotype in human
hepatocytes, through harnessing of the innate stress response, which will be
described in the following sections.
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1.4 The Stress Response
The stress response is a broad term which encompasses all of the ways in which a
cell or target organ responds to stress of any nature (Welch 1993). It incorporates the
upregulation of genes and alteration of cellular mechanisms in response to an
injurious stimulus and is exemplified by the induction of particular protective
proteins which prevent or lessen the severity of damage sustained. It was first
described in response to elevated temperature (Ritossa 1962), and hence has
subsequently been known as the heat shock response. A large number of stress-
inducible proteins have been identified, and many have been termed heat shock
proteins due to the stimulus with which they were first studied.
1.4.1 The Heat Shock Response
The heat shock response can be stimulated by a brief elevation of temperature to
approximately 5°C above normal. The significance of this response is that the tissue
is then rendered tolerant to subsequent heat injury. Detailed research has shown that
this response also occurs following many diverse stimuli including mechanical stress,
oxidants, cytokines and infection (Benjamin 1998). The protection afforded by this
response extends to other noxious stimuli, including hypoxia and oxidative stress.
For this reason the stress response is the term currently favoured.
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1.4.2 Classification of heat shock proteins
Many of the proteins involved in the stress response have been called heat shock
proteins (Hsps) as a virtue of the context in which they were first studied. Others are
termed glucose regulated proteins (Grps) as they were first identified in response to
periods of glucose deprivation. These proteins are grouped into families on the basis
of their molecular weight. Certain heat shock proteins are constitutively expressed,
whilst others are only inducible in response to a stimulus. Thus, in addition to being
described according to their molecular weight and method of induction (e.g. Hsp70),
there are inducible and constitutive forms i.e. Hsp70i and Hsp70c.
1.4.3 Functions of Heat Shock Proteins
There is great diversity of heat shock proteins which have specialised roles. Some are
limited to specific intracellular compartments and have highly specialised functions,
whilst others are more ubiquitous. Most heat shock proteins function as molecular
chaperones. Molecular chaperones mediate the correct folding of other proteins, but
do not take part in their final assembly (Fink 1999). Protein mis-folding is a common
result of cellular injury. It results in exposure of hydrophobic parts of proteins which
would have been hidden when the protein was in its native state. These hydrophobic
regions stick to other proteins, causing aggregations of proteins to form, which can
interfere with normal cellular machinery. Chaperones work by associating with these
damaged proteins, shielding them from the rest of the cellular environment. The
chaperone functions are highly specialised, and specific chaperones function to
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safely transport the damaged protein around the cell (e.g. Hsp70), whilst others work
to allow refolding of the protein to occur (e.g. Hsp60) (Fink 1999).
Many heat shock proteins have functions other than simple chaperones. Hsps can
display cytokine-like activity. Soluble Hsps released from cells can bind to the cell
surface Toll-like receptor TLR4/CD14 or CD91 (Kol 2000, Tobian 2004), and
trigger intracellular signalling through MAP kinase pathways (Kol 2000, Sasu 2001).
Hsps can also play a role in antigen presentation. They are known to associate with
cellular peptides, including antigenic peptides. Lysates from tumour cells are rich in
hsps, which may be associated with tumour antigens, and vaccination with the hsp
fraction from tumours has had very promising results in improving the survival after
many cancers, including colon cancer (Mazzaferro 2003). This may be a result of
their ability to induce maturation of dendritic cells (Somersan 2001)
1.4.4 Heat Shock Protein 70
Hsp70 is a ubiquitous Hsp, which exists in a constitutive form (Hsp70c, also termed
Hsc70) and an inducible form (Hsp70i). Hsp70c is expressed in all tissues, with very
low or non-existent basal levels ofHsp70i in non-stressed cells. Following stress,
Hsp70i is rapidly upregulated. Hsp70 can bind to unfolded or nascent proteins, and
then either refold the protein itself, transport it safely around the cell and deliver it to
other machinery that can refold the protein, or target it for destruction by delivering it
to the proteosome.
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In resting cells, Hsp70 stabilises unfolded nascent peptides and delivers them to their
destined intracellular compartment (Beckmann 1990, Artigues 1998). It also targets
misfolded proteins to lysosomes (Agarraberes 1997). Hsp70 may also have a role in
the maintenance of cellular structure, as it binds to actin and tubulin (Liang 1997).
Hsp70 has two important functional domains - a protein binding domain and an
ATPase domain. The conversion ofATP to ADP allows the release of the newly
folded protein. Thus binding is more stable in periods of low ATP levels, such as
occurs during stress (Mayer 2005).
Overexpression ofHsp70 can reduce lipid peroxidation by hydrogen peroxide (Su
1999), and it can protect against TNFa associated lethality (Van Molle 2002). In
vitro it protects human hepatocytes from oxidative stress (Hosoi 2002). In vivo, it
protects the liver from both chemical and ischaemia-reperfusion injury (Lee 2004,
Boeri 2003).
1.4.5 Other Heat Shock Proteins
Hsp90 forms an essential part of the steroid receptor. It can also bind to kinases,
microtubules and intermediate filaments. Hsp90 has been found to be associated with
inactive HSF-1 and it may contribute to the regulation ofHSF-1 activation (Duina
1998).
26
Hsp60 (also known as chaperonin) forms a large hetero-oligomeric complex, in
association with HsplO, which functions to refold misfolded protein. Stacks of
Hsp60 units form an enclosed space to which mis-folded protein is delivered. HsplO
functions as a lid on the barrel. Within this space, the dynamics favour refolding of
the protein. HsplO then dissociates and the refolded protein is released (Fink 1999).
The "small Hsp" group includes Hsp27 (Hsp27 in humans, equivalent of Hsp25 in
rodents) and aP crystallin. These form large oligomeric complexes and can bind a
wide variety of substrates (Stromer 2003). In contrast to Hsp60, unfolded proteins
bind to the surface of the oligomeric sHsp complex, and remain accessible to other
members of the Hsp family. It has been suggested that these complexes act as a sump
for unfolded proteins during times of cellular stress. After removal of the stress, the
unfolded proteins are available for binding to Hsp70, which can then perform its
function to refold the proteins, or to transport them to other areas of the cell
(Dillmann 1999).
1.4.6 Heat Shock Factor 1
Heat shock factor 1 (HSF-1) is the predominant transcription factor responsible for
the induction ofHsps in response to heat. Other HSFs exist (HSF 1-4 respectively).
HSF 2 appears to be important in development and differentiation. Although it is not
responsive to stress, it may potentiate HSF-1 activity in response to heat shock (He
2003). HSF-3 has only been identified in avian cells, and HSF-4 has not yet been
fully characterised (Pirkkala 2001). HSF-1 can be activated by mechanisms other
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than heat. These include, oxidising agents and heavy metals (Zou 1998), osmotic
stress (Caruccio 1997), and compounds such as salicylate and indomethacin (Cotto
1996).
The structure ofHSF-1 is complex, comprising of a trimerisation domain, a
regulatory domain and an activation domain. Each of these domains function as their
name suggests, and it is the regulatory domain that is responsible for the heat sensing
ability ofHSF-1 (Newton 1996).
HSF-1 exists as an inactive monomer in the cytoplasm of resting cells, and on
exposure to heat, multiple events occur to activate it. It becomes
hyperphosphorylated, undergoes trimerisation and migrates to the nucleus. Once
there it binds to DNA and upregulates target genes by binding to heat shock elements
(HSEs) in their promoter. This contains the motif 5'-nGAAn-3' (Sarge 1993, Zuo
1995). Following activation, HSF-1 remains in the nucleus in "stress granules"
bound to heterochromatin. These gradually disappear during the recovery phase
(Cotto 1997).
The process ofHSF-1 activation is not fully understood. It is subject to many
activating and repressing factors (figure 1.3). Phosphorylation appears to play a key


























Figure 1.3. Diagrammatic representation of HSF-1 activation and the multiple
inhibitory pathways which repress HSF-1 activity.
HSF-1 is usually present in an inactive state in the cytoplasm of resting cells, in
association with either Hsp70 or Hsp90 which inhibits HSF-1 activation. Further
inhibitory pressures are exerted by the activity of several kinases that phosphorylate
inhibitory residues ofHSF-1. The presence of a stress such as heat shock leads to
dissociation ofHsp70, and a series of changes in HSF-1 which lead to it migrating to the
nucleus, binding to its consensus sequence (the heat shock element - HSE) and gaining
transcriptional activity. Further inhibitory kinases act to limit the duration ofHSF-1
activity and to facilitate its inactivation upon the removal of the stressful stimulus.
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HSF-1 in resting cells is phosphorylated on specific residues, which results in
repression of transcriptional activity. This is mediated through phosphorylation of the
regulatory domain, the region from amino acid residues 201 to 370 (Newton 1996).
This contains several serine residues which are targets for MAP kinases. Serine 307
is phosphorylated by ERK, which subsequently allows serine 303 to be
phosphorylated by GSK-3 (Chu 1996, Kim 1997). Also, PKC a and C, can
phosphorylate serine 363 (Chu 1998). These three sites are responsible for repression
of the heat shock response at normal temperatures. Furthermore, the 303/307
phosphorylation allows binding ofHSF-1 to the signalling molecule 14-3-3 epsilon,
which is involved in the nuclear export and cytoplasmic sequestration ofHSF-1, thus
providing further repression of transcriptional activity (Wang 2003).
Inducible phosphorylation ofHSF-1 is essential for it to acquire transcriptional
activity (Cotto 1996, Ding 1997). The specific kinases responsible have proven to be
elusive, although at least four serine/threonine residues are inducibly phosphorylated
in response to heat shock (Xia 1997). Protein kinase CK2 is activated by heat, and
can phosphorylate HSF-1 (on threonine residue 142). Mutation analysis has
suggested that this phosphorylation is essential for the activation ofHSF-1, although
this is unlikely to be the sole regulatory step, as overexpression ofCK2 does not
result in the same degree of transactivation as that seen with heat shock (Soncin
2003). Phosphorylation of serine 230, possibly by CAMK II, also contributes to the
magnitude of the HSF-1 transcriptional activity (Holmberg 2001). Thus it appears
that many different pathways contribute to activation of HSF-1, providing the
capability for fine regulation of the degree of response to a given stimulus.
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Other changes in the phosphorylation of HSF-1 are important in the cessation or
down regulation of its activity after its initial activation. ERK-1, GSK-3 and JNK are
all activated by heat shock, and may contribute to the limitation ofHSF-1 activity by
phosphorylation of the sites detailed above (Kim 1997, Dai 2000).
Dephosphorylation ofHSF-1 is likely to be an important method of switching off
HSF-1, and phosphatase inhibition prevents dissociation ofHSF-1 trimers (Xia
1997). This has not been completely elucidated, but the calcium and calmodulin
dependent protein phosphatase calcineurin has been implicated in this regard (Soncin
2000).
Other proteins also contribute to the repression ofHSF-1 activation. One such
negative regulator is the Heat Shock Factor Binding Protein 1 (HSBP1). This nuclear
protein only associates with active, hyperphosphorylated HSF-1. It associates with
the trimerisation motif and reduces its transcriptional activity (Satyal 1998). Hsp70
also interacts with activated HSF-1 (Baler 1992), and associates with the activation
domain. This represses transcriptional activity and represents an autoregulatory step
where the heat shock response limits itself by the action of the nascent Hsp70 (Shi
1998). Interestingly, HSBP-1 also interacts with Hsp70. The HSBP-1/HSF-1
interaction occurs prior to the Hsp70/HSF-1 interaction and these two events
temporally coincide with the attenuation of transcriptional activity and the
disassembly of the HSF-1 trimer respectively, suggesting a possible multistep
attenuation process (Satyal 1998).
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The promoter regions of stress responsive genes commonly contain motifs for many
transcription factors including HSF-1, and these can potentially integrate multiple
signals regulating expression of the target gene. In the human Hsp70 and Hsp90
promoters, there is a combined HSE and STAT binding site, and study has shown
that not only can HSF-1 and STAT-1 have an additive effect on transactivation of the
gene, but that they also physically interact with each other (Stephanou 1999). Indeed,
both HSF-1 and STAT-1 seem to be required for the production ofHsp27 in
response to heat (Yokota 2003). In contrast, while both STAT-3 and HSF-1 are able
to independently activate the Hsp90 promoter, they are mutually antagonistic, and
activation of the gene is reduced in the presence of both factors (Stephanou 1998).
Thus regulation ofHSF-1 transcriptional activity reflects not only the balance of
factors regulating specific changes in HSF-1, but also depends on the influence of
other transcription factors and other cellular events.
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1.5 Heme Oxygenase 1
Heme oxygenase 1 (HO-1), also termed Hsp32, is a stress protein which does not
function as a chaperone. It is an enzyme, which catalyses the degradation of heme
proteins, and is the rate limiting step in heme breakdown (Tenhunen 1968). This
reaction produces carbon monoxide, biliverdin, and free divalent iron, by cleaving
the heme ring at the a-methene bridge (Tenhunen 1968). It is these products which
mediate the effects of HO-1 (Otterbein 2000). Three different heme oxygenases have
been identified - HO-1, HO-2 and HO-3. HO-1 is induced by stress. HO-2 is
expressed constitutively, and is located primarily in the brain and testes (Sun 1990,
Ewing 1995). HO-3 has a high degree of homology to HO-2, but it lacks significant
catalytic activity, and its role is unclear (McCoubrey 1997). Whilst all stress proteins
appear to have a protective function, HO-1 appears to be critical for cellular
protection from injury (Poss 1997), and it has been shown to provide protection in a
variety of conditions. HO-1 expression is induced by different factors in different
organisms. Heme rings are the prototypical inducer (Tenhunen 1969), although other
classic inducers include heavy metals such as cadmium (Alam 1989).
1.5.1 Mechanism of HO-1 mediated protection
The end products of heme oxygenase activity are biliverdin, carbon monoxide and
iron. Each of these products has been shown to contribute to the protective effects of
HO-1. The essential nature of enzymatic heme oxygenase activity to provide the
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protective effects of upregulated HO-1 has been shown by the loss of protection in
times of reduced substrate (Foresti 2001), reinforcing the finding that it is the
products ofHO activity which produce its effects.
1.5.1.1 Carbon monoxide
Carbon monoxide (CO) has traditionally been viewed as a toxin, and on a large scale
this is certainly true. However, in recent years, a role for CO as a signalling molecule
similar to nitric oxide (NO) has been established (Otterbein 2003). Evidence that CO
provides an important contribution to the observed effects ofHO-1 is seen by the
reproducibility ofmany ofHO-l's effects by the administration of exogenous CO
(Akamatsu 2004, Chauveau 2002). CO exerts its effects through intracellular
signalling pathways, including MAP kinases and guanylyl cyclase (Brouard 2000).
In particular, its anti-apoptotic effects on endothelial cells appear to be mediated
through p38 MAPK (Brouard 2000). This has been further refined, and Zhang has
shown that CO activates the p38a isoform through MKK3 stimulation. This results in
a reduction in Fas and Fas-ligand expression, and protection from apoptosis by
inhibiting caspase activation and increasing expression of the anti-apoptotic Bel
proteins Bcl-2 and Bcl-xl (Zhang 2003).
Carbon monoxide has the potential to bind to heme proteins and other heavy metal
containing proteins. As such, it is capable of binding to cyclo-oxygenase,
cytochrome p450 reductase, and iNOS (Botros 2002). It can also bind to
transcription factors with a heme domain, such as Bachl, which is important in the
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negative regulation ofHO-1, and may represent one part of a complex system of
autoregulation.
CO reduces levels of LPS-induced proinflammatory cytokines such as TNFa and IL-
1(3, whilst also increasing levels of anti-inflammatory cytokines such as IL-10. This
appears to be mediated through MAP Kinase pathways (Otterbein 2000). Hence CO
may be responsible for some of the altered cytokine profiles seen with HO-1
induction.
1.5.1.2 Biliverdin
Biliverdin generated from HO-1 activity is rapidly converted into bilirubin by the
enzyme biliverdin reductase, and it is helpful to think of biliverdin and bilirubin
together when considering their contribution to the effects ofHO-1. Both have strong
anti-oxidant effects. Bilirubin's anti-oxidant effects are sufficiently potent to be
protective against oxidative injury at the same level that it is produced in vitro (Clark
2000). That each of the end-products of HO-1 activity contributes to its beneficial
effects is reinforced by the finding that in certain models, biliverdin can provide an
effect analogous to that seen with elevated HO-1, whilst administration ofCO
cannot. This has been demonstrated in an inflammatory bowel disease model and in
alteration of endothelial cell activation (Otterbein 2003, Soares 2004). This provides
direct evidence that although some of the effects may overlap, each of the products




Free ferrous iron is generated from the centre of the heme ring by HO-1 activity.
This is potentially pro-oxidant, and may take part in intracellular Fenton reactions to
generate free radicals (Ligeret 2004). However, the cell responds by rapidly
upregulating the iron sequestering protein ferritin, as well as generating increased
levels of an ATPase pump which actively exports iron (Eisenstein 1991, Ferris
1999). This therefore limits the detrimental effect of free Fe2+. An augmented
9+
exportation of Fe may contribute to the cytoprotective effects of HO-1, as the
intracellular iron level is critical in contributing to cell death in the face of several
stressful stimuli, and the lower levels of intracellular iron seen with HO-1 induction
are associated with cell survival (Ferris 1999).
The elevated levels of ferritin also play a role in cellular protection, and exogenously
administered ferritin can replicate the effects ofHO-1 in some but not all models.
Ferritin is responsible for the protection afforded by HO-1 in a hyperoxic lung injury
model (Taylor 1998), although protection was independent of ferritin in a model of
endotoxic shock (Otterbein 1997).
1.5.2 Transcriptional Regulation of HO-1
The human HO-1 gene is located on chromosome 22. It contains 5 exons, spanning
approximately 14kb. Regulation ofHO-1 transcription is tightly regulated which can
be cell and species specific. The promoter region contains consensus binding sites for
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multiple transcription factors, which have both positive and negative effects on
transcription, thus allowing fine control ofHO-1 expression and a rapid response to a
wide variety of stimuli.
Alam has identified two promoter regions which confer responsiveness to most
inducers in the mouse HO-1 gene (Alam 1994 and 1995). These regions are termed
El and E2 (enhancer 1 and 2 respectively; previously termed SX2 and AB1). The
inducers which are active include heme, NO, heavy metals, hyperoxia and LPS
(Ryter 2002, Poole 2005). It has been proposed that all of these stimuli share a
common signal transduction mechanism, centred around a "stress response element"
(StRE) in these regions. The StRE comprises of three repeats of the sequence
(T/C)GCTGAGTCA. This resembles strongly the AP-1 consensus sequence, and
also permits binding ofNF-E2 and Nrf2 (Alam 2003).
Agarwal has examined the human HO-1 promoter for these sites, and found similar
elements at -4.0kb and -10.6kb respectively, (Sikorski 2004, Hill-Kapturczak 2003).
However, these two regions alone do not provide full induction ofHO-1 in response
to cadmium or heme, and they do not respond to other stimuli such as oxidised lipids,
hydrogen peroxide and hyperoxia. An enhancer has, however, been identified which
lies within the HO-1 gene itself, and restores the full responsiveness to heme and
cadmium (Hill-Kapturczak 2003).
The human HO-1 promoter also contains other interesting regions. The region -1976
to -1655 contains regulatory sites for AP-1, HNF-1, HNF-4, c-Rel and GATA-X,
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however, it is functional in the HepG2 hepatoma cell line, but not in HeLa cells,
demonstrating that the regulation ofHO-1 is likely to be different not only across
species, but also between different tissues (Takahashi 1999).
Near to the HO-1 start codon, there is a negative regulatory sequence comprising a
variable number ofGT repeats, which inhibits transcription if there are many repeats
and contributes to inter-individual differences in HO-1 inducibility (Exner 2004).
This area also includes a heat shock element (HSE), which has however, been found
to be at least functionally silent, or it may even have a repressive action on HO-1
gene transcription (Okinaga 1996, Chou 2005).
1.5.2.1 Nrf2
Nrf2 is fully known as NF-E2 related factor 2. It is a cap'n'collar transcription factor,
with a basic leucine zipper (bZIP) region. It is the basic portion which allows DNA
binding. The cap'n'collar region is common across all Nrf proteins, but its function is
unknown (Jaiswal 2004).
Nrf2 is important in the response to oxidative stress. First demonstrated in the gene
NQOl (NAD(P)H:Qiunone Oxireductase 1), overexpression ofNrf2 was found to
upregulate the induction ofNQOl in response to antioxidants and xenobiotics
(Venugopal 1996). Nrf2 has since been found to be an important influence on the
expression of several defensive genes including GST Ya, y-GCS and HO-1 (Wild
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1999, Alam 1999, Nguyen 2000). Thus it is a key regulator of the cell's response to
oxidative stress.
Nrf2 has several layers of control regulating its activity. It functions by
heterodimerising with other bZIP proteins, namely Jun and Maf proteins including c-
Jun, MafG, MafK and MafF. This binding is essential for Nrf2 activity. However,
small Maf proteins are capable of homodimerising and negatively regulating the
expression ofNrf2 dependent genes (Jaiswal 2004). The relationship between which
protein dimerises with Nrf2 and the functional effect on transcription is unclear at
present (figure 1.4).
Nrf2 also has several negative regulators. Keapl (also termed INrf2 - inhibitor of
Nrf2) acts to retain Nrf2 within the cytoplasm, possibly by binding to actin (Kang
2004). Keapl may also facilitate the ubiquitinisation ofNrf2 (McMahon 2003).
Keapl contains a large number of cysteine residues which are responsible for its
repression ofNrf2. Mutational analysis of residues C273 and C288 has revealed that
these contribute not only to maintaining Nrf2 in the cytoplasm, but also promote its
ubiquitinylisation (Zhang 2003, Levonen 2004), and this effect will be lost after
dissociation ofNrf2 from Keapl, increasing cellular levels. The cysteine residue
CI51 has also been shown to play a crucial role in the dissociation ofNrf2 from
Keapl following an oxidant stimulus (Levonen 2004), allowing it to migrate to the
nucleus. The mechanism through which this occurs is unclear, but may be the result
of a post-translational modification ofKeapl, involving this residue (Nguyen 2004).
It is known that protein kinase C (PKC) phosphorylates Nrf2 which allows its
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dissociation from Keapl (Bloom 2003). Phosphatidylinositol 3-kinase (PI3K) may
also play a role in allowing nuclear localisation of Nr£2, although this appears to be
mediated through depolymerisation of actin, and may not lead to dissociation from
Keapl (Kang 2002).
Bachl also represses Nrf2 activity. This is another bZIP protein which interacts with
small Maf proteins (Oyake 1996). It heterodimerises with MafK and binds to the
StRE, repressing gene expression, apparently by preventing Nrf2 binding (Sun
2002). Cadmium, a potent HO-1 inducer, binds to certain residues of Bachl, and
causes its displacement from the StRE, de-repressing gene expression and increasing
HO-1 levels (Suzuki 2003). This is possibly the mechanism through which heme
upregulates HO-1 expression, although recent data suggests that it may not be the
only mechanism (Shan 2004).
Further regulation ofNrf2 is achieved by its short half-life of 13 minutes. It is
degraded through the ubiquitin-proteosome pathway, and activation ofNrf2 may be
achieved by Nrf2 stabilisation and inhibition of its degradation (Stewart 2003).
Nrf2 activation can be stimulated through a variety ofmolecular pathways. Carnosol
increases HO-1 through Nrf2 activation, and this is associated with activation of the
ERK, p38 and PI3K systems, ofwhich PI3K and its downstream kinase AKT appear
to be instrumental (Martin 2004). Diallyl sulfide activation ofNrf2 requires ERK and




Figure 1.4. Currently accepted model pathway ofNrf2 activation.
Nrf2 is held in an inactive form in the cytoplasm of resting cells by the inhibitor
Keap-1. Following a stressful stimulus, these factors dissociate, and Nrf2 migrates to
the nucleus. Nrf2 then associates with small Maf proteins and binds to the stress
response element in the promoter region of the target gene (StRE). In resting cells,
this element is inhibited by the binding of Bach 1. Bachl repression is alleviated
following stress, allowing Nrf2 to bind.
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1.5.2.2 HIF-la
Hypoxia is a potent inducer of HO-1 and this appears to be through the activation of
Hypoxia Inducible Factor la (HIF-la) (Lee 1997, Kacini 2000). The relevant
upstream binding sequence in the promoter has been termed the HIF-la Response
Element (HRE). Whilst the human HO-1 promoter contains an HRE, it has been
established that hypoxia does not induce HO-1 in human tissues, although it does in
other species (Kitamuro 2003).
Of note, however, cobalt chloride (C0CI2) which has been used as a hypoxia
mimicking agent and a HIF-la stimulating chemical, does still induce HO-1 in
human cells (Gong 2001). This potentially misleading finding appears to be the result
of changes in Bachl, a negative regulator of HO-1 activation (see section on Nrf2).
Bachl is induced by hypoxia in human cells, preventing the induction of HO-1 by
hypoxia. Treatment with C0CI2, however, decreases Bachl levels, thus inducing HO-
1 (Kitamuro 2003).
1.5.3 Functional Importance of HO-1
HO-1 has been found to be a cellular protectant in virtually all tissues of the body,
ranging from neurons to muscle cells, and cells of all types of origin. The
observation that HO-1 deficiency leads to a chronic inflammatory state in both mice
and humans (Poss 1997, Yachie 1999) reinforces the essential nature ofHO-1
activity. HO-1 is critically important in human liver, both in maintenance of
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homeostasis under physiological conditions, and also during liver injury. The
following sections examine the role ofHO-1 in normal and diseased liver, and in
hepatic transplantation. Finally the role ofHO-1 in other transplantable solid organs
will be described.
1.5.3.1 Heme Oxygenase in the Liver
Heme oxygenase 1 has a normal homeostatic role in the liver, as shown by the
relative abundance of hepatic HO activity, being twice that seen in the kidney, and
only inferior to that seen in the spleen and bone marrow (Tenhunen 1970). The
parenchymal and sinusoidal cells appear to have disparate roles, with sinusoidal cells
destroying senescent red blood cells, and hepatocytes responsible for the degradation
of free and haptoglobin-bound haemoglobin (Bissell 1972). Consistent with this,
there is differential expression of HO isoforms in the resting liver, with 85% ofHO
activity being contributed by HO-2 in the hepatocytes. In contrast, hepatocytes
constitutively express minimal levels ofHO-1, although Kupffer, endothelial and
stellate cells all express HO-1 at high levels, but with lower levels ofHO-2 than that
found in the hepatocytes (Bauer 1998, Rensing 1999).
Bauer's study also examined the pattern ofHO-1 induction in the liver in response to
various stressors. Whilst all conditions studied led to increased HO-1 expression,
different stimuli produced different patterns of induction: LPS induced HO-1 in the
sinusoidal lining cells; GSH depletion increased it in pericentral parenchymal cells;
cobalt chloride increased it in periportal hepatocytes; haemorrhage and resuscitation
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induced HO-1 in both pericentral hepatocytes and sinusoidal lining cells. This may
reflect the spatial concentration of reactive oxygen species within the liver in these
different models, and is consistent with a common pathway of intracellular ROS
formation that induces HO-1 (Bauer 1998). This is also in agreement with studies
showing that primary rat hepatocytes subjected to anoxia and re-oxygenation appear
to require ROS to induce HO-1 (Ohlmann 2003).
Heme oxygenase 1 has been demonstrated to be protective in the liver in different
types of injury. Induction ofHO-1 prior to the onset of hepatic inflammation will
protect hepatocytes from CD95, LPS and TNFa induced apoptosis (Sass 2003). This
protection can be replicated by HO-1 gene transfer, and appears to be primarily due
to an effect in the hepatocytes, and is independent of Kupffer cells, with the
protection still being apparent in the presence of Kupffer cell depletion (Sass 2003).
1.5.3.2 HO-1 in Liver Transplantation
In the context of liver transplantation, the organ sustains significant ischaemia-
reperfusion injury, which is exacerbated by cold storage and the immunological
assault following re-implantation. Heme oxygenase has a physiological role in liver
transplantation, and has been found to be significantly elevated after graft
implantation, particularly being induced in non-parenchymal cells (Kobayashi 2005).
HO-1 induction could improve outcomes after transplantation. Adenoviral HO-1
gene transfer improves graft survival in a rat liver transplant model (Ke 2002). The
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various different functions of the three end products ofHO-1 activity are likely to
each contribute to this. For example, the apoptosis seen in IRI is mediated mostly
through ROS generation, which in endothelial cells is iron-mediated (Rauen 1999).
HO-1 induction results in increased transferrin as well as synthesis of an iron-
exporting pump which will lower intracellular iron levels (Eisenstein 1991, Ferris
1999). Biliverdin and bilirubin are potent antioxidants (Clark 2000, Soares 2004),
and bilirubin inhibits ROS induced hepatocyte death (Granato 2003). Furthermore, in
models of ex vivo perfusion and liver transplantation, biliverdin treatment resulted in
improved hepatic function and survival after transplant (Fondevila 2004). CO
activates p38 MAPK, which can be anti-apoptotic (Brouard 2000), and in liver
transplant models, the beneficial effect ofHO-1 gene transfer can be mimicked by
chemical delivery of CO by methylene chloride (Ke 2002). In keeping with this, in a
rat model of ex vivo perfusion, exogenous CO was capable of significantly improving
the function of liver grafts, (Amersi 2002).
The potential clinical use of HO-1 manipulation in liver transplantation was
demonstrated by the successful transplantation of steatotic livers from fatty Zucker
rats. These rats are genetically obese with fatty infiltration of the liver, a frequent
reason for non-retrieval or non transplantation of livers from human donors due to
the high rate of primary non-function. Pharmacological HO-1 upregulation or HO-1
gene transfer prior to transplantation significantly improved all measured endpoints
and improved graft function (and animal survival) from 40% to 80% (Amersi 1999).
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Other difficulties with liver transplantation include the limited permissible
preservation time. Preservation of liver allografts for longer than 12 hours risks
higher rates of primary non-function and poorer long term outcome (Adam 1992). In
rats, induction ofHO-1 will allow the successful transplantation of liver grafts
following 44 hours of preservation, a duration which would otherwise be universally
fatal (Redaelli 2002).
Livers are often unusable because the donor is older, which results in poorer long-
term graft function. Tullius demonstrated that HO-1 induction with cobalt
protoporphyrin was capable of improving long term function of grafts taken from
older, "marginal" donor rats from 40% to 80% survival at 24 weeks (Tullius 2002).
Thus, if reproducible in humans, HO-1 induction may enable the use of organs that
are currently being discarded, and so increase the number of available organs for
liver transplantation.
Whilst HO-1 can modulate the peri-transplant events, minimising cell death and
reducing primary non-function, chronic rejection is the current main cause of late
graft loss (Libby 2001). This is characterised by arteriosclerosis, intimal hyperplasia
and interstitial fibrosis, and is associated with activation of endothelial cells, graft
infiltration with leucocytes and abnormal proliferation of the vascular smooth muscle
cells. Early HO-1 induction may be able to prevent or abrogate these long-term
changes.
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Endothelial cell loss at the time of transplantation predisposes the graft to late
rejection. In a model of chronic rejection in aortic allografts, gene transfer with HO-1
at the time of transplantation reduced intimal hyperplasia and leucocyte infiltration
(Chauveau 2002), and this effect can be mimicked by delivery of exogenous carbon
monoxide (Chauveau 2002, Otterbein 2003). HO-1 can prevent apoptosis of
endothelial cells (Brouard 2000), thereby maintaining the endothelial barrier, and
limiting activation of adjacent endothelium. It is likely that HO-l's suppression of
chronic rejection is primarily effected by preventing endothelial injury at the time of
reperfusion, although it may also have long term effects.
1.5.3.3 Heme Oxygenase in Other Transplantable Organs
Because transplantation provides a useful clinical model of ischaemia reperfusion
injury, the effect of heme oxygenase has been examined in many models of
transplantation. The kidney is the most commonly transplanted solid organ, and
hence would be the candidate for greatest benefit ifHO-1 induction were to be
shown to be beneficial. The kidney constitutively expresses HO-2, mainly within the
tubules and arterioles, whilst basal expression ofHO-1 is relatively low (Da Silva
2001). However, when subjected to an appropriate stimulus, the kidney is capable of
increasing its HO activity up to four fold, by the induction ofHO-1 (Da Silva 2001).
It has been observed that the level ofHO-1 expression in the endothelial and smooth
muscle cells of cardiac transplants correlates with the continued survival of the graft
(Soares 1998), thus providing a physiological role for HO-1 in heart transplantation.
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Furthermore, induction ofHO-1 prior to graft harvesting, and the attendant ischaemia
reperfusion injury, protects the heart from transplant associated injury, as measured
by the continued function of the grafts (Akamatsu 2004). This effect was fully
reproducible by extrinsic CO administration either to the donor or to the graft during
cold storage.
Pancreatic islet cell transplantation is a relatively new form of transplantation, where
rather than transplanting the whole pancreas to treat diabetes, only pancreatic islets
are transplanted, which contain the p cells which secrete insulin. Recent research has
shown that this is a viable method and that the medium term results are acceptable
(Shapiro 2000) and use of this technique is likely to increase in the coming decade.
However, large numbers of donor islets are required, often necessitating the use of
several organs for one recipient to gain an acceptable result. This may be due to islet
cell apoptosis during the harvesting and transplantation. Experiments in rat islets
have shown that HO-1 can be induced with several agents, including IL-ip, nitric
oxide, cobalt protoporphyrin and cobalt chloride (Ye 1998), suggesting the
possibility ofHO-1 induction as a strategy to reduce the requirement for large
numbers of donor islets, allowing more patients to be treated with fewer organs.
Carbon monoxide has been shown to improve the function and survival of grafted P
cells in a murine model, demonstrating that enhanced HO-1 activity could have a
therapeutic role (Gunther 2002).
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1.6 Potential Pharmacological Preconditioning Agents
There are many ways in which to achieve a preconditioned phenotype, as described
earlier in this chapter. Although ischaemic preconditioning has been used with some
success, this exerts a global effect on the organ, and may result in undesired effects
on the liver. Furthermore it can only be applied at the time of surgery. It is for this
reason that there is interest in developing pharmacological treatments which can
precondition the liver. A pharmacological agent has the advantage that it may work
through a specific cellular pathway. There are many potential agents that could be
used and have been studied in a variety of in vitro and in vivo models (Selzner 2003)
This work studied in detail the effects of curcumin and cyclosporin A on human
hepatocytes.
1.6.1 Curcumin
Curcumin is a natural extract of turmeric, the spice produced from Curcuma longa L
(Zingiberaceae), part of the ginger family. This herb originates from the tropical
regions ofAsia, and has been used for many centuries as a herbal remedy for several
complaints. In ancient Hindu texts it is used to treat sprains and swellings, and in
Indian medicine it is traditionally used for biliary disorders, sinusitis and diabetic
wounds (Ammon 1991).
Over the past few decades there has been a great volume of research performed on
curcumin to establish its effects at the cellular level and to investigate its potential as
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an in vivo therapeutic agent for a wide variety of conditions. In vitro and in vivo
studies have shown that curcumin is able to induce the stress response (Dunsmore
2001) and to reduce the severity hepatic injury in several models of acute
inflammation (Park 2000, Gaddipati 2003), demonstrating that it may have potential
as a hepatic preconditioning agent.
1.6.1.1 Cellular Effects
At the cellular level, work has focussed on the effect of curcumin on transcription
factors and cell signalling cascades. Curcumin has been shown to inhibit NFkB in a
variety of cell types including macrophages, colorectal and prostatic cell lines and
endothelial cells (Pan 2000, Plummer 1999, Mukhopadhyay 2001, Kumar 1998).
This effect appears to be the result of IKK inhibition, mediated by inhibiting
signalling upstream of IKK (Jobin 1999, Pan 2000, Plummer 1999), and is the likely
mechanism through which curcumin reduces a variety of proteins such as ICAM-1,
ELAM-1, VCAM-1, and COX-2 (Kumar 1998, Plummer 1999). Curcumin also
inhibits AP-1, which in certain cell lines may be a result of JNK inhibition (Jobin
1999, Singh 1995).
Curcumin has been found alter the activity of several cell kinases in particular the
MAP kinases. These effects are complex and appear to vary between cell types,
although this may be due either to different experimental conditions or to intrinsic
differences in the cell lines (table 1.1).
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1.6.1.2 Redox Effects of Curcumin
Curcumin has been described as having both pro-oxidant and anti-oxidant effects,
and this has been linked to its effects on either producing protection from oxidative
stress, or in causing apoptosis. In a model of rat forebrain ischaemia-reperfusion,
curcumin administered after the onset of ischaemia reduced xanthine oxidase
activity, superoxide anion production and malonaldehyde levels, demonstrating anti¬
oxidant effects in this model (Ghoneim 2002). Interestingly, although curcumin
increases glutathione levels in Jurkat cells (Piwocka 2001), it did not prevent the
reduction of glutathione seen in the rat forebrain IRI model (Ghoneim 2002). In
contrast to these anti-oxidant properties, the induction of apoptosis by curcumin
demonstrated by several groups is associated with the generation of reactive oxygen
species (Khar 2001, Woo 2003, Ligeret 2004). These apparently conflicting results
may be explained by the different concentrations of curcumin used in these studies,
and in the relative sensitivity of different cell lines. Furthermore, other "anti¬
oxidants" such as the garlic extract DAS have been shown to induce ROS generation
(Gong 2004). Providing that the cell is not overwhelmed by ROS, it is the response
to this stimulus by the production of protective proteins that may mediate the "anti¬
oxidant" properties of these compounds (Gong 2004).
Curcumin predominantly induces apoptosis through a classical mitochondrial
pathway, associated with mitochondrial pore opening, swelling, cytochrome C
release and caspase activation (Anto 2002, Woo 2003). Atypical variants have been
described where chromatin clumping occurs, but there is no change in caspase
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activity, no mitochondrial depolarisation and glutathione depletion does not occur
(Piwocka 1999 and 2001). Curcumin can also promote apoptosis by inhibiting Bcl-xl
through NFkB inhibition (Han 1999). Indeed, NFkB inhibition may be critical as its
over-expression can prevent curcumin induced apoptosis (Anto 2000).
Curcumin-induced apoptosis only occurs in certain cell lines. These include
hepatocellular, colonic, reticuloendothelial and renal cells (Khar 2001, Woo 2003).
Cell lines which undergo apoptosis generate high levels of superoxide when treated
with curcumin, and the apoptosis can be prevented by the addition of the free radical
scavenger N-acetyl-cysteine (NAC) (Morin, 2001, Khar 2001, Woo 2003).
Superoxide may not explain all of the effects of curcumin, as in isolated rat
mitochondria, curcumin is capable of lowering superoxide levels, whilst also
inducing HO* production by facilitating the Fenton reaction due to its iron reducing
capabilities (Ligeret 2004).
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Cell Type P38 JNK ERK Reference
Intestinal epithelial t Jobin 1999
Renal epithelial t <-» t Balogun 2003
Breast cancer 4- I Squires 2003
Table 1.1 Varying effects of curcumin on MAPKs in different cell types.
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1.6.1.3 Curcumin and the Stress Response
Curcumin has been shown to induce Hsp70 in HeLa cells and colorectal cell lines
(Dunsmore 2001, Chen 2001). This has been associated with activation ofHSF-1.
However, these reports are inconsistent. Chen showed nuclear localisation of HSF-1,
and increased binding to the HSF-1 consensus sequence, but on cross linking studies
the HSF-1 was not trimeric following curcumin treatment, suggesting that the HSF-1
would not be transcriptionally active, and may not be responsible for the observed
rise in Hsp70 (Chen 2001). However, Dunsmore found that Hsp70 was clearly
induced by curcumin, and in HSF-1 -/- fibroblasts, the induction was markedly
reduced, implicating the involvement ofHSF-1 (Dunsmore 2001). In rat hepatocytes,
Kato found that curcumin had no effect on Hsp70 levels when given alone, although
it did potentiate the effects of other Hsp inducers, such as heat shock and arsenite
(Kato 1998).
Curcumin is also capable of inducing HO-1 in a variety of cells (Scapagnini 2002,
Motterlini 2000, Balogun 2003). This may be mediated through Nrf2 activation,
which binds to the ARE sequences in the HO-1 promoter (Balogun 2003). Of note,
curcumin does not induce HO-1 in HeLa cells, whilst it does induce Hsp70
(Dunsmore 2001). Thus the effects of curcumin may be cell type dependent.
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1.6.1.4 Clinical Application of Curcumin
The impetus for much of the research into curcumin has been the potential to apply it
in a therapeutic role. It was historically used to treat inflammation and swelling, and
early research focussed on these effects, establishing that curcumin reduces
inflammation in the rat paw oedema model, and in formalin induced arthritis
(Ammon 1991). This was extended into other models of organ damage, and
curcumin has proven effective in reducing liver injury from carbon tetrachloride
(Park 2000), aflatoxin B (Soni 1992), cyclophosphamide (Soudamini 1992) and
haemorrhage/resuscitation injury (Gaddipati 2003). It reduces the severity of renal
ischaemia-reperfusion injury (Shoskes 1998), and is protective in in vitro models of
endothelial cell injury (Motterlini 2000).
The protective effects of curcumin may be due to the modulation ofMAP kinase
cascades (Balogun 2003), or to the induction of stress proteins such as Hsp70 and
HO-1 (Dunsmore 2001, Scapagnini 2002). It should be noted, however, that there are
many other proteins which are induced by curcumin treatment which may also
contribute to the protection seen in the above models such as induction of the phase
II detoxifying enzymes glutathione S transferase and NADPH:QR (Okada 2001).
Hence the results available demonstrate that curcumin has potential preconditioning
properties, although this has not previously been tested in human hepatocytes.
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1.6.2 Calcineurin Inhibitors
Calcineurin inhibitors have been the mainstay of immunosuppressive therapies since
Roy Calne first demonstrated the clinical use of cyclosporin A (Calne 1981). This
was added to by the later development of tacrolimus, another calcineurin inhibitor.
Whilst these are structurally different, and originate from different sources, they both
function to inhibit the protein phosphatase calcineurin. Classically, their
immunosuppressive effect has been linked to inhibition of calcineurin and
subsequent downstream prevention of IL-2 production and T cell proliferation.
However, in recent years, these drugs have been found to have many other cellular
effects and may have the potential to be used in other clinical arenas.
1.6.2.1 Calcineurin
Calcineurin is a serine/threonine protein phosphatase which is essential for
production of IL-2, an important factor for T cell proliferation. It was initially
purified from mammalian brain (Klee 1988), and was identified as being dependent
on calcium and calmodulin as co-factors in its activation, and hence the name
calcineurin, although it has also been known as protein phosphatase 2B.
Calcineurin is a heterodimer of two different subunits - A and B. Calcineurin A
contains the catalytic region, a calmodulin binding domain and an autoinhibitory
domain, whilst calcineurin B contains the calcium binding domain. The
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autoinhibition is only overcome in the presence of both calcium and calmodulin,
allowing the phosphatase function to commence (Rusnak 2000).
Amongst other effects, calcineurin activity dephosphorylates the cytoplasmic
subunits of the transcription factor Nuclear Factor of Activated T cells (NF-AT),
resulting in its nuclear migration and DNA binding, leading to increased IL-2
synthesis (Rao 1997).
1.6.2.2 Cyclosporin A
Cyclosporin A was purified from the fungus Tolypocladium inflatum. It is a
lipophilic molecule which can easily enter the cell, where it binds to cyclophilin.
This is an immunophilin which acts as a cytoplasmic receptor for cyclosporin. It is
found in a wide variety of cells and species, and is characterised by chaperone-like
activity aiding the folding of ribonuclease, although this does not appear to be related
to the immunosuppressive effect of cyclosporin (Ruhlmann 1997).
1.6.2.3 Tacrolimus
Tacrolimus was isolated from Streptomyces tsukubaensis. Structurally it is a
macrolide, and it is also known as FK506. It was first discovered in 1984, and the
first experimental results were published in 1987 (Wallemacq 1993). Like
cyclosporin A, it is also lipophilic and enters the cell to bind to immunophilins which
are termed FK506 Binding Proteins (FKBPs). These have the same enzymatic
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activity seen in cyclophilin, allowing tacrolimus to interact with and inhibit
calcineurin (Dumont 2000).
1.6.2.4 Mechanism of action of Calcineurin Inhibitors
Despite the structural differences of tacrolimus and cyclosporin, their different
origins and their different cytosolic receptors, they both inhibit the action of
calcineurin. The drug-immunophilin complex interacts with the catalytic domain of
calcineurin, blocking its phosphatase activity. This results in the inability of the cell
to activate NF-AT and hence prevents upregulation of IL-2 production, which is
believed to be central to the immunosuppressive effects of these drugs (Beals 1997).
Calcineurin has a wide range of other physiological functions ranging from
osteoclast bone resorption to regulation of pituitary hormone secretion (Rusnak
2000). Thus calcineurin inhibitors will have effects other than those on NF-AT
activity. Calcineurin inhibitors stimulate the expression of several cytokines and
growth factors, including TGF-p, IFN-y, and IL-13. (Shin 1998, Rafiq 1998, van der
Pouw Kraan 1996). TGF-P has potent immunosuppressive effects, and much of the
effects attributed to cyclosporin may be through its stimulation of this cytokine
(Khanna 1999).
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1.6.2.5 Calcineurin Inhibitors and the Stress Response
Calcineurin inhibitors also affect stress protein production. The transcriptional
activity ofHSF-1 is tightly regulated by multiple repressive factors including
association with Hsp90 and Hsp 70 (see section 1.4.6). The association with Hsp90 is
dependent on the presence of Cyp40, a cyclophilin (Duina 1998). Calcineurin
inhibitors will displace Cyp40, potentially resulting in activation ofHSF-1.
Furthermore Hsp70 can bind to cyclosporin (Moss 1992). Thus cyclosporin could
derepress HSF-1, facilitating its induction in response to a stimulus. Consistent with
this mechanism, cyclosporin treatment ofHeLa cells produces a degree ofHSF-1 and
HSF-2 activation in resting cells, and also leads to a greater activation ofHSF-1 in
response to heat shock (Paslaru 2000). In rat hepatocytes, cyclosporin also leads to a
dose-dependent activation of HSF-1 (Andres 2002). The mechanism ofHSF-1
activation by cyclosporin has not been precisely delineated, but it may be due to ROS
generation (Andres 2002), or to inhibition of the proteosome (Paslaru 2000)
In keeping with its effect on HSF-1, cyclosporin is capable of inducing Grp78 (an ER
chaperone) and Hsp27 (Paslaru 1994, Paslaru 2000). The effect of tacrolimus on
HSF-1 has not been directly tested, but it has different effects on Hsp production in
comparison to cyclosporin. Both tacrolimus and cyclosporin induce Hsp70 in rat
hepatocytes (Kaibori 2001, Andres 2002). In contrast, tacrolimus has no effect on
Grp78 expression in HeLa cells, whilst cyclosporin strongly induces it.
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Calcineurin inhibitors also have effects on other transcription factors and kinase
pathways which are relevant to any potential preconditioning effects. Cyclosporin
has been found to affect the activity of AP-1 and NFkB (Mattila 1990, Rincon 1994,
Andres 2002). CsA can also activate ERK 1 and 2 (Paslaru 1997). Cyclosporin
inhibits JNK and p38 pathways in T cells (Matsuda 1998), as does tacrolimus
(Matsuda 2003).
Regulation ofmitochondrial events is important in the response of cells to stress. The
collapse of the mitochondrial membrane potential is a key component of cell death in
ischaemia-reperfusion injury, and results from the development of the mitochondrial
permeability transition pore (see section 1.2.1). This pore contains several protein
subunits which are assembled at the contact point between the inner and outer
mitochondrial membrane to create an opening (Marzo 1998). Mitochondrial
cyclophilin D is a key constituent of the pore and cyclosporin treatment prevents its
recruitment to the pore, inhibiting pore formation, preventing cell death (Pastorino
1993, Halestrap 1997). The combined effect of upregulation ofHsps and inhibition
of the mitochondrial permeability transition pore suggests that cyclosporin may have
cytoprotective effects which make it a candidate preconditioning agent.
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1.6.2.6 Preconditioning Effects of Calcineurin Inhibitors
The understanding of the effects of calcineurin inhibitors on the stress response has
led to interest in using them as preconditioning agents. Cyclosporin ameliorates the
degree of liver injury in a rat IRI model (Konukoglu 1998). This effect was achieved
by administering the drug at the time of reperfusion and as such is unlikely to be the
result of de novo protein synthesis. There was a lower level of lipid peroxidation in
the treated group, suggesting that this preconditioning effect may be due to inhibition
ofROS production.
In a rat model of renal ischaemia reperfusion injury, pretreatment with either
cyclosporin or tacrolimus was able to reduce the degree of reperfusion injury (Yang
2001). In this model, the dose and timing of the drugs was designed for the ischaemic
injury to be applied at the time ofmaximal Hsp70 expression. Thus the
preconditioning effect in this experiment may have been due to increased Hsp levels.
An in vitro model of IRI in cardiomyocytes found that preconditioning with
tacrolimus improved cell survival, but that cyclosporin did not have the same effect
(Cumming 1996). This study allowed time for new protein synthesis (18 hours
between pretreatment and the injury) but no difference was found in the expression
of the various putative proteins examined (Hsp72, Hsp60, Hsp56, Hsp90).
Calcineurin inhibitors can also protect from other types of injury. Pretreatment with
tacrolimus protects rat livers from cold ischaemia (Okano 1994). Pretreatment of the
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recipient with cyclosporin improved survival after liver transplantation, although
donor pretreatment did not have the same effect. Of note, pretreatment was given for
3 days in both groups (Kai 1994).
Hence there is sufficient evidence to implicate cyclosporin as a candidate
preconditioning agent which may be effective in human hepatocytes, and thus is
worthy of further study.
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1.7 Conclusion
Liver surgery and transplantation is an area of clinical practice in which
preconditioning treatments could have a beneficial effect. Such treatments could
reduce perioperative hepatic impairment following elective liver resection, or
primary non-function following transplantation. The damaging effect of both of these
clinical situations reflects the ischaemia-reperfusion injury that is an unavoidable
part of the surgical process. This is characterised by a complex series of harmful
cellular events. The stress response is part of the natural defence mechanisms of the
cell, and it acts to limit the severity of this injury. Preconditioning can upregulate this
response prior to surgery, resulting in protection of the liver cells from injury. There
are many aspects of the stress response which could be targeted to achieve
preconditioning, and current evidence suggests that curcumin and cyclosporin may
both be candidate preconditioning agents. However, there is limited knowledge of
their effects in human hepatocytes.
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1.8 Hypotheses
1. Curcumin induces the stress response in human hepatocytes.
2. Curcumin exerts a preconditioning effect on hepatocytes that protects them
from ischaemia-reperfusion injury.
3. Cyclosporin A induces the stress response in human hepatocytes.
4. Cyclosporin A preconditions human hepatocytes and protects them from
ischaemia-reperfusion injury.
5. Induction of the preconditioned phenotype does not impair differentiated cell






All cell cultures were performed in standard conditions of 37°C, 5% CO2. HepG2
(Morris 1982) and Huh7 (Nakabayashi 1982) human hepatoma cell lines were
obtained from the European Tissue Culture Collection (Porton Down, UK). Both
lines were maintained in Dulbecco's Modified Eagle's Medium containing 10% fetal
calf serum, 50u/ml penicillin G and 50pg/ml streptomycin. Cells were trypsinised
• . 9 • •••• •
and passaged twice weekly in 75cm flasks. Plating densities in different dishes are
shown in table 2.1. Cells were used for experiments at 60 to 80% confluence.
2.2 Primary Hepatocyte Isolation
Normal liver tissue was collected at the time of hepatic resection from patients who
had given preoperative written consent. Local ethical approval had been obtained
(LREC reference number LREC/2000/5/23). Preparation of hepatocytes was
essentially as described previously (O'Riordain, 1999). Approximately 20g of liver
tissue was cut from the operative specimen following removal from the patient. All
visible vessels were irrigated immediately with sterile ice cold heparinised saline
(lOu/ml) until the flow through was clear. The sample was then transferred to the
laboratory in ice cold saline. All following steps were performed within a laminar
flow cabinet. Cannulae (16G venflons) were inserted into at least 4 different vessels,
sutured in place and connected to tubing via a pump. Unused open vessels were
closed with sutures. The specimen was placed on a sterile container dish floating in a
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96 well plate 12 well plate 35mm dish/
6 well plate
10cm dish 75cm2 flask
Cell
Number
2 xlO4 1.5 xlO5 3xl05 2 xlOb 3xl0b
Medium
Volume
lOOpl 1ml 2ml 10ml 17ml
Table 2.1 Culture conditions of cells in different dishes
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water bath set at 37°C, and perfused with sequential oxygenated buffers A to C
warmed to 37°C in a separate water bath. Oxygenation was achieved by bubbling
medical oxygen through the buffer at 11/min. Waste buffer was continuously drained
from the container by a siphon drain. Buffer D, containing collagenase and
hyaluronidase was perfused through the tissue for 1 hour at 37°C. During this time
the drain was removed from the container and the buffer was continuously
recirculated. Following digestion the liver capsule was teased apart and hepatocytes
collected by irrigating with serum free medium (William's E, with penicillin and
streptomycin). The suspension was passed through a 200 micron mesh filter, and
then centrifuged 3 times at 50g for 2 minutes at 4°C. The pellet was retained and
resuspended in medium following each centrifugation. Following washing and
centrifugation, the cells were gently mixed with equal volumes of a 100% Percoll
gradient and centrifuged at 50g for 10 minutes at 4°C. The pellet was then
resuspended in medium containing 10% fetal calf serum and the cell number counted
using a graticule. The percoll gradient removes dead hepatocytes, and results in a
highly purified population. Cells prepared in this way contain no CD 14 positive
staining cells on flow cytometry and have a final viability as tested with trypan blue
of>98% (O'Riordain 1999). The yield of each preparation varied from 3 million to
over 20 million hepatocytes depending on the donor. The cells were plated out in
collagen coated (Worthington, 5pg/cm ) dishes, and left overnight to adhere.
Experiments were performed the following day. The cells were maintained in
William's Medium containing 10% fetal calf serum with 50u/ml penicillin G and
50pg/ml streptomycin as above.
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2.3 Liver Tissue Slices
Normal liver tissue was collected at the time of hepatic resection from patients who
had given preoperative written consent. A small cube of liver tissue was collected in
theatre under aseptic conditions and transferred to the laboratory in ice cold saline.
This was placed in a sterilised custom built clamp and slices were cut by hand to
coverslip thickness using a skin graft blade. These slices were then placed in 35mm
tissue culture dishes containing 2mls Williams' medium with 10% FCS and
incubated in standard conditions (37°C, 5% CO2).
2.4 Immunohistochemistry
Sections were cut from paraffin embedded tissue and mounted on APES (a-propyl
ethoxy silane) coated glass slides. The sections were initially dewaxed in xylene for
ten minutes and then rehydrated by 2 minutes washes in stepped alcohols, decreasing
from 100% to 50% alcohol. Endogenous peroxidase activity was blocked by
incubating the slides in 3% hydrogen peroxide in water for 15 minutes. The slides
were then rinsed in distilled water followed by 5 minutes incubation in TBS.
Subsequently antigen retrieval was performed. The slides were placed in citrate
buffer in a sealed plastic container and then microwaved for three 5 minute periods
(800W microwave on full power). The slides were rotated in the container after each
period, and then left to stand for twenty minutes in hot buffer.
69
The slides were washed twice in TBS for 5 minutes and then appropriate blocking
serum was applied, diluted 1 in 5 in TBS and incubated for 20 minutes. The serum
selected was from the same species in which the secondary antibody was raised. The
blocking serum was then tapped off and the slide dried prior to application of the
primary antibody, which was then incubated for either 1 hour at room temperature or
overnight at 4°C. The slides were washed three times in TBS for 5 minutes, after
which the secondary antibody was applied and incubated at room temperature for 30
minutes. The slides were washed as before and then incubated with diamino-
benzidine solution (DAB), prepared as per the manufacturers instructions (Sigma
Fast, Sigma). The slides were then rinsed in water and counter-stained with
haematoxylin for twenty seconds, rinsed in running water, blued in Scott's Tap
Water Substitute for one minute and rinsed in water. Finally the slides were
dehydrated by consecutive rinsing in ascending alcohols and cleared in xylene. They
were then mounted with a coverslip using DPX mountant and left to set overnight.
If a biotin conjugated secondary antibody was used, endogenous biotin was blocked
using a commercially available kit (Vector Laboratories), which was applied to the
slides prior to the primary antibody. Avidin D was applied and incubated for fifteen
minutes, rinsed off and then biotin blocking solution was added to the slides and
incubated for a further fifteen minutes. The slides were then treated with primary and
secondary antibodies as above. However, prior to application of the DAB solution,
there was a thirty minute incubation in streptavidin-biotin-HRP complex (DAKO)
following which the slides were then rinsed again and the DAB applied. All other
steps were as described above.
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2.5 Viability Assays
Cell viability assays were performed on using a modification of an established MTT
(methylthiazole tetrazolium) dye technique (Takahashi 2002). This method relies on
the reduction of tetrazolium salts by mitochondria, generating formazan crystals. It is
a measure of cell viability and may be more sensitive the lactate dehydrogenase in
detecting impaired cell function (Liu 1997, DaCosta 1999). The formazan crystals
are then solubilised with SDS, and the concentration is read spectrophotometrically.
Cells were cultured in 96 well plates at 2.5 xlO4 cells per well in lOOpl ofmedium.
Following the requisite treatment, 10pl ofMTT solution (5mg/ml in DPBS) was
added to each well and the plate returned to the incubator for 4 hours. Subsequently,
lOOpl of extraction buffer (10% SDS, pH 3) was added and the plate incubated at
37°C overnight, following which the optical densities were measured at 570nm using
a plate reader (Dynex MRX II, Dynatech).
2.6 Cell Death Assays
Assessment of cell death was performed by measuring lactate dehydrogenase release
in cell culture supernatants, as described by Bergmeyer and Bernt (Bergmeyer 1974).
This method results in the generation of formazan crystals, the concentration of
which is then measured spectrophotometrically. Following the treatment of cells, an
aliquot of supernatant was collected and frozen at -70°C for later analysis. To
perform the assay, lOpl of supernatant was pippetted into a well in a 96 well plate,
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and 20)a.l of tris buffer (1M Tris-HCl, pH 8.5) and 50pl of substrate (O.lmM 1-lactate,
pH5.5) were added. The plate was warmed for five minutes in an incubator at 37°C
and then 20pl of chromogen (5mg/ml NAD, 2mg/ml INT, 0.5mg/ml PMS) was
added and the plate returned to the incubator for exactly five minutes before 1 OOpl of
0.5M HC1 was added to each well to stop the reaction. The plate was read within 20
minutes, in a plate reader at 540nm. All reactions were performed in triplicate and
the mean value obtained. Blanks were obtained by substituting 10pl of blank (0.01M
sodium oxalate) solution in place of a supernatant. All values were expressed as a
ratio of control samples, which were obtained from untreated cells cultured at the
same time and in the same conditions as the treatment group, and which had the
LDH assay performed on the same plate.
2.7 Models ofHepatocellular Injury
Several different models of cell injury were developed, as described in chapter 6.
Three are described here in detail: hydrogen peroxide/glucose oxidase, sodium
arsenite and reperfusion after cold storage. Other methods that were tested during
model development are described in chapter 6.
2.7.1 Hydrogen Peroxide/Glucose Oxidase
Cells were cultured in 96 well plates and pretreated as required. Subsequently the
were challenged with medium containing either ImM hydrogen peroxide for four
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hours or with 75-100mU glucose oxidase for two hours. An MTT assay was then
performed as described above. Results were expressed as percentage protection,
which is calculated by the following formula: ((X/H2O2 group)-l)x 100, This
represents the improvement in survival over the group which had received no
pretreatment. Each experiment contained an untreated group for such a comparison.
2.7.2 Sodium Arsenite
Initial experiments with sodium arsenite used an MTT assay as the end measurement
of survival, and well performed in a 96 well plate format, as described above. This
was subsequently altered to a 6 well plate format using flow cytometry to assess
survival, as follows. Cells were cultured in 6 well plates and pretreated as required.
The cells were then treated with 1 to lOmM sodium arsenite for times ranging from
thirty minutes to two hours. The cells were recovered in normal medium for 18 hours
and then harvested for flow cytometry using propidium iodide and annexin V
To ensure floating cells were included, the medium was aspirated from each well and
placed in a LP3 tube. From this point on, the tube was kept on ice unless otherwise
stated. The well was washed with 200pil ofwarm DPBS, which was then aspirated
and added to the tube. 200pl ofwarmed trypsin was then added to each well, and the
plate replaced in the incubator at 37°C. The plate was checked every minute, and
removed from the incubator when it was seen that the cells came off the plate when it
was gently tapped. 200pl of ice-cold DPBS was then added to the well and then the
well was aspirated and added to the LP3 tube. A further 200pl wash was performed
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and collected. The tubes were then centrifuged at 2,000g for five minutes at 4°C. The
supernatant was removed and the cell pellet washed and resuspended in 0.5mls of
cold DPBS. Two further washes were then performed.
For dual staining with annexin V and propidium iodide, the Annexin V-FITC
Apoptosis Detection Kit (BD Pharmingen) was used as per the manufacturer's
instructions. Briefly, the pellet of cells was resuspended in lx binding buffer at lxl 06
cells per ml. lOOpl of the cell suspension was placed in a fresh tube, and 5pl each of
annexin V and propidium were added. The tube was briefly vortexed and then
incubated for fifteen minutes at room temperature in the dark. Subsequently, 400pl
of lx binding buffer was added, the tube was placed on ice and read within sixty
minutes.
Cells were analysed on an Epics XL-MCL machine (Coulter). Gates were set on
initial control cells, which included the following groups: unstained; annexin V only;
propidium only; propidium and annexin. These controls were repeated with an
injured population. The programme was set to register a either 5,000 or 10,000
events depending on cell numbers.
2.7.3 Cold Storage and Reperfusion
Storage of cells in University ofWisconsin solution (UW) was used to induce cold
injury. Cells were pretreated as required and then the medium was removed and
replaced with UW at 4°C. The lids of the plates were sealed with parafilm, and then
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they were incubated for the required period of time at 4°C. For recovery, the UW
was removed and replaced with medium containing 10% FCS, pre-warmed to 37°C,
and the plate was replaced in the normal incubator (37°C, 5% CO2). After the
required recovery period, cell injury or survival was assessed by using either
measurement of released LDH in the supernatant, or by performing an MTT assay.
2.8 Preparation of cell lysates
2.8.1 Whole cell extracts
Whole cell extracts were obtained using RIPA buffer with protease inhibitors. The
medium was removed from the cells and they were placed on ice and washed with
ice cold PBS. This was then removed and the well aspirated dry prior to addition of
the lysis buffer. The cells were scraped in this buffer and collected in an eppendorf
which was then centrifuged at 10,000g for 10 minutes at 4°C. The supernatant was
then collected and placed in a fresh tube.
2.8.2 Nuclear and cytoplasmic extracts
Nuclear and cytoplasmic fractionation was performed using Gobert's method
(Gobert 1996). The medium was removed from the cells and they were placed on ice
and washed with ice cold PBS. This was aspirated to dryness and buffer E was
added. The cells were scraped in this buffer and collected in an eppendorf prior to
centrifugation at 10,000g for 2 minutes at 4°C. The supernatant containing the
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cytoplasmic extract was collected and stored. The pellet was resuspended in buffer F
and incubated on ice for 30 minutes prior to centrifugation at 10,000g for lOminutes
at 4°C. The supernatant was then collected and stored as the nuclear extract.
2.8.3 Native whole cell lysates
Cells were washed on ice with PBS and the wells dried as above. Fresh PBS was
added to the well and the cells scraped with a cell lifter and collected into an
eppendorf. The tube was spun for 10s at 3000g to pellet the cells, and the supernatant
was removed. The tube was snap frozen in liquid nitrogen and then thawed on ice.
Native lysis buffer was added at twice the pellet volume and the pellet was
resuspended and incubated on ice for 30 minutes. The tube was then centrifuged at
10,000g for 15 minutes and the supernatant containing the extract was collected.
2.9 Protein Assay
A protein assay to ascertain the concentration of protein in cell extracts was
performed on all samples prior to further analysis. The BioRad DC Protein Assay kit
was used according to the manufacturers instructions. Concentrations were
established by comparison to a standard curve formed from a known commercially
available standard of bovine albumin (BioRad). Plates were read on a Dynatech plate
reader (Dynex MRX II, Dynatech).
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2.10 Western Blotting
Western blots were performed using acrylamide gels and a standard protocol, with
only minor adjustments being made for certain antibodies. Minigels were cast and
run using the BioRad Miniprotean II or III systems. Larger gels were cast on the
BioRad II xi cell system. Most samples were run on a 10% gel separating gel with a
4% stacking gel. Certain applications required gels ranging from 5 to 20%. For non-
denaturing gel electrophoresis to examine the trimeric state ofHSF-1, native gradient
gels were poured using a specially constructed mixing device based on the
commercially available BioRad Gradient Former. When used these gels contained a
3-20% gradient with no stacking gel, and a special non-denaturing sample loading
buffer was used.
Protein samples were prepared by the addition of loading buffer and denatured by
heating to 95°C for 5 minutes. Samples were then loaded onto the gels and run at
200V until the dye front reached the bottom of the gel. The gel was then removed
from its glass plates and placed next to a nylon membrane, in a sandwich of blotting
paper. The paper and membrane had previously been soaked in transfer buffer. The
sandwich was then placed in a Pharmacia Novablot Semidry transfer blotter and
transferred at 0.8mA/cm for one hour. The membrane was then removed from the
sandwich and stained with Ponceau red to examine the protein loading and to ensure
adequate transfer. This was then washed out with TBS and then the membrane was
washed in blocking solution (5% non-fat milk) for 30 minutes on a rocking platform
at room temperature.
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Subsequently the membrane was placed in primary antibody at the required
concentration and either incubated for one hour at room temperature or a 4°C
overnight. The membrane then underwent three five minute washes in TBS-Tween
before being incubated in secondary antibody at room temperature on a rocker for 30
minutes. Finally the membrane was washed twice in TBS-Tween (for five minutes
each time) and then placed in TBS ready for transfer to the dark-room.
In the dark-room membranes were placed on cards and chemiluminescence was
performed using the Amersham ECL system. Membranes were incubated with ECL
as per the manufacturer's instructions. The ECL was then removed, the membrane
dried with a tissue and covered in Saranwrap and then placed in a cassette with
radiographic film (Kodak) and exposed for the required length of time. The films
were developed either by hand using traditional developer and fixer chemicals, or
using an Amersham Hyperprocessor automated developer.
2.11 RNA Extraction
All reaction compositions are as detailed in Appendix B. RNA was extracted from
cultured cells using Trizol reagent (Invitrogen) as per the manufacturer's
instructions, and quality and quantity assessed by spectrophotometry. Following the
required treatment the medium was aspirated and 1ml of Trizol solution was applied
per 10cm of surface area (1ml for a 35mm dish). The cell lysate was then passed
several times through a pipette tip and then incubated at room temperature for five
minutes. Chloroform was then added (0.2mls per 1ml of Trizol) and the tubes shaken
78
vigorously by hand before a three minute incubation at room temperature, followed
by centrifugation at 10,000g for 15 minutes at 4°C. The upper aqueous phase was
collected in a fresh tube and isopropanol (0.5mls per 1ml of initial Trizol) added
before a ten minute incubation at room temperature and then centrifugation as before
for ten minutes. The supernatant was removed and the RNA pellet washed once with
75% ethanol, vortexed and then centrifuged at 7,000g for five minutes at 4°C. The
alcohol was removed and the pellet air dried for five minutes prior to rehydration in
RNAse free water. The quantity and quality of the RNA was assessed
spectrophotometrically (Ultrospec 2000, Pharmacia Biotech) by measuring the
A26O/28O ratio. Partially dissolved samples with a ratio of less than 1.6 were incubated
at 60°C for ten minutes to aid in redissolving the pellet.
2.12 Reverse Transcription
Prior to reverse transcription, the extracted RNA was then treated with RQ1 DNAse
(Promega) as per the manufacturer's instructions (8pl RNA, lpl lOx DNAse Buffer,
lpl DNAse, incubated at 37°C for 30 mins; then add lpl stop solution and incubate
at 65°C for 10 mins). For quality control, an aliquot was then used for a PCR of
cytochrome B to confirm the absence of genomic DNA contamination. Reverse
transcription was performed using random primers using AMV reverse transcriptase
(Promega). A master mix reaction (see appendix B) was prepared and added in equal
volume to lOpl ofDNAse treated RNA, prior to incubation at 42°C for one hour, and
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95 °C for ten minutes. Confirmation of adequate cDNA was confirmed by PCR for
cytochrome B.
2.13 Standard PCR
Specific primers were designed using the primer 3 web-based software
(http://frodo.wi.init.edu/cgi-bin/primer3/priincr3 www.cgi). MgCl2, Taq polymerase,
dNTPs and Taq buffer were obtained from Promega. A reaction mix was prepared
containing: MgCl2, lxPCR buffer, ImM dNTPs, lpM each of the forward and
reverse primers, lpl cDNA, DNAse free water and 0.2pl Taq polymerase, to a total
reaction volume of 25pl. The concentrations of primers and MgCb were optimised
for each set of primers. The thermocycler programme was also optimised for
particular reactions.
Following the termination of the thermocycler programme, the PCR products were
analysed by electrophoresis on either an acrylamide or agarose gel, depending on
requirements. Agarose gels were cast in horizontal gel tanks (Owl Scientific,
Woburn, USA). Gel mixtures of 0.8 to 4% agarose were used depending on the size
on the product to be run. The agarose was dissolved in lxTAE buffer and
microwaved to dissolve fully. Once set, the gel was bathed in lxTAE, lOpl of each
sample was mixed with 2pl of loading dye (Promega) and added to the wells. The gel
was then run at 80V for 30 minutes. A variety ofDNA ladders were run alongside
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the experimental samples (25bp, PCR markers and lkb markers, all from Promega)
to allow assessment of product size.
If greater resolution was required, acrylamide gels were used. These were cast in the
Miniprotean III system (BioRad), and gels of 10 to 20% were used as required.
These contained and were run in 1 xTBE buffer. Samples and ladders were prepared
as above. lObp ladders (Invitrogen) were used when required. Gels were stained in
ethidium bromide after running, and visualised by UV transillumination on a Gel
Doc 2000 (BioRad).
2.14 Real Time PCR
Real time PCR was performed using the FRET (fluorescence resonance energy
transfer) based Taqman system (Applied Biosystems). Specific primers and probes
for each target were designed using Primer Express software version 1.0 (PE
Biosystems). Oligonucleotides were then purchased from Applied Biosystems.
Probes were labelled with a 5'-FAM reporter and a quencher. Sequences are listed in
Appendix B. 18S was used as an internal control and its probe labelled with 5'-VIC
and 3'-TAMRA. 2.5pl cDNA was mixed with lOOnM primers and probe, and
TaqMan Universal PCR Master Mix (Applied Biosystems) to obtain a 25pi reaction.
Real Time PCR was performed in 96 well plates with optical caps (Applied
Biosystems) and run on an ABI PRISM 7700 real time thermocycler (PE
Biosystems). All reactions were performed in duplicate. Serial dilutions of a stock
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cDNA from control hepatocytes and negative controls with no template were used to
obtain a standard curve, obtained by plotting the dilution factor against the Ct values.
Samples generating FAM Ct levels of greater than 36 or VIC Ct levels of greater
than 23 were discarded as inaccurate. Relative quantity values were generated as fold
difference with respect to the standard curve. Results are expressed as fold difference
with respect to matched untreated controls, and corrected for the 18S internal
controls. Data analysis was performed using Microsoft Excel.
2.15 Transfections
Transient transfections were performed using Fugene reagent (Roche) as per the
manufacturer's instructions, at a ratio of 6pl fugene/pg plasmid DNA. HUH7 cells
were plated at 4xl05 cells per 35mm dish, and transfected the day after plating. The
standard protocol cultured the cells in 2mls ofmedium. 6pl of Fugene reagent was
added to lOOpl of antibiotic free medium and incubated at room temperature for 15
minutes. 1 pg of plasmid DNA was then added and incubated for 15 minutes. The
mix was then added to the cell culture dishes. All reporter transfections were dual
transfections with an appropriate reporter as a control. As a result, the reaction
contained 0.5pg of each plasmid. The (3-galactosidase/Hsp70 reporter construct was
a kind gift from WJ Welch (UCSF, USA). The pHOGL3/l 1.6 reporter construct
containing 11,6kb of the human HO-1 promoter was a kind gift from Dr Agarwal,
(University of Alabama, USA). The HIF-la was a kind gift from Professor Esumi
(National Cancer Center, Kashiwa, Chiba, Japan) through Dr Dulak (Jagiellonian
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University, Krakow, Poland) PSV-pGalactosidase or pGL3-Control vectors
(Promega) were co-transfected with the reporter constructs, to control for
transfection efficiency. The cells were treated the following day and the p-
galactosidase or luciferase activity assayed using a proprietary kit as per the
manufacturer's instructions, following cell lysis in Reporter Lysis Buffer (Promega).
Results were calculated as units of luciferase activity per units of P-Galactosidase
activity for pHOGL3/l 1.6 and PSV transfection and vice versa for the Hsp70/pGal
and pGL3-Control combination.
2.16 Heme Oxygenase Activity Assay
Heme oxygenase activity was determined using a modification of previously
published methods (Tenhunen 1968 and 1972, Motterlini 1996, Cuturi 1999), and
development of the assay within this laboratory is discussed in appendix A.
Following the required treatment, the medium was aspirated from the cells and then
the cells were washed once with DPBS. This was then removed, and a small volume
of buffer G (lOOmM potassium phosphate, 2mM MgCH, pH 7.4) added. Cells were
then harvested by scraping gently with a cell scraper. The suspended cells were
collected, and the dish washed with a further small volume of buffer G, which was
also collected. The cells were pelleted by centrifugation at 2,000g for two minutes at
4°C and then resuspended in 220pl Buffer G and subjected to three cycles of freeze
thawing. A protein assay was then performed as described above to calculate the
concentration of protein in the sample. As a source of biliverdin reductase, human
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liver cytosol was obtained by homogenising samples of liver in buffer H (0.1M
sodium citrate, 10% glycerol, pH 5), and collecting the supernatant following
centrifugation at 105,000g for 30 minutes. A 400pl reaction mixture was then
created, containing: 500pg of cell protein; 1.5mg liver cytosol; 0.8mM NADPH;
2mM glucose; 6 phosphate; 0.2 units glucose 6 phosphate dehydrogenase; and 20pM
hemin. The volume was made up to 400pl in buffer G. The mixture was then
incubated in the dark at 37°C for one hour. The reaction was terminated by adding
400pl of chloroform and vortexing for 20 seconds, followed by centrifugation at
10,000g for one minute. The chloroform phase was then collected, and the bilirubin
content measured by spectrophotometry, using the difference in absorption at 464
and 530nm, and an absorption coefficient of 40mM"1cm"1. Results were expressed as
pmoles of bilirubin formed per mg protein per hour.
2.17 DNA Mobility Shift Assay
DNA mobility shift assays (EMSAs) were performed using two different methods -
either digoxigenin or y-32P labelled probes. Digoxigenin labelled EMSAs were
performed using a proprietary kit (DIG Gel Shift Kit, Roche) as per the
manufacturer's instructions. Radioactive EMSAs were performed as previously
published (Patel 2004). Oligonucleotides containing the desired consensus binding
site were purchased from a commercial company (TAGN, Newcastle, UK. see
appendix B for sequences). The single stranded oligonucleotides were annealed by
placing lng of each strand in a volume of 10pl of 0.2M NaCl, and heating to 95°C
84
for 3 minutes, then allowing it to cool to room temperature. Briefly, the double
stranded probe was labelled with y- P ATP and purified on Sephadex G-25
(Pharmacia, UK) spin chromatography columns. Nuclear protein extracts were
incubated in a reaction mixture with 1 pi y-32P-labelled probe at 20°C for 15 minutes.
Specificity of binding was ascertained by co-incubating samples with unlabelled wild
type or mutant probe or an anti-HSF-1 antibody (StressGen). Protein-nucleic acid
complexes were resolved using a 5% non-denaturing acrylamide gel run in 5mM
Tris, pH 8.3 for 3 hours at 200V. Gels were transferred to blotting paper, dried under
a vacuum at 80°C for 1 hour and exposed to radiographic film at -70°C with an
intensifying screen.
2.18 Glutaraldehyde Crosslinking
Following treatment, nuclear and cytoplasmic cell extracts were obtained as
described above. 20pg of protein was incubated with equivalent volumes of either
distilled water or glutaraldehyde in 3 different doses (0, 0.02, 0.2 and ImM
respectively) for 15 minutes. The reaction was stopped by adding lysine and then the
samples were boiled at 95°C for 5mins. Loading buffer was added and the samples
run on a 5% polyacrylamide gel and probed for HSF-1.
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2.19 Measurement of Reactive Oxygen Species
ROS generation was measured using two methods - H2DCFDA and
dihydroethidium. Both of these dyes fluoresce following exposure to ROS.
H2DCFDA is more sensitive for hydrogen peroxide and hydroxyl radicals, whilst
dihydroethidium is more sensitive for superoxide, although neither is species specific
(Lee 1998, Zhang 2001, Zhao 2003). For the H2DCFDA, cells were plated in 96 well
plates at a density of 2x 104 cells per well and left overnight. The next day the cells
were washed three times with HBSS and then treated as required, in the presence of
H2DCFDA at a final concentration of 1OpM. The plate was placed in a preheated
fluorimeter (at 37°C) and continuous measurement performed for 1 hour, at
excitation 480nm and emission 530nm. Following this, the supernatant was removed
and a protein assay was performed on the cells. The plate was snap frozen, and the
protein retrieved by applying hot (95°C) Laemmli buffer. The protein concentration
was measured using a proprietary kit (BioRad). The final results were corrected for
variations in the protein concentration between wells and were expressed as a
percentage with activity in untreated cells being 100%. Dihydroethidium was used
with cells prepared as above. The required treatments were applied in the presence of
1 OOpM dihydroethidium (final concentration). The cells were then placed back into
normal conditions for 4 hours. The wells were washed 3 times with FIBSS and
ethidium fluorescence was measured with an excitation of 480nm and an emission of
560nm. Protein was retrieved from the wells as above, and assayed, allowing the
final results to be corrected for protein concentration. The results were expressed as a
percentage as above.
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2.20 Mitochondrial Membrane Potential - DiOC6
The mitochondrial membrane potential was measured by two different techniques -
3,3'-dihexyloxacarbocyanine (DiOC6) and MitoTracker Green and Red. For the
DiOC6, HUH7 cells were treated with the required dose of curcumin or vehicle for
one hour, then trypsinised as described above, washed three times in PBS and
resuspended in LP3 tubes in PBS at 106 cells/ml. They were then incubated in
DiOC6 (50nM final concentration) for 15 minutes at room temperature. Propidium
iodide (5pg/ml final concentration) was added and the cells were read immediately
on an Epics XL-MCL flow cytometer (Coulter).
2.21 Mitochondrial Membrane Potential - MitoTracker
Green/MitoTracker Red
The DiOC6 method does not allow for variations in total mitochondrial mass. For
this reason, a normalised mitochondrial membrane potential was measured using
MitoTracker Green and MitoTracker Red. Cells were treated with the required dose
of curcumin or vehicle for 1 hour, trypsinised, washed three times in PBS and then
resuspended in LP3 tubes in PBS at 106 cells/ml. The 2 MitoTracker dyes were
added at a final concentration of lOOnM each, and the cells incubated at 37°C in the
dark for 30 minutes. The cells were then placed on ice and read immediately on the
flow cytometer. The ratio of red:green fluorescence represents the normalised
mitochondrial membrane potential.
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2.22 Measurement of Caspase Activity
Caspase activity was measured following curcumin treatment using the Apo-One
Homogenous Caspase 3/7 Assay (Promega). This is a fluorometric method, and was
performed using the manufacturer's protocol. The cells to be tested were cultured
and treated as required in 96 well plates in standard conditions. Following the
requisite treatment, the plate was removed from the incubator and a 1:1 ratio ofApo-
One reagent was added to each well. This was mixed on a plate shaker for 30
seconds, and then the plate was incubated at room temperature for 4 hours prior to
the fluorescence being read at an excitation wavelength of 485nm and an emission
wavelength of 530nm. Blank and untreated control wells were performed on each
occasion. 6 wells were included in each treatment group to allow statistical
comparison.
2.23 siRNA Mediated Inhibition of Gene Expression
An siRNA method was used to inhibit the expression ofNrf2 and HIF-la, using
sequences and reagents from Santa Cruz. The original manufacturer's protocol was
followed. A new protocol has since been published, but it was the original method
that was used for all of these experiments. 2x 105 HUH7 cells were plated into 6well
plates, in 2mls of antibiotic free medium (with 10% FCS) and cultured for 24 hours.
For each well to be transfected, 6ql of siRNA was added to lOOpl of Transfection
medium and incubated at room temperature for 5 minutes (part A). 6pl of
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Transfection Reagent was added to 24.2pl of Transfection medium ad incubated for
5 minutes at room temperature (part B). Parts A and B were then mixed together and
incubated at room temperature for 20 minutes. The cells were changed to fresh
antibiotic free medium, with 1ml per well. 130pl of the siRNA mix was then added
to each well. The cells were then cultured for 24 hours prior to experimentation.
Controls without any siRNA, and with a control siRNA sequence were used on each
occasion.
2.24 Phosphatase Activity
Phosphatase activity was measured using two proprietary kits - the Tyrosine
Phosphatase Assay System and the Serine/Threonine Phosphatase Assay System,
both from Promega. This is a non-radioactive molybdate-dye based kit which
measures freed phosphate generated from a substrate peptide as an index of
phosphatase activity. The cells were treated with curcumin for the required time.
Subsequently, they were placed on ice, the supernatant removed, and the cells
scraped in Phosphatase Storage Buffer (PSB), then passed through a 21G needle. The
samples were centrifuged at 100,000g at 4°C for one hour. During this time the spin
columns were prepared by washing with de-ionised water, and then loading with
Sephadex G-25 (initially stored in Sephadex Storage Buffer) and washing with cold
PSB. The columns were allowed to drain by gravity, then centrifuged at 600g for 5
minutes at 4°C to remove the remaining buffer. 250pl of the previously centrifuged
supernatant is then placed on the column and centrifuged at 600g for 5 minutes at
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4°C. The sample lysate is then collected from below the column and a protein assay
performed as described above.
Phosphate standards are made from 0 to 2000pmol, by diluting the supplied standard
(ImM KH2PO4) in phosphate free water, and a standard curve was generated by
adding molybdate dye solution and proceeding as below. Assays were run in the
supplied 96 well plates. The reaction conditions were slightly different for each of
the phosphatases studied, and were varied by using slightly different buffer
composition as detailed in the buffers section. The phosphopeptide used was
END(pY)INASL for tyrosine phosphatase activity and RRA(pT)VA for
serine/threonine activity. Premixed solutions containing 10jE phosphatase 5x
reaction buffer, 5pi ImM phosphopeptide and 25pl ofwater were pippetted into each
well. The plate was warmed to 37°C for 5 minutes. Reactions were commenced with
the addition of the samples, containing 5pg of protein in 1 OjlxI (final reaction volume
50pl), and the plate was incubated at 37°C for 30 minutes. The reaction was
terminated by the addition of 50pl molybdate dye solution and the colour was
developed for 30 minutes at room temperature prior to being read at 630nm on a
plate reader. All samples were run in duplicate. The amount of phosphate released
was then calculated from the standard curve.
90
2.25 Enzyme Linked Immunosorbent Assays for Acute Phase
Proteins
ELISAs were performed for CRP, transferrin and fibrinogen. A standardised protocol
from DAKO was used for all assays, utilising a sandwich technique. 96 well plates
(Corning) were coated with a specific antibody by diluting the antibody in coating
buffer at lOOpl per well, and incubating it overnight at 4°C. The following morning
the coating buffer was removed and the wells washed three times with wash buffer
using an automated plate washer machine (Skan Washer 300, Skatron Instruments).
A standard curve was prepared using commercially available standards diluted in
wash buffer. In addition to the standards, wash buffer was used as a blank and
medium containing 10% FCS was used as a further control. Supernatants were
prepared for addition to the plate. Those from cell lines were used neat, whilst those
from cultures of primary hepatocytes were diluted 1 in 5 in wash buffer. 1 OOpl of test
sample or standard was added to each well, and all samples were assayed in
duplicate. Quality controls of a known concentration were placed on the plate near
the beginning and end to provide assessment of intra-assay variability. The plate was
then incubated at room temperature for two hours. Subsequently, the plate was
washed as above, and lOOpl of an HRP conjugated primary antibody (different to the
coating antibody) was added and the plate incubated for one hour at room
temperature.
The plate was then washed again and lOOpl of chromogenic substrate (DAKO OPD
tablets, diluted as per the manufacturer's instructions) was added to each well. The
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plate was covered, and placed in the dark at room temperature to develop for fifteen
minutes. Subsequently the development was stopped by adding lOOpl of 0.5M
sulphuric acid to each well. The results were then read using a Dynatech plate reader
(Dynex MRX II, Dynatech) on a 490nm filter (reference filter 630nm). A standard
curve was obtained from the plate reader, using a semilog fit for the known
standards. This was then used to calculate the concentrations of the assayed samples.
2.26 Cytochrome p450 Assays
Cytochrome p450 activity in primary cultures of human hepatocytes following HO-1
induction was measured using a luminescent kit from Promega - the P450-Glo Assay
System. The assay was performed according to the manufacturer's protocol. Three
different isoforms were tested - 1A2, 2C9, and 3A4. These all require slightly
different conditions and buffers. The optimal conditions for each isoform are detailed
in appendix B. The general protocol follows. 12.5pl of 4x substrate reaction mix and
12.5pl of cell lysate was added to each well of a 96 well plate. 25pl of 2x NADPH
generating system was added, and the reaction was incubated as required. 50jul of
luciferin detection reagent was then added, the reaction was incubated at room
temperature for 20 minutes and the plate was read in a luminometer. The amount of
protein in each cell lysate was measured using the protein assay described earlier,
and the results were corrected for the amount of protein, and then expressed as a
percentage of untreated controls.
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2.27 Urea Assay
Measurement of urea production was performed using an adaptation of a
commercially available Urea Nitrogen Kit (Sigma), modified to allow analysis in 96
well plates. Cell culture supernatants were used for analysis, and all samples were
performed in triplicate. 25pl of sample was placed in each well, and 50pl of urease
solution was added, and the plate incubated at 37°C for one hour. Subsequently, 25pi
each of phenol nitroprusside and alkaline hypochlorite solution were added to each
well, in addition to 125pl of distilled water. The plate was briefly agitated and
incubated at room temperature for thirty minutes before being read at 630nm on a
plate reader. To allow quantitative analysis and comparison of results between plates,
a standard curve assayed on each plate, using a urea standard diluted to provide a 0 to
500pM range.
2.28 ATP Assay
ATP levels in hepatocytes following treatment was performed using the ATP Assay
Kit from Calbiochem (catalogue number 119107) in accordance with the
manufacturer's instructions. This method uses luciferin and luciferase, and the
amount of luminescence generated indicates the amount ofATP present within the
sample. The medium was removed from the treated cells (20,000 per well in 96 well
plates), which were then treated with 80pl Nucleotide Releasing Reagent (NRR) for
5 minutes with shaking at room temperature. 20pi of further NRR containing 1 pi of
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ATP monitoring enzyme was then added and the sample was read immediately in a
luminometer as described for the luciferase reporter assay. Negative controls
containing no cells and untreated controls were assayed on all runs.
2.29 Data Analysis
All values are expressed as means +/- standard error (SEM). SPSS software was used
for statistical analysis (SPSS, IL, USA). Excel (Microsoft) software was used for
simple descriptive statistics. The majority of data was non-parametric, and so
Wilcoxon's Sum Rank test was used for statistical analysis. The differences between
groups were considered to be significant at P<0.05.
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Chapter 3
Curcumin and the Stress Response
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3.1 Introduction
Curcumin has been shown in previous studies to induce several stress proteins. The
aim of this chapter was to explore the pattern of stress protein induction by curcumin
in human hepatocytes.
Curcumin is a derivative from the root of the plant Curcuma longa, and is the major
constituent of the spice turmeric. It has a wide variety of biological effects and has
long been used in Chinese and Indian medicine for its medicinal properties, which
are predominantly anti-inflammatory in nature (Ammon 1991). It is for this reason,
with the pressure to. develop new therapies for medical use, that there has been a
significant interest in the mechanisms through which curcumin may work to exert its
effects.
At a cellular level, curcumin has been shown to have a variety of effects on the
expression of stress proteins. It has been shown to induce Hsp70 in HeLa cells
(Dunsmore 2001), through activation ofHSF-1. It can also induce HO-1 (Motterlini
2000). Curcumin has also been described as having a potentiating effect on cells
undergoing stress, enabling higher expression of heat shock proteins such as Hsp70
and Hsp27 in response to a set stimulus (Kato 1998). The effect of curcumin on
human hepatocytes has not previously been examined.




The pattern of stress protein expression was studied using the methods described in
chapter 2, with mRNA and protein levels and reporter activity used as outcomes.
These studies necessitated preliminary dose toxicity and vehicle experiments.
3.2.1 Choice of vehicle
Curcumin is highly lipophilic and was found to be virtually insoluble in water or cell
culture medium. It was found to be soluble in both ethanol and dimethylsulfoxide
(DMSO) at maximum concentrations of 10 and lOOmM respectively. Initial
experiments suggested that the use ofDMSO would minimise the contributing effect
of any vehicle to stress protein induction, as ethanol was found to mildly induce
Hsp70 in the required dose range. The highest concentration used was lOOpM, which
resulted in a 1% (v/v) concentration of ethanol. Thus DMSO was used for all
subsequent experiments with curcumin.
3.2.2 Stress protein expression
The pattern of heat shock protein expression in response to curcumin treatment was
examined in HUH7 cells. Initial experiments were guided from the literature, and
doses ranging from 100pM to InM were used. Cells were treated with curcumin and
western blots were run for Hsp70 initially as a protein that was expected to be
induced. There was no response in Hsp70 in the range tested, despite the dose
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response being repeated using a variety of treatment durations. Subsequent western
blots were performed for other Hsps including HO-1 which was found to be induced
at lOpM. Having identified an approximate target dose, all subsequent experiments
were performed using a dose range from 1 to 50pM.
Maximal induction ofHO-1 was confirmed to be after treatment with 10-25pM
curcumin (figure 3.1). Time course experiments revealed that induction ofHO-1
occurred after treatment of between 4 and 12 hours (figure 3.2). Induction ofHO-1
occurred at 6 hours after initial exposure to curcumin, even if the treatment had only
lasted one hour. Further western blots performed on cells treated with curcumin at
the above doses and times demonstrated that there was no induction of Hsp70, BiP
(Grp78), Grp94, Hsp90, or Hsp27 (figure 3.1). Identical results were found when the
above experiments were repeated in primary cultures of isolated human hepatocytes.
3.2.3 Localisation of HO-1 within the liver
Fresh slices of human liver were cultured as described in chapter 2, in the presence
of lOpM curcumin or controls for 6 hours. These were then fixed in formalin, slides
cut and immunohistochemistry performed for HO-1 as described. There was evident
concentration ofHO-1 expression within Kupffer cells in untreated liver, with a low
basal level ofHO-1 expressed in hepatocytes. The localisation of HO-1 in Kupffer
cells was unchanged following curcumin treatment, and there was increased staining
in the hepatocytes, consistent with the western blot results in isolated hepatocytes.







Curcumin(pM) 1 10 25 50
Vehicle 1 10 25 50
Figure 3.1 Curcumin induces HO-1 but not Hsp70 in HUH7 cells.
Western blot of whole cell lysates from cells treated with curcumin for 8 hours run in
parallel with matched vehicle controls as indicated. HO-1 was induced after
treatment with 10 and 25pM curcumin compared with vehicle and nil controls. No
other consistent increases were seen. Grp 94 and Hsp27 were reduced after 50pM
curcumin, reflecting toxicity at this dose. Blots shown are representative of three
separate repeats. Results shown are from two different membranes a and b. Both
actin loading controls are shown and the corresponding membranes indicated
adjacent to each strip.
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Figure 3.2 Curcumin induces HO-1 in a time dependent manner.
HUH7 cells were treated with lOpM curcumin for increasing periods of time up to 36
hours and HO-1 expression measured by western blot. Maximal induction ofHO-1


















Figure 3.3 Immunohistochemistry for HO-1 in Cultured Liver Slices.
A. Treatment withlOuM curcumin for 6 hours. B. Equivalent DMSO for 6 hours.
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3.2.4 Curcumin demonstrates dose dependent toxicity
HUH7 cells and isolated human hepatocytes were treated with curcumin or matched
vehicle controls for 24 hours, in doses ranging from 1 to lOOpM curcumin. Survival
was then assessed by MTT. Both cell types responded in a similar manner, with
doses of lOOpM being uniformly toxic and doses of 10p,M being well tolerated with
viability virtually 100% of controls. There was a clear relationship of dose to toxicity
in treatments between 10 and lOOpM (figure 3.4).
HUH7 cells were treated with increasing doses of curcumin and the degree of
caspase 3/7 activity was measured. Caspase activity was increased after treatment
with curcumin at 50pM or greater (p<0.05, figure 3.5). A similar induction of
caspase activity was seen whether it was measured after 6 or 24 hours of curcumin
treatment.
3.2.5 Confirmation of HO-1 induction
Initial results with western blotting had demonstrated that HO-1 protein was induced
by lOpM curcumin. In order to confirm this induction was the result of de novo
synthesis and led to an increase in functional enzymatic activity of HO-1, further
experiments were performed to measure HO-1 promoter activity using a human HO-
1 reporter, measure changes in mRNA levels, and assess heme oxygenase activity
after 8 hours of treatment with 1 OpM curcumin.
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B
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Curcumin (uM) 0 1 10 25 50 75 100
Figure 3.4 Curcumin demonstrates dose dependent toxicity.
MTT assay demonstrating dose dependent curcumin mediated toxicity.
A. HUH7 cells. B. Primary human hepatocytes. Cells were treated for 24 hours,
before cell viability was assessed. Data are expressed as a percentage of the medium
control, and represent the mean ± SEM of 6 wells. *p<0.01.
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Figure 3.5 Curcumin treatment activates caspase 3/7.
HUH7 cells were treated with curcumin for 6 or 24 hours (panels A and B
respectively) and caspase 3/7 activity measured. Caspase activity was increased at
doses of 50 pM and above (f = p<0.05 vs nil control). Each bar represents the mean
± SEM of six repeats from one experiment. Each experiment was performed 3 times
with similar results.
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HO-1 reporter activity was assessed in HUH7 cells. Activity was significantly
increased with curcumin treatment (10pM for 8 hours) with a mean induction of 1.75
fold greater than controls (*p<0.01, figure 3.6). Vehicle had no effect on reporter
activity.
HO-1 mRNA was measured using real time PCR which was performed on both
HUH7 cells and on isolated human hepatocytes. HO-1 mRNA levels were
significantly increased by curcumin treatment in both cell types (f=p<0.05, figure
3.7). The results obtained in HUH7 cells were very consistent, with a mean induction
of 535% of control cells. Whilst HO-1 mRNA was always increased by curcumin
treatment, there was much greater variability in the results obtained with isolated
hepatocytes, with a range of induction from 2 to 2000 fold, and a median induction
of 6.5 fold over untreated controls.
Heme oxygenase activity was measured in HUH7 cells following curcumin
treatment. Total HO activity was increased approximately 2.5 fold from 171 to 455
pmoles bilirubin/mg protein/hour (*p<0.01, figure 3.8). Vehicle had no significant
effect, lowering the activity slightly to 148 pmoles bilirubin/mg protein/hour.
In order to assess the effectiveness of curcumin in inducing HO-1, it was compared
with the HO-1 inducing ability of equimolar amounts of the classical HO-1 inducer
hemin. It was found that curcumin induced HO-1 to a similar degree and that there
was no evidence of synergy between the two inducers when given together (figure
3.9).
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Figure 3.6 Curcumin treatment increases HO-1 reporter activity.
HUH7 cells were co-transfected with a human HO-1 reporter and a control vector.
HO-1 activity was elevated following treatment with 1 OpM curcumin for 5 hours.













Figure 3.7 Curcumin increases HO-1 mRNA levels in human hepatocytes.
A. HUH7 cells. B. Primary human hepatocytes. Cells of each type were treated with
lOpM curcumin for 5 hours and mRNA levels measured using Real Time PCR. Data
shown represent mean ± SEM of 6 independent repeats. fp<0.05. DMSO vehicle
control.
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Figure 3.8 Curcumin increases HO-1 activity.
HUH7 cells were treated with lOpM curcumin for 6 hours and then HO-1 enzymatic
activity was measured. Curcumin significantly increased HO-1 activity (*p<0.01)
from 171 to 415 pmoles bilirubin/mg protein/hour. Results shown are the mean ±
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Figure 3.9 Curcumin is as effective as hemin as an inducer of HO-1.
A. Western blot of whole cell lysates from cells treated with hemin and curcumin
(10pM) showing that the addition of hemin does not increase HO-1 levels beyond
that attained by curcumin alone. B. Quantitation by densitometric scanning of the
bands. The results shown represent the means +/- S.E.M. of three independent
experiments.
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3.2.6 Confirmation of lack of Hsp70 induction
The western blotting results showing that curcumin did not induce Hsp70 were
surprising and ran contrary to expectations based on the published literature
(Dunsmore 2001, Chen 2001). In view of this, confirmation was sought using a
reporter for the human Hsp70 promoter, and mRNA levels were measured with real
time PCR.
HUH7 cells transfected with the Hsp70 reporter were treated with 10pM curcumin or
vehicle for 8 hours. Curcumin and DMSO were both found to reduce the activity of
the reporter significantly to 15 and 22% of untreated controls respectively (*p<0.01
vs untreated control, figure 3.10).
Hps70 mRNA levels were measured in HUH7 cells and in primary human
hepatocytes treated with 10pM curcumin. There was a modest 2.5 fold induction of
Hsp70 mRNA in HUH7 cells (f=p<0.05, figure 3.11), whilst vehicle had no effect.
In primary cultures, there was induction of the Hsp70 mRNA levels to 38 fold
greater than untreated controls. As seen in the HO-1 mRNA results, this was skewed
by one large induction of Hsp70, although the median induction was 16 fold, with a
range of 7 to 113 fold greater than untreated controls. The DMSO vehicle also had a
modest effect and induced Hsp70 mRNA 4 fold (not significant). For comparison,
Hsp70 mRNA was measured in response to heat shock (43°C for 45 minutes), and
was found to rise dramatically with a median induction of 20 fold in HUH7 cells and
900 fold in primary human hepatocytes.
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Figure 3.10 Curcumin does not induce Hsp70 reporter activity.
HUH7 cells were co-transfected with a human Hsp70 reporter and a control vector.
Reporter activity was measured after 5 hours of treatment with 1 Op curcumin or
equivalent vehicle control (DMSO). Both led to a reduction in reporter activity
(*p<0.01 vs nil control). There was no significant difference between treatment with
curcumin and its vehicle. Data represent the mean ± SEM of 6 repeats.
Ill
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Figure 3.11 Curcumin increases Hsp70 mRNA levels in human hepatocytes.
A. HUH7 cells. B. Primary human hepatocytes. Both cell types were treated with
lOpM curcumin or equivalent vehicle (DMSO) for 5 hours and Hsp70 mRNA levels
measured by Real Time PCR. Curcumin significantly increased Hsp70 mRNA levels
in both cell types (fp<0.05). Data shown represent the mean ± SEM of 6 repeats.
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In light of the contradictory findings of the Hsp70 reporter and mRNA measurement,
the level ofHsp70 mRNA was explored in more detail using HUH7 cells. A time
course ofHsp70 mRNA following curcumin or heat shock treatment was performed,
and it was demonstrated that the rise in Hsp70 mRNA with curcumin treatment was
very modest in comparison to that seen with heat shock (figure 3.12A). However,
this was still not consistent with the apparent lack of reporter activity. Hsp70 mRNA
levels can be increased by post transcription means, and so the effect of curcumin on
Hsp70 mRNA levels was assessed during treatment with the transcriptional inhibitor
actinomycin D (figure 3.12B). There was a rapid reduction in the level ofHsp70
mRNA following treatment with actinomycin D to 11% of control levels in cells that
received no treatment. This drop was prevented by treatment with lOpM curcumin,
which resulted in a maintenance ofHsp70 mRNA at approximately 100% for 3
hours, although this dropped to 43% after 5 hours of treatment. Consistent with
known post transcriptional mechanisms, heat shock was able to increase Hsp70
mRNA levels even in the presence of actinomycin D, which was sustained for
several hours before decaying. This experiment was performed twice with similar









Figure 3.12 A. Heat shock strongly induces Hsp70 mRNA.
Time course of Hsp70 mRNA induction following heat shock (43°C for 45 mins) or
curcumin treatment (10pM). Curcumin led to a very modest induction ofHsp70 in
comparison with the large (>300 fold) increase seen with heat shock.
B. Hsp70 Curcumin stabilises Hsp70 mRNA levels. HUH7 cells were treated with
curcumin or vehicle (DMSO) or heat shock (HS, 43°C for 45 mins) in the presence
of actinomycin D (5pg/ml). Curcumin treatment delayed the decline in HSp70 levels
seen in control and vehicle treated cells.
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3.3 Discussion
Curcumin has been described in the literature as a potent inducer ofHO-1 and Hsp70
(Motterlini 2000, Dunsmore 2001) although this ability had not previously been
examined in human liver cells. The intention of this work was to ascertain whether
curcumin was able to induce this response in human hepatocytes. Curcumin induces
HO-1 in bovine endothelial cells and in renal epithelial cells (Motterlini 2000,
Balogun 2003). However, the human HO-1 promoter differs significantly to that of
other species, and certain stimuli which induce HO-1 in rodent cells either repress
HO-1 or have no effect in human cells (Sikorski 2004). For this reason it could not
be assumed that curcumin would induce HO-1 in human hepatocytes, and this
required evaluation. The induction ofHO-1 was confirmed by human hepatocytes,
both in the HUH7 cell line and in primary cultures of isolated human hepatocytes.
There was a consistent induction in all lines of investigation which resulted in a clear
increase in functional activity.
In contrast, there was no identifiable elevation in Hsp70 levels with curcumin
treatment. There are several potential reasons for this result. Hsp70 induction is one
of the cell's responses to injury, and previous reports ofHsp70 induction by
curcumin have been associated with impairment of cell survival. Curcumin was
found to be toxic when administered in doses greater than 25pM. As discussed in the
introduction (see section 1.6.1.2), curcumin has been found to have either pro-
oxidant or anti-oxidant properties, dependent upon cell type and conditions (Piwocka
2001, Khar 2001, Ghoneim 2002, Woo 2003, Ligeret 2004). It is likely that the toxic
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profile demonstrated here reflects its pro-oxidant properties in inducing reactive
oxygen species generation (chapter 5). The results are consistent with the toxicity
seen in other groups work (Dunsmore 2001). However, even when administered at
toxic doses, there was still no rise in Hsp70 protein. This may be because the
mechanism of curcumin- induced toxicity in our cells does not permit the induction
ofHsp70. It has been established that curcumin has different effects in different cell
lines, and that some do not respond by producing Hsp70. Indeed, Khar found that
those cells most sensitive to the pro-apoptotic effects of high dose curcumin
produced no Hsp70 response (Khar 2001). It is likely that this was the case in the
HUH7 cells.
The mechanism of cell death which curcumin triggers has been a matter of debate,
with conflicting reports being published regarding caspase activation and a classical
mitochondrial pathway, and non-classical pathways in different cell types (Anto
2002, Piwocka 1999). In HUH7 cells there was clear induction of caspase 3/7
activity consistent with findings in hepatocyte, renal and leukaemia cell lines
(Gomez-Lechon 2002, Woo 2003, Anto 2002). Caspase 3 is the common end-
mechanism through which caspase dependent apoptosis occurs. However, this was
the only method used to assess the mechanism of cell death in relation to curcumin
toxicity, and as such, it cannot be confirmed that definite apoptosis of the cells
occurred, only that there was an increase in caspase activity which is consistent with
apoptosis. It is traditionally thought that apoptosis and necrosis are distinct pathways
to cell death, however, Jaeschke has described an indeterminate mechanism termed
necrapoptosis, the occurrence ofwhich is dependent on the energy state of the cell
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(Jaeschke 2003). It is possible that this is the mechanism of cell death in some of the
curcumin studies where caspase activation has not been found to occur. Indeed, the
finding of lower caspase activity in cells that were treated with curcumin for 24
hours may reflect necrosis or necrapoptosis.
Whilst Hsp70 protein was not elevated by curcumin treatment, there were conflicting
results regarding the Hsp70 reporter and mRNA levels. Reporter activity was
reduced, suggesting that there was a reduction in activity of the Hsp70 promoter.
However, mRNA levels were increased. The reporter used in this study is a
commercially available Hsp70 reporter containing 2.5kb of the human Hsp70B
promoter (Stressgen). It would be expected that this would be of sufficient length to
encompass most of the functional upstream units in the promoter, and it has been
used successfully by many groups (Cippitelli 2003, Suzuki 1998), although far
removed enhancer regions will not be included. It does contain the HSF-1 binding
motifwhich is central to the heat responsive character of the protein, and therefore if
curcumin were inducing HSF-1 activity, it would be expected to respond. The lack of
response is consistent with the lack ofHSF-1 activity following curcumin treatment
(chapter 4).
The reporter is P-galactosidase based and the method of detection may not be
sufficiently sensitive to monitor subtle changes in reporter activity. Even though
major induction seen in response to heat shock can be detected, the response to heat
is of a different magnitude, as demonstrated by the mRNA results. Thus minor
induction ofHsp70 promoter activity may be missed due to the assay conditions.
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However, even if there was a subtle induction ofHsp70 promoter activity resulting in
increased mRNA levels, it was insufficient to produce a demonstrable increase in
Hsp70 protein as measured by western blot.
Hsp70 mRNA levels were increased both in HUH7 cells and in primary cultures of
isolated hepatocytes. There was a marked difference in the level of induction seen in
the two cell types, and the primary cultures showed a wider spread of level of
induction. This is the result ofmany factors such as the differences between the
individuals from which the cells were isolated, in comparison to the controlled
environment of the HUH7 cells which would be expected to give more consistent
results. Indeed, the variability between hepatocyte preparations was also observed in
HO-1 mRNA levels.
Hsp70 mRNA levels were consistently elevated after curcumin treatment. The level
of induction was very low in comparison to that seen in response to heat shock. The
reason for this comparison was the suspicion that the level ofmRNA achieved may
not produce detectable increases in Hsp70 protein. Heat shock represents a standard
inducer which does produce detectable increases in Hsp70 protein. There is a great
redundancy in Hsp70 mRNA levels (Theodorakis 1987) and a modest induction of
Hsp70 mRNA may not result in an increase in translation and hence no change in
protein levels. Hsp70 mRNA also has many post transcriptional controls, and it can
be stabilised following physical or chemical stress (Theodorakis 1987, Kaarniranta
1998, Alfieri 2002). The results of the experiments with actinomycin D suggest that
curcumin may stabilise Hsp70 mRNA, and this stabilisation may be the reason for
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the increase in Hsp70 mRNA levels in the absence of increased promoter activity.
This experiment was performed twice, and so no statistical comparison can be made,
although the results were similar on both occasions.
3.4 Conclusion
The above experiments demonstrate that curcumin can readily induce HO-1 in
hepatocytes and that Hsp70 protein is not induced even after administration of toxic
doses of curcumin. However, curcumin did consistently increase Hsp70 mRNA
levels, and this remained incompletely explained. Hsp70 is induced by the
transcription factor heat shock factor 1 (HSF-1), which has been shown in other cell
lines to be activated by curcumin treatment (Dunsmore 2001). The human HO-1
promoter also contains an HSF-1 consensus binding site. This raised the question of
what effect curcumin treatment had on HSF-1.
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Chapter 4
Curcumin and Heat Shock Factor 1
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4.1 Introduction
Curcumin is reported in the literature to activate the transcription factor heat shock
factor 1 (HSF-1) (Dunsmore 2001, Chen 2001). In human hepatocytes curcumin was
found to induce HO-1 and increase Hsp70 mRNA levels (see chapter 3), both of
which could result from increased HSF-1 activity. The aim of this chapter was to
examine the effect of curcumin treatment on HSF-1 activation in human hepatocytes.
Heat shock factor 1 is the main transcription factor regulating the heat responsive
nature of heat shock proteins (Morimoto 1992). It has a complex structure and
activation process. In resting cells it exists in an inactive monomeric form in the
cytoplasm. Activation involves it migrating to the nucleus, and undergoing a
conformational change which allows homo-trimerisation and hyperphosphorylation.
It is the trimeric hyperphosphorylated form which is required for transcriptional
activation (Jurivich 1995).
This complex process can be examined at each stage and certain stimuli also can
cause potential activation (Jurivich 1995).




4.2.1 Nuclear localisation of HSF-1
Curcumin had been shown to increase Hsp70 in a dose dependent manner in HeLa
cells in the range of 10-30pM (Dunsmore 2001). In HUH7 cells there is a clear dose
dependent toxicity after treatment with doses over 25pM (chapter 3), and Hsp70
mRNA had been found to rise after treatment with 10pM curcumin. For this reason,
nuclear localisation ofHSF-1 was examined using doses ranging from 10 to 50pM.
Curcumin treatment for two hours led to nuclear localisation after treatment with
50pM (figure 4.1). There was no consistent, discernible effect on HSF-1 nuclear
localisation after treatment with doses of 10 and 25pM.
4.2.2 Activation of HSF-1
The profound nuclear localisation ofHSF-1 seen following treatment with 50pM
curcumin was likely to represent a toxic effect. In view of the desire to assess
curcumin as a therapeutic inducer of the stress response, further examination ofHSF-
1 proceeded using non-toxic doses. 10pM was chosen because an increase in Hsp70
mRNA was seen with treatment at this dose (chapter 3).
Nuclear HSF-1 was examined by non-denaturing gel electrophoresis to assess
whether it had trimerised. HUH7 cells were treated with 1 OpM curcumin for two
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Figure 4.1 Toxic levels of curcumin lead to nuclear localisation of HSF-1.
HUH7 cells were treated with curcumin 50pM or vehicle for 2 hours prior to lysis.
Other cells were treated solely with medium or exposed to heat shock (43°C for 45
mins). Nuclear and cytoplasmic extracts were obtained and western blotting was
performed for HSF-1. Nil, medium only; V, DMSO vehicle equivalent to curcumin
dose for 2 hours; C, curcumin 50pM for 2 hours; HS, heat shock. Actin was used as
a loading control for the cytoplasmic extracts, and lamin for the nuclear extracts.
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hours and native extracts obtained. The HSF-1 was found to have remained in the
inactive monomeric form distinct from the trimeric form induced by heat shock
(figure 4.2).
The monomeric form ofHSF-1 is capable of constitutive binding to a consensus heat
shock element sequence, and so this was assessed by gel mobility shift assay
(EMSA). HUH7 cells were treated with 1 OpM for increasing times up to two hours.
The curcumin treated extracts contained HSF-1 that bound to the consensus
sequence. However this was distinct from the transcriptionally active trimeric form
seen following heat shock (figure 4.3).
The final step in activation ofHSF-1 is hyperphosphorylation, which is a
requirement for transactivation. This was examined by relative electrophoretic
mobility following in vitro treatment of cell lysates with alkaline phosphatase. The
lysates were nuclear extracts from HUH7 cells which had been treated with 1 OpM
curcumin for two hours. Comparison ofHSF-1 from curcumin or heat shocked cells
revealed that curcumin does not induce the hyperphosphorylation of HSF-1 that is
seen with heat treatment. Curcumin treated cells show the same degree of
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Figure 4.2 Curcumin does not activate HSF-1 at non-toxic doses.
Cells were treated with 1OpM curcumin or equivalent DMSO and whole cell extracts
obtained and subjected to native gel electrophoresis alongside heat shocked and
medium only controls. 50pg of extract was run on a 3 to 20% gradient non-
denaturing gel, and blotted for HSF-1. Monomeric and trimeric forms ofHSF-1 are
indicated, as is the Hsp90/HSF-1 complex present in resting cells. Nil, medium only;
HS, heat shock; C, curcumin lOpM for 2 hours; V, Equivalent vehicle treatment
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Figure 4.3 Non-toxic curcumin treatment does not induce trimeric HSF-1 DNA
binding.
Cells were treated with lOpM curcumin for increasing amounts of time (0-120
minutes as indicated) and nuclear cell extracts were obtained. Gel mobility shift
assay was used to assess HSE binding activity. For comparison a heat shocked cell
lysate was run to demonstrate the active trimeric form ofHSF-1 (HS). Cold native
probe (Cld), antibody supershift (Shf) and cold mutant probe competition (Mut)
controls are indicated and were performed using a heat shocked cell lysate. CHBA,
constitutive HSE binding activity; Trimer, transcriptionally active trimeric form of
HSF-1; Supershift, supershifted trimer position.
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Phosphatase - + + - +
Control Curcumin Heat Shock
Figure 4.4 Non toxic curcumin treatment does not cause hyperphosphorylation
of HSF-1.
Whole cell lysates were collected from cells treated with curcumin lOpM for 2 hours
and from control and heat shocked cells. 20pg aliquots of each sample were treated
either with lambda phosphatase or with buffer (+/- respectively) for 15 minutes and
then run in parallel on a 7.5% gel and probed for HSF-1.
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4.2.3 Effect of HSF-1 inhibition on HO-1 induction by Curcumin
To demonstrate that HO-1 induction by curcumin does not depend on HSF-1,
experiments were performed using quercetin, an HSF-1 inhibitor. Quercetin was
found to inhibit the induction ofHsp70 by heat shock when administered at 50pM. In
contrast, the induction of HO-1 by curcumin was not reduced by quercetin treatment.
Indeed, quercetin itself induced HO-1 and the combination of quercetin and
curcumin had an additive effect on HO-1 induction (figure 4.5).
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HO-1 — — —
Heat Shock + +
Curcumin
Quercetin + +
Figure 4.5 Quercetin does not inhibit the induction of HO-1 by lOpM curcumin.
HUH7 cells were treated with 50pM quercetin for 1 hour prior to and during
curcumin exposure (curcumin 10pM or equivalent DMSO for two hours) or heat
shock (43°C for 45 mins). Subsequently the medium was changed and the cells were
recovered for 6 hours. Whole cell lysates were collected and then run on a 10% gel
and probed for HO-1 and Hsp70.
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4.3 Discussion
Initial experiments have shown that curcumin induced HO-1 and increased Hsp70
mRNA levels, both ofwhich could potentially result from HSF-1 activation. For this
reason, the effect of curcumin on HSF-1 in hepatocytes was examined. Curcumin
was found to induce nuclear localisation ofHSF-1 only after treatment with toxic
doses. This was consistent with published results in the literature regarding HSF-1
and curcumin. Dunsmore found increased nuclear localisation ofHSF-1 in HeLa
cells after treatment with 30pM curcumin (Dunsmore 2001), a dose which was
associated with significant toxicity.
In view of the finding that curcumin treatment at lOpM increased Hsp70 mRNA
levels (although not Hsp70 protein), the effects of curcumin on HSF-1 were
investigated in detail at this dose. This dose did not produce a detectable change in
nuclear localisation. However, it was desirable to confirm whether there were any
other changes in HSF-1 which may have resulted in transcriptionally active HSF-1.
Activation and acquisition of transcriptional activity by HSF-1 is a complex multi-
step process and some compounds such as salicylate can cause partial activation
(Sarge 1993, Jurivich 1995). For this reason, all of the activation steps were assessed.
However, in all methods used there was no evidence of changes in HSF-1, such as
trimerisation or hyperphosphorylation, that would permit transcriptional activation.
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Thus this does not explain the increase in Hsp70 mRNA levels. The increase could
result from the activation of other transcription factors, or it could be the result of
some kind of stabilisation event, as discussed in chapter 3.
The final experiments performed on HSF-1 examined whether curcumin
pretreatment had a priming effect on HSF-1, allowing it to be more readily activated
by other stimuli. This type of effect had been noted by other groups examining other
cells types, where HSF-1 activation by sodium arsenite was prolonged by curcumin
treatment (Kato 1998). No such priming effect was found in human hepatocytes. The
method used to assess this was western blotting for HSF-1, and examination of its
electrophoretic mobility. This is not a very sensitive method, and it may have been
difficult to identify minor differences between experimental groups.
The human HO-1 promoter contains an HSF-1 consensus binding sequence (Heat
Shock Element - HSE). In the rat this is active and HO-1 is a heat responsive
protein. However, in human the HSE appears to be at least silent and it may be
inhibitory (Okinaga 1996, Chou 2005). Quercetin was used to inhibit HSF-1, to
establish if the HO-1 induction by curcumin was HSF-1 dependent. Quercetin is a
weak partial agonist ofHSF-1 and does have effects on pathways other than HSF-1
(Davies 2000), but nevertheless it is a commonly used HSF-1 inhibitor. It was found
to have no inhibitory effect on HO-1 induction by curcumin, suggesting that this is
an HSF-1 independent effect. Furthermore, quercetin was found to increase HO-1
levels and to have an additive effect on HO-1 induction by curcumin. This would be
consistent with the observation that HSF-1 can have an inhibitory effect on HO-1
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expression in human cells (Chou 2005), such that inhibition ofHSF-1 should
increase HO-1 levels. Accordingly, heat shock was noted to reduce HO-1 protein
levels in this study.
4.4 Conclusion
Curcumin does activate HSF-1 after treatment with high doses and this is associated
with significant toxicity. However, there was no increase in the transactivating
potential of HSF-1 after treatment with 10pM curcumin. Thus the effect on HO-1
protein and Hsp70 mRNA is not the result of increased HSF-1 activity. As discussed
earlier (see chapter 3), increases in Hsp70 mRNA levels could be the result of








Initial experiments with curcumin had demonstrated that it is a potent inducer of
heme oxygenase-1 in human hepatocytes. This chapter explores the mechanisms
through which this induction may occur.
Heme oxygenase-1 regulation is a complex and tightly regulated phenomenon. HO-1
is a stress responsive enzyme and it is upregulated in response to a wide variety of
stressors including hypoxia (Lee 1997, Kacini 2000), heavy metals and oxidative
stress (Alam 1989). However, as explored in the introduction, there is marked
variation in the regulation ofHO-1 between species and between cell types (Sikorski
2004).
Curcumin has previously been shown to have certain properties which may underpin
its ability to induce HO-1. It has been associated with generation of reactive oxygen
species (Bhaumik 1999), which are toxic, and can induce HO-1, although the link
has not been previously examined. Curcumin has also been shown to activate Nrf2
and the antioxidant response element (Balogun 2003), which will also induce HO-1.
MAP kinases also have a role in the regulation of HO-1 induction (Kietzmann 2003),
and curcumin has varied effects on MAP kinases depending on cell line and
treatment conditions (Jobin 1999, Balogun 2003, Squires 2003).
The diverse effects attributed to curcumin, as described in the general introduction,
and the variable responses seen in different cell lines suggest that curcumin may act
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through an indirect pathway to induce HO-1, rather than a specific receptor mediated
mechanism. Indeed, as HO-1 responds to many varied stimuli, the potential trigger
mechanisms through which curcumin may act to induce HO-1 are similarly varied.
However, the wealth of information on HO-1 induction by other agents and the
effects of curcumin detailed above allowed identification of key mechanisms that
were implicated in the mechanism ofHO-1 induction by curcumin in human
hepatocytes. For this reason, work to understand this mechanism concentrated on
reactive oxygen species and downstream signals triggered by ROS generation -
namely MAP kinases and the transcription factors Nrf2 and HIF-la.




5.2.1 Curcumin induces ROS production
Cells were treated with increasing doses of curcumin and ROS production was
measured by two different methods. Using H2DCFDA the ROS generation was
measured continuously for two hours. ROS were generated at a high rate within a
minute of commencing curcumin treatment, and continued to be produced for the
entire period studied, although the rate slowed as time progressed. In HUH7 cells,
ROS production was maximal after treatment with 10 to 25pM curcumin, but near
basal levels after treatment with 50pM (figure 5.1 A). Addition of the protonophoric
uncoupler CCCP to cells treated with IOjiM curcumin prevented ROS production,
suggesting it had a mitochondrial origin. Vehicle (DMSO) had no effect on ROS
generation. The experiment was repeated on three occasions, with 6 replicates on
each occasion. It was performed twice in isolated human hepatocytes, where similar
results were obtained, except that after treatment with 50pM of curcumin, ROS
generation was also elevated, and indeed was greater than that seen with 10 and
25pM (figure 5.IB).
The above experiment was repeated in HUH7 cells using the ROS sensitive dye
dihydroethidium (figure 5.2). There was a significant induction ofROS in a dose
dependent manner. This was consistent with the previous results after treatment with
10 and 25pM curcumin, but the greatest level of ROS generation was seen after
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Figure 5.1 Curcumin induces ROS production in human hepatocytes.
A. HUH7 cells. B. Isolated primary hepatocytes. ROS production was measured
continuously using H2DCFDA. Data shown represents total ROS production after
one hour of treatment, as means ± SEM of 6 repeats. Each experiment was
performed 3 times with similar results. CCCP lOpM CCCP; Vehicle DMSO
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Figure 5.2 ROS production in HUH7 cells following curcumin treatment.
HUH7 cells were treated with curcumin and total ROS production at 4 hours
measured with dihydroethidium. Curcumin induced ROS production in doses from
10-50pM. Each bar represents the mean ± SEM of six repeats from one experiment.
Each experiment was performed 3 times with similar results. CCCP lOpM CCCP;
Vehicle DMSO equivalent to 10|iM curcumin. f = p<0.05 vs nil and vehicle control.
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5.2.2 Curcumin treatment results in partial mitochondrial depolarisation
In view of a possible mitochondrial origin for the ROS production, curcumin induced
changes in the mitochondrial membrane potential were measured. This was
performed using two different methods - MitoTracker green and red dye, and
DiOC6. Curcumin treatment with 10-50pM curcumin led to loss of the mitochondrial
membrane potential as measured by MitoTracker red and green dye (p<0.01, figure
5.3A). This was confirmed with use ofDiOC6, which similarly demonstrated
depolarisation of the mitochondria at 25-50pM, although using this method, 10pM
had no effect, and the degree of depolarisation was much less pronounced (figure
5.3B).
5.2.3 Induction of HO-1 by Curcumin is mediated through Nrf2
Nrf2 is an oxidant-responsive transcription factor that has previously been shown to
be involved in curcumin mediated induction ofHO-1. In light of this and the above
findings on ROS generation, Nfr2 was measured following curcumin treatment.
Total cellular Nrf2 was increased following curcumin treatment, in doses of 10-
25pM. This was the result of de novo synthesis, and it could be prevented by
inhibiting transcription or translation with actinomycin D and cyclohexamide
respectively (figure 5.4A).
The induction ofNrf2 by lOpM curcumin was assessed in the presence of CCCP, to
examine ifROS generation had a role in increasing Nrf2. The increase in Nrf2 with
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Figure 5.3 Curcumin induces loss of the mitochondrial membrane potential.
A. Mitotracker red and green were used to measure the mitochondrial membrane
potential (MMP). HUH7 cells were treated with curcumin for one hour. 10-50pM
curcumin reduced the MMP (* = p<0.01 vs nil control). B. DiOC6 was used to
measure the MMP in HUH7 cells treated as above. 25-50pM curcumin lead to
reduced MMP (f = p<0.05 vs nil control). Data represents the mean ± SEM of six














Figure 5.4 Curcumin induces HO-1 through Nrf2.
A. Nrf2 (upper band, arrowed) was measured in whole cell lysates from cells treated
with lOpM curcumin for 3 hours. Nrf2 was strongly induced by curcumin treatment,
and this was inhibited by treatment with actinomycin D (5gg/ml) or cyclohexamide
(lOpg/ml). B. Nrf2 (upper band, arrowed) induction by lOpM curcumin was partially
inhibited by CCCP (lOpM), which prevents ROS production.
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curcumin treatment was more muted with CCCP treatment (figure 5.4B), suggesting
that ROS may be involved in the upregulation ofNrf2.
The contribution ofNrf2 towards mediating the HO-1 induction seen with curcumin
treatment was assessed using siRNA. The use of siRNA led to a reduction in Nrf2
levels following curcumin treatment, and this was found to partially abrogate the
induction ofHO-1 by curcumin. Using this method, control siRNA and siRNA for
the transcription factor (HIF-la) had no effect, whilst Nrf2 siRNA did partially
inhibit the induction of HO-1 by curcumin (figure 5.5).
5.2.4 Hypoxia Inducible Factor la does not contribute to HO-1 activation
Activation ofHIF-la following curcumin treatment was assessed by use of a HIF-la
sensitive reporter containing three repeats of the HIF response element. Transfected
HUH7 cells were treated with 10pM curcumin or vehicle for 6 hours and reporter
activity measured. Cobalt chloride was used as a positive control. Curcumin
treatment led to a reduction in reporter activity to 62% of control cells, which was
similar to the effect of the vehicle (58% of controls, figure 5.6). The contribution of
HIF-la was also assessed by siRNA (see figure 5.5) and by EMSA, but in keeping











Figure 5.5 siRNA for Nrf2 but not HIF-la reduces the HO-1 induction by
curcumin.
HUH7 cells were treated with siRNA for eitherNrf2, HIF-la or a control sequence,
and 48 hours later treated with curcumin (lOpM) for 6 hours. Whole cell lysates were
collected and a western blot for HO-1 and Nrf2 (upper band, arrowed) was
performed. Blot shown is representative of 3 independent repeats.
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Figure 5.6 HIF-la activity is not increased by curcumin treatment.
HUH7 cells were double transfected with the HIF-la reporter and a pSV-(3-Gal
control construct and 48 hours later were treated with curcumin (lOpM) for 5 hours
and then lysed. Results are corrected for transfection efficiency and expressed as fold
transactivation compared with controls. Cobalt chloride (CoC12) was used as a
chemical HIF-la stimulus. There was no significant difference between curcumin
and the effect of vehicle alone. Data shown represent the mean ± SEM of 5
independent repeats.
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5.2.5 Antioxidants inhibit HO-1 induction by curcumin
Earlier experiments had demonstrated that curcumin led to production ofROS. To
confirm the role of oxidative stress in the induction of HO-1 by curcumin,
antioxidants were used. HUH7 cells were pretreated with the antioxidants N-
acetylcysteine or vitamin E for 30 minutes and then continuously during treatment
with 10pM curcumin for 6 hours. Both antioxidants led to a reduction in HO-1 levels
following curcumin treatment (figure 5.7). Treatment with catalase also reduced the
induction ofHO-1 in a dose dependent manner, suggesting hydrogen peroxide as an
important contributing ROS (figure 5.8).
5.2.6 PKC and p38 contribute to the induction of HO-1 by curcumin
Kinase inhibitors were used to examine the contribution ofMAP kinase activity to
the induction ofHO-1 by curcumin. This included inhibitors of protein kinase C
(PKC), p38 MAPK, PI3K and ERK. The treatment concentrations were taken from
published studies, using the most specific inhibitors identified in the literature
(Davies 2000). HO-1 induction was measured by HO-1 reporter activity following
treatment with 10pM curcumin in the presence of the various inhibitors. Inhibition of
PKC and p38 significantly reduced HO-1 induction (280% down to 168% and 184%,
p<0.01 and p<0.05 respectively, figure 5.9). Inhibition of PI3 kinase also reduced the
HO-1 induction, although this did not reach significance (280% to 231%, p=0.181),
and inhibition ofERK had no effect. The results obtained from using the reporter
were confirmed by western blotting which confirmed dose dependent inhibition of
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HO-1 induction with PKC inhibition (figure 5.10A). The p38 inhibitor (SB203580)
was so potent that it was effective even at
2pM (figure 5.1 OB). Activation of p38 by curcumin was confirmed by western
blotting for the phosphorylated active form (figure 5.11).
5.2.7 Curcumin inhibits phosphatase activity
Phosphatase activity was examined after curcumin administration (10pM). PP2A
activity was significantly inhibited within 5minutes of curcumin treatment and
remained reduced for one hour (80% of basal activity, p<0.05, figure 5.12). PP2C
activity was unchanged by curcumin treatment. Tyrosine phosphatase activity was
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Figure 5.7 Antioxidants inhibit HO-1 induction by curcumin.
A. HUH7 cells were pretreated with increasing doses ofN-acetylcysteine (NAC) for
30 minutes prior to treatment with lOpM curcumin. B. Pretreatment with 50pM
vitamin E for 30 minutes reduced the HO-1 induction seen with lOpM curcumin.






Figure 5.8 Catalase inhibits the induction of HO-1 by curcumin.
HUH7 cells were co-transfected with an HO-1 luciferase reporter (pHOGL3/l 1.6)
and a control vector (PSV [3Gal), and treated with lOpM curcumin in the presence of
varying concentrations of catalase (2-10 thousand units, MU). Catalase treatment
reduced the HO-1 reporter activity seen with curcumin treatment alone, f = p<0.05
vs curcumin only.
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Figure 5.9 PKC and p38 contribute to HO-1 induction by curcumin.
HUH7 cells were transfected with pHOGL3/l 1.6 and the response to 10pM
curcumin was measured in the presence of a panel of kinase inhibitors. Nil no
inhibitor; SB 20pM SB203580, a p38 inhibitor; PD 5pM PD98059, an ERK
inhibitor; LY 2pM LY294002, a PI3K inhibitor; GFX 5pM GF109203X, a PKC
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Figure 5.10 PKC and p38 are involved in the induction of HO-1 by curcumin.
A. Dose response of two different PKC inhibitors, staurosporine and GF109203X
(GFX) showing inhibition ofHO-1 the HO-1 inducing activity of lOpM curcumin.
B. Dose response of an ERK inhibitor (PD PD98059) and a p38 inhibitor (SB





Time (mins) 0 30 60 120 180
Figure 5.11 p38 MAPK is activated following curcumin treatment.
Western blot showing activation of p38 following treatment with lOpM curcumin.
p38 was activated after 30 minutes of curcumin treatment. p-p38 phosphorylated



























Figure 5.12 Curcumin inhibits protein phosphatase activity.
HUH7 cells were treated with 1OpM curcumin and phosphatase activity was
measured at 5, 15 and 60 minutes. PP2A and PP2C protein phosphatase 2A and 2C
respectively. PP2A and tyrosine phosphatase activity were significantly reduced after
one hour of treatment (*=p<0.05). PP2C activity was unchanged. Data shown
represent the mean ± SEM of 8 independent repeats.
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5.3 Discussion
Curcumin has many attributed cellular effects, and this chapter examines in detail the
relevant mechanisms through which curcumin may act to induce HO-1.
Curcumin treatment induced ROS production in a dose responsive manner. These
ROS may originate from the mitochondria, as they could be inhibited by the
uncoupler CCCP, and curcumin treatment was also associated with mitochondrial
depolarisation, which is often linked with high level mitochondrial ROS production.
Curcumin has been found to generate superoxide in cell lines that are sensitive to its
pro-apoptotic properties (Khar 2001) and, in isolated rat mitochondria, curcumin
induces mitochondrial depolarisation in an ROS dependent manner (Ligeret 2004).
This is consistent with the earlier results demonstrating caspase activation with
increasing doses of curcumin (chapter 3), reinforcing that treatment with curcumin in
high doses can lead to apoptosis through a classical, mitochondria-dependent
pathway, likely as a result of its ROS inducing capabilities.
The two methods used for ROS measurement produced slightly different results.
This is likely to reflect differences in sensitivity to the different ROS species.
H2DCFDA is more sensitive for hydrogen peroxide and hydroxyl radicals, whilst
dihydroethidium is more sensitive for superoxide although neither is species specific
(Lee 1998, Zhang 2001).
153
Slightly different results were also found when using isolated human hepatocytes and
HUH7 cells. There was consistent induction ofROS after treatment with 10 and
25pM of curcumin, but divergent results when measuring ROS generation after
treatment with 50pM. The reason for this is unclear. There are many differences
between an immortalised cell line and primary cultures, and it may be that the fresh
primary cells retain some unspecified enzymatic activity which is lost in the HUH7
cells. The results obtained using dihydroethidium in HUH7 cells are consistent with
those obtained with H2DCFDA in the primary hepatocytes, raising the possibility
that there is a difference in the relative abundance of different ROS species being
produced in the two different cell types. However, the level of endogenous
antioxidants was not measured, which may vary between the cell types and
contribute to the observed differences.
The ROS generating properties of curcumin reflect its chemical structure, and certain
other flavonoids can also generate ROS (Pan 2005), although they are more often
associated with antioxidant activity (Paola 2005, Yamaguchi 2005). Ligeret
examined the effects of curcumin derivatives on rat liver mitochondria, and found
that the phenolic group was essential to effect depolarisation of the mitochondria
• • • "3+ 9+ •
(Ligeret 2004). This allows curcumin to reduce Fe to Fe , which subsequently
allows generation of hydroxyl radicals by the Fenton reaction. Thus Ligeret proposes
that it is the reductive "antioxidant" properties of curcumin which results in
increased ROS production. If the Fenton reaction was a contributor to ROS
generation then could be tested using an iron chelating agent, however, this was not
directly tested in this work. If the Fenton reaction were involved in the induction of
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HO-1 by curcumin, then such induction should have been prevented by catalase.
However, despite the high concentrations of catalase used in these experiments, there
was only an attenuation ofHO-1 induction. This suggests that hydrogen peroxide
may contribute to the rise in HO-1, but it is not the sole responsible reactive oxygen
species.
In examining the transcription factor Nrf2, it was found to be induced by curcumin
treatment. Nr£2 is rapidly induced by oxidative stress, and binds to consensus
sequences in the HO-1 promoter to mediate its induction. Nrf2 has previously been
shown to be involved in the HO-1 induction by curcumin (Balogun 2003), although
this was examined in non-human kidney cells. There are significant interspecies
differences in the HO-1 promoter (Sikorski 2004), and this work confirms this
finding for the first time in human cells, and for the first time using siRNA. Attempts
were made to perform gel shift assays to detect Nrf2 DNA binding, however, despite
several methods being tested, this was unsuccessful. This would have been helpful as
another layer of evidence to demonstrate Nrf2 activation by curcumin, although this
has been shown previously (Balogun 2003). The presence of increased levels ofNrf2
after curcumin treatment and the reduction in HO-1 levels with the Nrf2 siRNA
supports the activation ofNrf2 as a mechanism through which curcumin induces
HO-1, even in the absence of gel shift data.
Hypoxia inducible factor 1 a was examined as a potential contributor to the induction
ofHO-1. It is as its name suggests a hypoxia sensitive transcription factor, and it is a
potent stimulator ofHO-1 production (Lee 1997). It has also been shown to respond
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to chemical oxidative stress in the liver (Tacchini 2002). It was for this reason that
HIF-la activity was studied. However, whilst the human HO-1 promoter contains a
consensus binding sequence for HIF-la, it has recently been established that hypoxia
does not induce HO-1 in human tissues, although it does in other species (Kitamuro
2003). Whilst this cannot be attested to from the experiments performed here, HIF-
1 a does not appear to be activated by curcumin, as evidenced by the lack of reporter
activity. This finding was corroborated by the lack of effect ofHIF-la siRNA on
HO-1 induction by curcumin.
These experiments demonstrate for the first time that HO-1 induction by curcumin
can be inhibited by the use of the antioxidants N-acetylcysteine and vitamin E. It is
proposed that curcumin generates mitochondrial ROS and that this is the trigger for
Nrf2 induction and subsequent upregulation ofHO-1. If curcumin is administered in
toxic doses the mitochondria undergo the permeability transition pore, and the cell is
destined to apoptose. However, in non-toxic doses curcumin generates sufficient
ROS to trigger activation ofNr£2, PKC and p38, and inhibit phosphatase activity, all
ofwhich contribute to HO-1 induction (figure 5.13). This is consistent with
experiments performed using the garlic extract DAS, another HO-1 inducer which
has recently been found to stimulate ROS production (Gong 2004).
Scapagnini found, in astrocytes, that curcumin was associated with toxicity at doses
of 50pM and over, and that this could be inhibited by the addition ofN-
acetylcysteine, which is consistent with our findings regarding curcumin-induced
ROS generation and its apparent association with cellular toxicity. However, when
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examining the effect ofN-acetylcysteine on HO-1 induction by curcumin,
Scapagnini found no apparent inhibition when used at a concentration of ImM
(Scapagnini 2002). This may a result of the dose ofN-acetylcysteine used. The
results from this chapter show that curcumin is a very potent inducer ofROS.
Furthermore, there was a dose responsive decrease in HO-1 induction with
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Figure 5.13 Proposed mechanisms through which curcumin induces HO-1.
Curcumin penetrates the cell and leads to ROS generation from mitochondria. If it is
given in high doses (>25pM) the mitochondria undergoes the permeability transition
pore and cell death ensues. If given at non toxic doses (25pM and less), the ROS
generated triggers Nrf2 accumulation and activation, activation of PKC and p38, and
inhibition ofprotein phosphatases, all of which contribute to induction ofHO-1 and
protection of the cell from injury.
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ImM. It is possible that in astrocytes, as in hepatocytes, the volume of ROS
produced is too great to be quenched by ImM N-acetylcysteine, and that higher
doses are required. It remains possible that the high doses ofN-acetylcysteine that
were effective in hepatocytes (3 tolOmM) are exerting their effect through other
changes in the cell rather than simply the antioxidant effect of the drug. However,
vitamin E and catalase were able to reproduce the effect, supporting the contention
that the induction of HO-1 by curcumin is a direct result of its ability to induce ROS
production.
Glutathione is one of the cell's natural anti-oxidants and maintenance of reduced
glutathione is important in the ability of a cell to resist oxidant-induced apoptosis
(Boggs 1998, Si 1998). It has been shown that some anti-apoptotic proteins exert
their protective effect through maintenance of glutathione, such as Bcl-2 (Voehringer
1999, Schor 2000). Curcumin has been shown to elevate glutathione levels in Jurkat
cells and thymocytes (Piwocka 2001, Jaruga 1998). It is conceivable that elevation of
glutathione could contribute to the cytoprotective properties of curcumin, in addition
to increasing the level ofHO-1. However, it is important to note that this elevation of
glutathione was only seen after treatment with 50pM curcumin, and that this dose led
to significant cell death in Jurkat cells (Piwocka 2001), in keeping with that seen in
this work (chapter 3).
In addition to the effects ofNrf2, PKC and p38 activity are important in the
induction ofHO-1 by curcumin. Protein kinase C (PKC) is involved in activation of
Nrf2, by phosphorylating it to allow dissociation from the cytoplasmic inhibitor
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Keapl. This allows nuclear migration ofNrf2 where it binds to the requisite
promoters (Bloom 2003). Whilst this would explain the contribution ofPKC activity
to HO-1 induction by curcumin, a direct effect on other transcription factors cannot
be excluded.
p38 has previously been found to contribute to HO-1 induction by cadmium and
curcumin, although the mechanism is unclear and it may be intimately linked with
Nrf2 activation (Alam 2000, Balogun 2003). Balogun examined the contribution of
MAP kinases to the induction of HO-1 by curcumin in porcine renal cells (Balogun
2003). p38 MAPK was found to be activated by curcumin treatment and inhibition of
p38 was found to reduce the level of induction, consistent with the results of this
chapter. Inhibition ofERK and JNK had no effect in that study, and the contribution
ofPKC was not examined.
Protein kinases are dependent on phosphorylation of threonine and tyrosine residues
to stimulate their activity, the result of which is that control of cellular processes is
regulated through a delicate balance of protein kinase and protein phosphatase
activity. After having demonstrated the involvement of kinase activation in
curcumin's induction ofHO-1, cellular phosphatase activity was examined. It was
found that PP2A was rapidly inhibited by curcumin and that tyrosine phosphatase
activity was inhibited after one hour of treatment. It is likely that this plays a role in
the HO-1 induction seen with curcumin, as the PP2A inhibitor okadaic acid is a
potent HO-1 inducer (Immenschuh 2000). PP2A can be inhibited by ROS (Kim
2003), and although not directly tested, this would be consistent with the rapid
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decrease seen in its activity, as ROS were generated constantly at high levels from
within a minute of treatment. PP2A acts directly on p38 resulting in its inactivation
(Alvarado-Kristensson 2005). This may represent part of the link between curcumin
treatment and p38 activation, as the inhibition ofPP2A activity would directly result
in increased p38 activity.
PP2A also acts directly on caspase 3, leading to its inactivation (Alvarado-
Kristensson 2005). Curcumin treatment leads to a dose dependent increase in caspase
3/7 activity (chapter 3), and although a dose response was not performed in this
study, it is possible that increasing curcumin concentrations could cause greater
inhibition ofPP2A and hence contribute to the pro-apoptotic events which occur
following high dose treatment.
5.4 Conclusion
Curcumin treatment results in ROS generation, activation ofNrf2 and MAP kinases
and the inhibition of phosphatase activity in hepatocytes, and when curcumin is not
administered in toxic doses, these multiple pathways converge to induce HO-1
(figure 5.13). Thus curcumin can be used at low doses to pharmacologically induce
HO-1, and its induction is through generation of non-lethal levels of reactive oxygen
species. Whilst several of these mechanisms have individually been demonstrated by
other investigators, this is the first study to look at them all in combination and
confirm their contribution to the induction ofHO-1 by curcumin.
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That curcumin could robustly induce HO-1 in hepatocytes without causing toxicity
had been demonstrated in chapter 3. However, it remained to be seen whether the







The stress response is the cell's natural response to injury and underpins its ability to
protect itself from further insults. Having found that curcumin can induce HO-1 in
human hepatocytes, the next step was to investigate the protective effect of HO-1
induction by curcumin and assess its preconditioning potential.
In liver surgery there are two particular scenarios where preconditioning may be of
benefit: resectional liver surgery and liver transplantation. During resectional liver
surgery the inflow of blood to the liver may be temporarily interrupted for technical
reasons by application of the Pringle manoeuvre, whereby the hepatic pedicle
containing the hepatic artery and portal vein is clamped (Dixon 2005). This results in
a period ofwarm ischaemia followed by subsequent reperfusion injury when the
hepatic inflow is restored (figure 1.1). During liver transplantation, the liver is
perfused with cold preservation solution, removed from the body and placed on ice
for a period of time prior to reimplantation and restoration of its circulation. This
therefore results in a period of cold ischaemia, followed by a brief period ofwarm
ischaemia (while the liver is in the body cavity and anastamoses are being performed
to restore vessel continuity), and then a period of reperfusion (figure 1.1).
HO-1 induction has been shown to be protective against ischaemia-reperfusion injury
and cold preservation injury (Akamatsu 2004, Wang 2005, Uchida 2003). If
curcumin is to be a clinically useful preconditioning agent it must be able to protect
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hepatocytes from both of these insults. This has not previously been tested in human
hepatocytes using curcumin as an HO-1 inducing agent.
Aim: To establish whether HO-1 induction by curcumin can precondition human




6.2.1 Development of in vitro models of ischaemia reperfusion injury
Initial experiments aimed to establish a reliable in vitro model of ischaemia-
reperfusion injury. Several models were explored, including: sodium arsenite; anoxia
and reperfusion; ultraviolet light; simulated chemical ischaemia reperfusion; glucose
oxidase with or without prior anoxia; and hydrogen peroxide. A significant
contributor to the damage of reperfusion injury is oxidative stress, and each model
mimics this to some degree. Whilst examining the various models, hemin was used
as a positive control, representing a known HO-1 inducer which is cytoprotective
(Clark 2000, Attuwaybi 2004). Thus a model would be rejected on technical grounds
if it was unable to demonstrate protection by hemin.
Sodium arsenite (SA) was the first model used, initially in combination with
propidium iodide and annexin V flow cytometry as an outcome measure. However,
this method was unstable, with SA treatment producing inconsistent levels of cell
death, despite titrations of doses from 1 to 5mM. Two attempts were made to identify
a preconditioning effect, but there was no significant difference between treatment
with either hemin or curcumin (figure 6.1).
It was considered that the process of cell harvesting for flow cytometry and the
prolonged preparation process may have been damaging to the cells. For this reason,




Figure 6.1 Curcumin does not protect from arsenite mediated injury.
HUH7 cells were treated with 5mM sodium arsenite for 30 minutes after
pretreatment with either 1 OpM curcumin or corresponding vehicle. Cell viability was
then assessed using propidium iodide and annexin V flow cytometry. There was no
significant difference between the treatment groups.
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testing found that 5mM SA reproducibly reduced survival by approximately 40%.
Experiments performed subsequently using prior treatment with hemin or curcumin
showed no preconditioning effect. This was performed twice with the same result
(figure 6.2). Thus sodium arsenite was rejected as a model.
The next model tested was anoxia and reperfusion. Cells were placed in a sealed
chamber at 37°C and subjected to anoxia by flooding the chamber with a 5%
CC>2/95% N2 mixture. After five hours, the cells were returned to normal culture
conditions for four hours and survival was assessed by either MTT assay or
propidium iodide flow cytometry. This model was examined using primary cultures
of isolated human hepatocytes as well as HUH7 cells. Five hours of anoxia resulted
in insufficient cell death to distinguish any differences between treatment groups
(figure 6.2). The period of anoxia was extended to 16 hours and tested with HUH7
cells, but similar results were obtained and this model was abandoned.
Ultraviolet light is toxic through generation of intracellular reactive oxygen species
which damage DNA (Zhang 1997). UVC was used, in doses of 50, 100, 150 or 200J.
Survival was assessed by assaying released LDH in the culture medium 16 hours
after UVC treatment. There was a clear dose dependent increase in cell death with
increasing doses ofUVC. 50J was chosen for further study, and lOpM curcumin was
found to be protective against injury, reducing LDH release to 75% that of untreated
cells. Furthermore, this protective effect was prevented by addition of the HO-1
inhibitor zinc protoporphyrin (ZnPPIX), suggesting that the protective effect was due
to heme oxygenase activity (p<0.05, figure 6.3). This experiment was performed in
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triplicate on two occasions, and the results combined to allow statistical analysis.
However, due to the prolonged time between injury and assessment of
survival/death, there was significant potential for confounding due to various factors
including cell proliferation, rendering the model flawed, and so it was not pursued
further (see discussion).
Simulated ischaemia reperfusion was achieved by use of a buffer containing
deoxyglucose and sodium dithionite, with survival after treatment assessed by MTT
assay. This method was taken from published studies examining ischaemia
reperfusion in cardiomyocytes (Cumming 1996). This showed promising results with
a clear and consistent dose responsive decrease in survival with increasing duration
of exposure to the buffer (figure 6.4). However, this method was piloted at the same
time as the glucose oxidase/hydrogen peroxide models, and it was decided to focus
mainly on the latter.
Models using glucose oxidase or hydrogen peroxide to generate reactive oxygen
species were tested simultaneously. Glucose oxidase catalyses the degradation of
glucose, generating hydrogen peroxide in the process. This generates a constant level
of hydrogen peroxide over the treatment period. In contrast, bolus administration of
hydrogen peroxide has a short half-life. It was found that both curcumin and hemin
were capable of protecting HUH7 cells in both models. The glucose oxidase model
proved to be more brittle than bolus administration of hydrogen peroxide, with
greater variability in the degree of cellular injury between experiments. Thus
although both models were used successfully, hydrogen peroxide was more
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Figure 6.2 Arsenite toxicity and anoxia and reperfusion are inadequate models
to test HO-1 mediated cytoprotection by curcumin.
Isolated human hepatocytes were treated with 1 OpM curcumin, vehicle (DMSO)or
20pM hemin for 8 hours. They were then subjected to either 5mM sodium arsenite
for 30 minutes or anoxia for 5 hours. Survival was assessed by MTT assay. Hemin
was unable to precondition hepatocytes in these models. Data represent the mean ±









Figure 6.3 Pretreatment with lOpM curcumin protects against UVC mediated
cell toxicity.
HUH7 cells were pretreated with lOpM curcumin for 8 hours prior to UVC
irradiation (50J). They were then recovered for 16 hours in the presence or absence
of the HO-1 inhibitor ZnPPIX (50pM). Curcumin pretreatment protected against cell
death and this protection was removed by the presence of ZnPPIX. *p<0.05 vs
untreated control, vehicle or curcumin and ZnPPIX.
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Figure 6.4 Simulated ischaemia reperfusion buffer tested in HUH7 cells.
A chemical buffer simulating ischaemia-reperfusion was piloted in HUH7 cells.
There was a clear relationship between exposure time and cell survival. Data shown
represent mean ± SEM of 6 replicates from a single experiment. The experiment was
performed twice.
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predictable. A variation on this model, subjecting the cells to a period of anoxia prior
to glucose oxidase treatment was also tested. However, the addition of anoxia failed
to induce any additional cellular injury in the HUH7 cells, and it was not
implemented as part of the model.
6.2.2 Hemin protects in a model of oxidative injury
HUH7 cells were pretreated with 20pM hemin for 6 hours, which is sufficient to
induce HO-1. The cells were then treated with 90mU/ml of glucose oxidase. Other
groups included treatment with ZnPPIX (50pM, an HO inhibitor), bilirubin (lpM) or
dichloromethane (0.1%, a chemical source of carbon monoxide). Hemin was found
to significantly protect against injury (p<0.01). This protection was reduced in the
presence of HO-1 inhibition (p<0.05), and could be restored by the addition of
carbon monoxide, suggesting that the protection was a direct result of the HO-1
induction by hemin (figure 6.5).
6.2.3 Curcumin protects in a model of oxidative injury
Curcumin was evaluated for a preconditioning effect in HUH7 cells using bolus
administration of ImM hydrogen peroxide as a model of oxidative injury. Curcumin
pretreatment significantly improved cell survival compared with either no
pretreatment or vehicle (25±6 vs. 0±3 and 3±4, p<0.01 and p<0.05 respectively,
figure 6.6). This represented protection of one third of the cells that would otherwise
have died. Further experiments were performed to establish the contribution of HO-1
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Figure 6.5 Heme oxygenase induction by hemin protects hepatocytes from
oxidative injury.
HUH7 Cells were pretreated for 2 hours with 20pM hemin, recovered in normal
conditions for 4 hours and then challenged with lOOmU glucose oxidase. MTT assay
was performed 16 hours later. Results are expressed as percentage protection and
represent the mean of 3 experiments +/- SEM. The first column represents healthy
cells that did not receive glucose oxidase. ZnPPIX 50pM zinc protoporphyrin;
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Figure 6.6 Curcumin pretreatment protects hepatocytes from oxidative injury.
HUH7 cells were pretreated for 8 hours with curcumin 1 OpM or equivalent dose of
vehicle, and challenged with ImM H2O2. MTT assay was performed 4 hours later.
Results are expressed as percentage protection and represent the mean of 3
experiments ± SEM. The first column represents healthy cells that did not receive
hydrogen peroxide. H2O2 Hydrogen Peroxide; ZnPPIX 50pM zinc protoporphyrin;
CO 0.1% dichloromethane; Bilirubin lpM bilirubin. * = p<0.01 and f = p<0.05
compared with curcumin only group.
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activity to this effect. Administration of zinc protoporphyrin abrogated the
cytoprotection seen with curcumin (7±3, p<0.01). Addition of 0.1% dichloromethane
partially restored the protection seen prior to HO-1 inhibition (17±4, p<0.05 vs.
curcumin and ZnPPIX), demonstrating the protective effect of carbon monoxide
generation. Full restoration of protection was provided by addition of lpM bilirubin
(27±4, p<0.01 vs. curcumin and ZnPPIX). This was performed three times with
similar results.
6.2.4 Development of a model of cold preservation injury
A model of cold preservation injury was developed to mimic the clinical scenario of
cold preservation during transplantation. University of Wisconsin solution (UW) is
currently the most commonly used preservation fluid in clinical practice in the
United Kingdom, and was used for this reason. Cells were pretreated as required and
then placed in ice cold UW and stored at 4°C for varying periods of time prior to the
UW being replaced with pre-warmed culture medium and being restored to normal
culture conditions at 37°C. Lactate dehydrogenase release into the culture medium
was used as an outcome marker of cell death.
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6.2.5 Curcumin induces HO-1 and is cytoprotective in cold preservation injury
Initial experiments were performed to establish if the HO-1 upregulated by curcumin
remained upregulated during the cold storage and reperfusion stage. Time courses
performed earlier had revealed that HO-1 was upregulated after 4 to 12 hours of
treatment with lOpM curcumin (chapter 3). Treatment with curcumin for 6 hours was
chosen for further study. HUH7 cells which had been treated with curcumin for 6
hours had their culture medium removed and replaced with UW solution at 4°C, and
kept at this temperature for the required period of time, after which they were
returned to normal medium and normal culture conditions. Following curcumin
treatment, HO-1 was found to remain upregulated during cold storage of up to 48
hours duration. However, after this length of cold storage, there was significant cell
death on rewarming, and HO-1 levels dropped dramatically after rewarming. After
16 to 24 hours of cold storage, HO-1 levels remained high following rewarming
(figure 6.7). Cold storage for 18 hours was toxic to non-pretreated cells, however
curcumin pretreated cells were protected against this toxicity (p<0.01, table 6.1). The
degree of toxicity was dependent on the duration of cold storage, and the maximum
protection afforded by curcumin pretreatment was found between 16 and 24 hours of
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Figure 6.7 Heme Oxygenase 1 remains elevated during cold storage and
reperfusion.
Cells were treated as above with curcumin for 6 hours and then incubated in UW
solution for 18 hours, followed by reperfusion in normal conditions for 6 hours as
indicated. Cell lysates were collected at each stage and a western blot performed for HO-
1. Blots shown are representative of three separate repeats.
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Replicate Nil UW Curcumin Curcumin + UW
1 1+0.21 27.92±0.51 1.54+0.14 1.56+0.08*
2 1±0.41 6.91+0.97 1.35+0.62 1.76+1.27*
3 1±0.01 18.61+0.05 1.18+0.04 2.16+0.2*
Table 6.1 Curcumin protects hepatocytes from cold preservation.
Cells were pretreated with 10pM curcumin for 6 hours and then incubated in UW
solution at 4°C for 18 hours, and then restored to normal culture conditions for 4
hours, after which the medium was collected and assayed for lactate dehydrogenase
activity. Control cells were pretreated for 6 hours. The cells were then cultured in
fresh warm medium for 4 hours and the medium collected and assayed for lactate
dehydrogenase activity. Data represent three individual experiments, each ofwhich
contained 6 repeats within each group, and are shown as mean ± SEM. Nil No
pretreatment; UW cold preservation for 18 hours in UW solution at 4°C; Curcumin
pretreatment with lOpM curcumin for 6 hours; Curcumin + UW pretreatment with
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Figure 6.8 Protection from cold preservation is time dependent.
Cells were pretreated with curcumin for 6 hours and then incubated in UW solution
at 4°C for a variable length of time, after which they were restored to normal culture
conditions for 4 hours. The medium was then collected and assayed for lactate
dehydrogenase activity. Results shown are the mean of 6 independent repeats ±
SEM. Nil No pretreatment; Curcumin pretreatment with 10pM curcumin. * =
p<0.01 and f =p<0.05.
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6.3 Discussion
6.3.1 Development of in vitro models of ischaemia reperfusion injury.
A significant amount of time was invested in developing a robust, reliable and
clinically relevant model of cellular injury. There are many such models in the
literature, and several were tested before settling on hydrogen peroxide/glucose
oxidase as the model of choice.
Sodium arsenite was investigated initially. It is well established as a mediator of
oxidative injury and an inducer of the stress response in its own right. It induces ROS
production and the MPTP (Petronilli 1994, Kitchin 2001). However, much of its
cellular toxicity may be associated with its ability to induce cross-linking of
sulfhydryl groups (Petronilli 1994). It therefore does not reflect the events seen in
ischaemia-reperfusion injury, and it was a poor choice to model the clinical scenario.
Initial results with the model were disappointing. As this was the first model
developed, two outcome methods were tried - flow cytometry and MTT assay.
However, the results were similar when either method was used. The sodium arsenite
was deemed a poor model and abandoned, although the consistency of results
between the flow cytometry and the MTT assay suggested that either method could
be used with equal validity as an outcome measure in subsequent models.
Anoxia and reperfusion was subsequently studied. Pilot experiments were tested with
both primary hepatocytes and HUH7 cells, initially using primary cultures subjected
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to 5 hours of anoxia. Previous data in our laboratory predicted that this should be
sufficient to cause a measurable degree of cell death. However, no such death
occurred. There is always an intrinsic variability in the preparations of isolated
hepatocytes obtained from surgical resection specimens, as seen by their variable
mRNA responses to a given stimulus (chapter 3). It is likely that the particular
preparation of hepatocytes used was more "hardy" than other studied preparations,
and so were resistant to the toxic effect of hypoxia. To avoid such variability, HUH7
cells were used subsequently, with a longer duration of hypoxia (16 hours). Again,
however, there was little effect on cell viability. Work by others in our laboratory
found that HUH7 cells are highly tolerant of anoxia for prolonged periods of time,
readily tolerating oxygen deprivation for 24 hours, maintaining metabolism through
glycolysis (Ian Currie, personal communication, unpublished results).
Ultraviolet exposure was also used as a model of cellular injury. UVC treatment
leads to ROS generation which induces DNA damage, subsequently resulting in
apoptosis. Induction of the stress response (by heat) has been shown to be protective
against UVC mediated cell death (Chen 1999). It was for this reason that there was
some interest in examining the effect of curcumin pretreatment on UVC induced cell
death. Initial results were promising and showed that curcumin could protect in this
model of cell injury. However, this type of injury is far removed from the clinical
scenario of liver surgery. Furthermore, the delayed onset of apoptotic cell death after
UVC treatment meant that there was a requirement for a prolonged recovery period
before cell death could be assessed. In the setting ofHUH7 cells this allows for
differences in cell proliferation rates to affect the measured results. Demonstrating
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that HO-1 was the protective mechanism in this model would also be difficult.
Despite the protective effect of curcumin being removed by treatment with ZnPPIX,
this cannot be definitely concluded to be the result ofHO-1 inhibition (and thus the
protection cannot be definitely shown to be due to HO-1 induction). Prolonged
incubation with ZnPPIX may itself be toxic to some degree as there was an increase
in cell death treatment with this inhibitor. It was for these reservations and potential
confounding factors that this model was rejected.
Use of glucose oxidase and hydrogen peroxide to generate oxidative injury became
the models of choice. These were developed from published literature which had
demonstrated that these models were suitable for demonstrating HO-1 mediated
cytoprotection (Clark 2000). Glucose oxidase generates hydrogen peroxide
enzymatically throughout the period of treatment, rather than just the effect of the
initial bolus seen with using hydrogen peroxide directly. However, these models
were developed and used in tandem. The main difference between the two models
was a very variable response to glucose oxidase treatment. Whilst a fairly consistent
proportion of cells would die after treatment with a set dose of hydrogen peroxide,
these was marked inter-experiment variability in the extent of injury when using
glucose oxidase. The reason for this was unclear. Glucose oxidase enzymatically
oxidises glucose, generating hydrogen peroxide. All experiments were performed in
DMEM (HUH7s) or William's E medium (primary cultured hepatocytes) which both
contain high levels of glucose. Thus, substrate limitation should not be a contributing
factor. The enzyme does however, function optimally at 38°C (Gibson 1964).
Experiments were performed with medium that had been pre-warmed to 37°C. It is
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possible that during the addition of glucose oxidase to the medium and addition of
the medium to the cells, with a necessary and slightly variable time spent at room
temperature prior to treating the cells, there may have been a fall in temperature,
leading to a variation in enzymatic activity between experiments. The consistent
results obtained from the hydrogen peroxide model suggest that the variation seen
was not the result of differences in the HUH7 cells between experiments. In
retrospect, xanthine oxidase may have been a more physiologically relevant agent to
use as it is present in and contributes to, the ischaemia-reperfusion injury seen in
vivo. The results obtained may have been significantly different, as xanthine oxidase
will produce superoxide radicals, and the degree of ROS generation could have been
limited by lower levels of xanthine in vitro than are found in vivo.
6.3.2 Preconditioning by curcumin in models ofwarm and cold injury
Pretreatment with curcumin prior to oxidative injury led to cellular protection. HO-1
induction is known to protect against oxidative stress (Tullius 2002, Clark 2000). To
demonstrate that the effect of curcumin was due to increased HO-1 activity, an HO-1
inhibitor was used. This removed the cytoprotective effect, suggesting that it was
directly due to heme oxygenase activity. No HO-1 inhibitor is perfect, and ZnPPIX
can actually induce HO-1 after prolonged treatment (Yang 2001). However, the short
duration of treatment used in these experiments, with application of ZnPPIX only 30
minutes prior to and during treatment with glucose oxidase/hydrogen peroxide, was
thought to be unlikely to have such an effect. The addition of carbon monoxide (via
dichloromethane) or bilirubin, both end products ofHO-1 activity, partially restored
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the protective effect of curcumin. The combination of bilirubin and CO may have
had additive effects, fully restoring the protection of curcumin, however this was not
tested. This provides strong evidence that the predominant effect of curcumin as a
cytoprotective agent in the model studied is a result of increased HO-1 activity.
However, it must be considered that the cytoprotective effect could be mediated
through a different and parallel mechanism. If HO-1 activity is essential for survival
in the model used, then its inhibition will result in a decrease in survival, and
provision of its end-products (bilirubin and carbon monoxide) will improve survival.
Conceivably, curcumin could improve survival through a completely independent
pathway, whereby chemical inhibition ofHO-1 would still lead to impaired survival.
For example, many different cellular effects have been attributed to curcumin. It does
not induce Hsp70 induction in HUH7 cells (chapter 3), but other factors, such as its
ability to inhibit NFkB (Bharti 2003) were not assessed. A further level of proof of
the HO-1 dependent nature of curcumin's protective effect could be obtained by
demonstrating that curcumin has no protective effect in HO-1 deficient cells, for
example using either transgenic hepatocytes or siRNA. However, as it stands, the
experimental design used does suggest that the protective effect of curcumin is
mediated through HO-1, and is consistent with the increase in HO-1 levels seen with
curcumin treatment and the known effects of HO-1 induction by other agents such as
hemin (Clark 2000, Motterlini 2000).
Curcumin pretreatment also protected cells from cold preservation injury. Curcumin
treatment resulted in upregulation and maintenance of HO-1 levels during cold
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preservation and reperfusion, and this was associated with cytoprotection. University
of Wisconsin solution was chosen for the model of cold injury because this is the
medium in which liver grafts are most commonly stored, and if curcumin was ever to
have a clinical role in transplantation, it would have to be able to exert its effect
within this environment. Also, UW solution contains many elements such as
glutathione which help to minimise the injurious effect of cold storage (Southard
1990). If curcumin was found to be beneficial in the setting of a different solution
which did not contain these components, the finding would be of interest, but may be
less clinically relevant. It is important to also consider that only cold injury and
rewarming occurs in the experimental conditions used. The multiple events seen with
in vivo reperfusion were not mimicked in any way. It would be possible to perform
this experiment with exposure to glucose oxidase during the re-warming phase which
would in part address this deficiency.
If curcumin were to be used to precondition human livers for transplantation, it
would have to be able to induce HO-1 prior to the organ being harvested. Liver
transplantation usually occurs with retrieval of the organ from a brain dead
individual (heart beating donor). Curcumin would have to be administered between
the time of diagnosis of brain death and the organ retrieval. Despite all efforts to
keep this time as short as possible, in clinical practice there are often many hours
between the diagnosis of brain death, the gaining of consent for organ donation, and
the physical harvesting of the organ. Curcumin requires a minimum of four hours to
induce HO-1 in HUH7 cells (chapter 3), and in the experiments in this chapter, 6
hours of pretreatment with curcumin was used prior to cold preservation as this is a
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common length of time from consent to donation and the organ being harvested.
There is therefore sufficient time for curcumin administration to upregulate HO-1.
Although the experiment was not performed, it would be of interest to know if the
presence of curcumin during the rewarming period would induce a beneficial effect,
as this would be simple to administer in the clinical setting.
Balogun examined curcumin as an inducer of HO-1 in kidney cells, and its ability to
protect from cold storage injury (Balogun 2003). Following a three hour incubation
with curcumin at 37°C, a stepped reduction in temperature to 20°C and then 10°C for
1.5 hours each was used to enable curcumin to efficiently upregulate HO-1 prior to
subjecting the cells to storage at 4°C. This phased cooling was effective, however, it
may be difficult to deliver clinically, and maintaining a liver graft at 20°C and then
10°C may lead to harm to the graft that cold storage was designed to eliminate.
Whilst the implementation of curcumin preconditioning in heart beating donors may
be difficult, it may be of greater use during living donor donation or in elective liver
surgery. In such elective situations, there is ample time to administer a
preconditioning agent which may require several hours or even days to have its full
effect.
It was also of interest that curcumin lead to protection from cold injury for up to 24
hours duration, but not beyond. Some preconditioning treatments do allow prolonged
storage of liver grafts prior to successful reimplantation, even up to 48 hours of
storage (Redaelli 2002), which is far in excess of the 12 hour limit currently used in
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clinical practice. Curcumin treatment could potentially enable prolongation of cold
storage to 24 hours, which may be of use in certain situations where a prolonged
period of cold storage is envisaged.
Initial studies to test the efficacy of curcumin as a preconditioning agent in a whole
organ would require an animal model. This would be best achieved using a partial
hepatic ischaemia model, for example clamping the left lobe for a period of 30
minutes, followed by 24 hours recovery. The effect of curcumin could be established
by measuring transaminase release and assessing the degree of histological damage.
This would demonstrate protection from ischaemia-reperfusion injury. To confirm if
this protection remained in cold ischaemic injury, an ex-vivo reperfusion model
could be used, subsequently proceeding to a full liver transplant model. Confirmation
of an HO-1 dependent mechanism could be studied with the use of chemical
inhibitors ofHO-1 (e.g. ZnPPIX), and lentiviral shRNA. Additional confirmation of
HO-1 dependency could be achieved by comparison with adenoviral delivered HO-1,
and assessment of the ability of carbon monoxide and bilirubin to reproduce the
effect in the face ofHO-1 inhibition.
Whilst the application of curcumin to animal models would be straightforward,
clinical studies would be more challenging primarily due to its poor oral bio¬
availability and the lack of a parenteral preparation. The significant attraction of
curcumin as a therapeutic agent to induce HO-1 is that it is a dietary constituent and
is normally taken in up to lg/day in certain areas (Ammon 1991). Furthermore there
have been phase I and II trials of curcumin which have established its tolerability in
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high doses, up to 3.6g/day (Sharma 2004), with few side effects other than some mild
gastrointestinal upset.
However, when given orally, the absorption of curcumin is poor and the greatest
concentration occurs in the bowel epithelium (Garcea 2005), and so the systemic
levels reached may be insufficient to induce HO-1. One study which examined the
concentration of curcumin following oral administration found that it was present at
2jj.M in the liver tissue, and that it was not present in measurable amounts in serum
(Garcea 2004). The results from chapter 3 demonstrate that lOpM curcumin is
required in vitro to induce HO-1. However, this was performed as a single treatment.
The effect of regular exposure to 2pM may be sufficient to induce HO-1 if given
over a period of time. Also, curcumin is rapidly glucuronidated and expelled in the
bile. Thus a global measurement of 2pM in the liver biopsy may not reflect the level
to which hepatocytes themselves were exposed.
Another consideration is that in the liver, hepatocytes do not exist in isolation.
Experimental evidence suggests that Kupffer cells play a role in signalling danger to
hepatocytes, and hence may play a role in hepatocellular HO-1 regulation (Paxian
2001). It may be that a smaller dose of curcumin reaching the Kupffer cells may
trigger intercellular signalling such that hepatocytes are stimulated indirectly to
induce HO-1. Whilst this has not been tested in the experiments presented here, this
model could be tested in vitro in isolated Kupffer cells and hepatocytes, in a variety
of co-culture conditions. If Kupffer cells are not stimulated to produce an
amplification of the stimulus, oral absorption of curcumin can be increased by
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concomitant administration of black pepper (Shoba 1998), which increases
bioavailability by 2000% in human subjects. This could potentially provide a hepatic
concentration of 40p.M based on previous studies (Garcea 2004). If sufficient
systemic levels could not be achieved, parenteral administration of curcumin could
be considered. However, this would require suitable preparation and approval by the
Medicines Health Regulatory Authority (MHRA).
Once a method of administration which produced relevant tissue levels of curcumin
was established in a phase I trial, its ability to induce HO-1 in vivo in humans could
be assessed by its administration to patients undergoing elective liver surgery. This
will provide a sample of tissue which could be used to assess HO-1 protein
expression and activity, and also the effect of systemic administration of curcumin in
patients undergoing liver surgery could be assessed. A larger study would be
required to demonstrate evidence of a protective effect with HO-1 induction, and this
would need to be performed in a group of patients undergoing major liver resection
(3 or more segments) with portal clamping (the Pringle manoeuvre) to provide
ischaemia-reperfusion injury. Only after this study was completed and found to be
safe could curcumin be tried in the setting of human organ transplantation.
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6.4 Conclusion
Curcumin robustly induced HO-1 in human hepatocytes, and this was cytoprotective
in two in vitro models of cellular injury that mimic the clinical scenarios of
ischaemia-reperfusion and transplantation. This suggests that curcumin may be a
clinically useful preconditioning agent, although more work is required to
demonstrate this in a human study.
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Chapter 7
Cyclosporin and the Stress Response
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7.1 Introduction
The work in previous chapters has examined the effect of curcumin on the stress
response and assessed whether it could be used as a preconditioning agent in human
hepatocytes. Cyclosporin has been implicated by other groups as a potential
preconditioning agent, through its ability to induce the stress response (Yang 2001,
Chen 2002), although this has not been established in the human liver. The
experiments in this chapter examine the effect of cyclosporin treatment on stress
protein expression in human hepatocytes, and whether pretreatment with cyclosporin
has a cytoprotective effect.
Cyclosporin A is an immunosuppressant drug commonly used in transplantation. It
was purified from the fungus Tolypocladium inflatum, and was the mainstay of
immunosuppressive therapy for several decades, although in some areas it is now
being replaced by newer agents (Regazzi 2005). The effect of cyclosporin on stress
protein expression has been examined in the past by other groups. Paslaru's group
have found that in induces Hsp27 and Grp78, and this is associated with activation of
HSF-1 and HSF-2 (Paslaru 1994 and 2000). It has been found to induce Hsp70 in
primary cultures of rat hepatocytes, and to reduce the severity of ischaemia
reperfusion injury in a rat liver model (Andres 2000, Saxton 2002). However, its
effects have not previously been tested in human hepatocytes.
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Aim: To establish the effect of cyclosporin A on the expression of stress proteins in




7.2.1 Choice of vehicle
Cyclosporin A is highly lipophilic and it is virtually insoluble in water or cell culture
medium. Previous groups using cyclosporin have used cremophor, ethanol or
dimethylsulfoxide (DMSO) as vehicles. Initial experiments examining the effect of
the various vehicles alone demonstrated that cremophor would be unsuitable as it had
a degree of toxicity at higher doses, and it also induced a degree of Hsp expression.
DMSO and ethanol had no effect in the required concentrations, and it was decided
to use ethanol for all subsequent experiments with cyclosporin.
7.2.2 Cyclosporin is toxic in high concentrations
HUH7 cells were treated with increasing concentrations of cyclosporin for 24 hours
and then cell survival measured by MTT assay (figure 7.1). There was a dose
dependent reduction in survival with increasing doses greater than lOpM (fp<0.05).
7.2.3 Heat shock protein expression
The pattern of heat shock protein expression following cyclosporin treatment was
examined in HUH7 cells. Initial experiments were guided from the literature, and
doses ranging from 0.1 pM to 50pM were used. Cells were treated with cyclosporin




Cyclosporin (nM) 0 1 10 25 50 V
Figure 7.1 Cyclosporin is toxic in high concentrations.
HUH7 cells were treated with increasing doses of cyclosporin for 24 hours and survival
measured by MTT. Concentrations of 1 OpM and greater led to a dose-dependent
reduction in survival. fp<0.05.
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There was no response in Hsp70 in the range tested, despite the dose response being
repeated using a variety of treatment durations. On some occasions Hsp70 was
elevated after treatment with 50pM, but this effect appeared to be due to a vehicle
effect, as the same concentration of ethanol produced a similar induction of Hsp70.
HO-1 was found to be induced at 10 to 50pM, which was maximal when cells were
treated for 24 hours (figure 7.2). This dose responsive induction was consistent
within experiments. However, there were often differences between experiments, and
on many occasions there was no detectable HO-1 induction.
Further western blots performed on cells treated with cyclosporin at the above doses
demonstrated that there was no induction of BiP (Grp78), Grp94, Hsp90, or Hsp27
when treated for up to 24 hours. When repeated in primary cultures of isolated
human hepatocytes, induction of HO-1 was variable between preparations, and was
induced to a lesser degree than that seen in HUH7 cells. No consistent induction was
seen in the expression of any other Hsps examined.
7.2.4 Confirmation of HO-1 induction
Initial western blotting results had demonstrated that HO-1 protein was induced by
10pM cyclosporin in HUH7 cells. In order to confirm that this induction was the
result of de novo synthesis and led to an increase in functional enzymatic activity of
HO-1, further experiments were performed to measure activity of an HO-1 reporter





Cyclosporin (nM) 0 1 10 25 50 V
Figure 7.2 Cyclosporin induces HO-1 but not Hsp70 in HUH7 cells.
Cells were treated with increasing doses of cyclosporin for 8 hours as indicated
(l-50p.M), and then western blot performed for Hsp70 and HO-1. V vehicle (ethanol,
equivalent of 50pM).
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levels, and to measure heme oxygenase activity after treatment with 1OpM
cyclosporin.
HO-1 and Hsp70 reporter activity was measured in HUH7 cells (figure 7.3). HO-1
reporter activity was increased after cyclosporin treatment for 21 hours. The
induction was modest, with a mean induction of 1.2 fold greater than control (non¬
significant). Hsp70 reporter activity was reduced following 10-25pM cyclosporin
treatment (p<0.05). Vehicle had no effect on HO-1 reporter activity, but did slightly
increase Hsp70 reporter activity (non-significant).
HO-1 mRNA was measured using real time PCR. It was performed on isolated
human hepatocytes from three different liver preparations. HO-1 was increased by
cyclosporin treatment in a dose responsive manner (figure 7.4). As with the western
blotting results, there was a large degree of variability in the results obtained with
isolated hepatocytes, although HO-1 mRNA levels were increased in every treatment
group. The dose response was performed only three times, which did not permit
statistical analysis of the results. Hsp70 mRNA was also measured in isolated human
hepatocytes. There was no induction ofHsp70 mRNA, consistent with results from
the western blotting.
Heme oxygenase activity was measured in HUH7 cells following treatment with
lOpM cyclosporin for 24 hours. Total activity was increased greater than two-fold
from 141 to 321 pmoles bilirubin/mg protein/hour (*p<0.01, figure 7.5). Vehicle had
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Cyclosporin (uM)
Figure 7.3 Hsp70 and HO-1 reporter activity in HUH7 cells after cyclosporin
treatment.
Cells were treated with increasing doses of cyclosporin for 21 hours (l-25p,M) and
reporter activity measured. Cyclosporin led to a modest induction ofHO-1 reporter
activity (non-significant), and reduced Hsp70 reporter activity at doses of 10-25pM
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Figure 7.4 HO-1 mRNA levels in isolated human hepatocytes following
cyclosporin treatment.
Cells were treated with cyclosporin for 5 hours and then mRNA isolated. HO-1





Figure 7.5 Heme oxygenase activity in HUH7 cells after treatment with lOpM
cyclosporin for 24 hours.
Cyclosporin treatment significantly increased heme oxygenase activity from 141 to
321 pmoles/bilirubin/mg protein/hour (*=p<0.01). Vehicle equivalent ethanol
treatment.
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no significant effect, lowering the activity slightly to 126 pmoles bilirubin/mg
protein/hour.
7.2.5 Localisation of HO-1 expression in Liver Slices
Liver slices were prepared as described in chapter 2, and cultured in the presence of
lOpM cyclosporin or equivalent vehicle controls. There was a concentration ofHO-1
in the Kupffer cells which was seen in control groups and was unchanged by
cyclosporin treatment. Hepatocytes demonstrated a low basal expression of HO-1,
and this appeared to be unchanged by cyclosporin treatment (figure 7.6).
7.2.6 Effect of Cyclosporin on HSF-1
Although Hsp70 was not induced in hepatocytes treated with cyclosporin, previously
published reports from other cell lines had suggested that HSF-1 could be activated
by cyclosporin treatment. For this reason, the activation state of HSF-1 was
examined following cyclosporin treatment.
It was decided to see if cyclosporin had any effect on HSF-1 when given at lOpM, a
dose which was sufficient to induce HO-1. HUH7 cells were used, and HSF-1
activation was assessed by native gel electrophoresis to assess trimerisation, gel
mobility shift assay (EMSA) to assess DNA binding, and differential electrophoretic




















Figure 7.6 Immunohistochemistry for HO-1 in Cultured Liver Slices.











Figure 7.7 Cyclosporin does not activate HSF-1 in HUH7 cells.
Cells were treated with lOpM cyclosporin for 2 hours and whole cell extracts were run
on a denaturing gel for relative electrophoretic mobility. Heat shock (43°C for 45
minutes) induced a slower mobility band demonstrating hyperphosphorylation ofHSF-1.
No such band was seen in cells treated with cyclosporin. Cyclosporin also had no effect
on prolongation of the period ofhyperphosphorylation.
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treatment had no discernible effect on HSF-1 activity or status in any of the
modalities tested.
7.2.7 Activation of HIF-la
HIF-la activation can induce FlO-1, and for this reason, it was examined by gel
mobility shift assay (EMSA) to see if cyclosporin may be inducing HO-1 through
HIF-la. Cyclosporin treatment was demonstrated to stimulate HIF-la binding as
measured by EMSA (figure 7.8). This was only evident after treatment with 30pM of
cyclosporin for two hours.
7.2.8 Cytoprotective Effects of Cyclosporin Treatment
Cyclosporin was assessed as a potential preconditioning agent. Following earlier
model development the glucose oxidase model of injury was used (see chapters 2 and
6). Both HUH7 and primary cultures of isolated human hepatocytes were tested.
Doses of 0.1 pM to lOpM cyclosporin were used as doses which induced HO-1
without leading to toxicity.
In HUH7 cells, cyclosporin was used on three separate occasions to precondition the
cells, with 6 replicates in each treatment group on every occasion. The cells were
treated with 0.1 to 10pM cyclosporin continuously for 24 hours prior to challenge
with glucose oxidase. After treatment with 10pM cyclosporin, there was a small
increase in survival on one occasion, which was statistically significant (109% vs
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100%, p<0.05). However, this was not reproducible on two subsequent repeats (see
table 7.1A). There was no effect with doses lower than lOpM.
In primary cultures of isolated human hepatocytes, cyclosporin was tested for a
preconditioning effect on 6 occasions, with 6 replicates each time treated as above.
On two occasions cyclosporin treatment led to an increase in survival, although this
was still less than that seen with vehicle treatment (ethanol, see table 7.IB). On the
other four occasions there was no protective effect seen with cyclosporin treatment.
On one occasion there was an increase in survival with treatment of 0.1 pM, but this
was also less than that seen with the relevant vehicle control.
To explore the possibility that cyclosporin might predispose the cells to protection if
a further stimulus was applied, additional heat shock treatment was introduced.
Primary cultures of isolated human hepatocytes were pretreated with lOpM
cyclosporin for 7 hours before being heat shocked at 43°C for 45 minutes, and then
returned to normal conditions in the cyclosporin containing medium for the
remaining 16 hours before being treated with glucose oxidase. In two experiments
the combination treatment led to a statistically significant increase in survival which
was greater than that seen with untreated controls (p<0.05, table 7.1C). However,
only one of these was statistically significant when compared with the vehicle
control. Four subsequent separate experiments failed to reproduce the protective
effect.
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Cyclosporin (uM) 0.1 1 10 30
Positive control +
Cold (+ve con) +
Supershift (+ve con)
Figure 7.8 HIF-la is activated in HUH7 cells by cyclosporin A.
Cells were treated with increasing doses of cyclosporin A for two hours and then nuclear
extracts were prepared. Cyclosporin treatment led to the appearance of a lower band at I
and l OpM (unlabelled arrow). After treatment a higher weight band appeared, similar to
the band seen in a hypoxic control.
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A
Nil CsA 10 V
1 100 109 f 101
2 100 75 58
3 100 92 97
B
Nil CsA 10 V
1 100 92 77
2 100 310 t 392
3 100 96 113
4 100 119 122
5 100 91 96
6 100 71 93
C
Nil CsA 10 V
1 115 146 f 114
2 116 263 f 242
3 109 100 96
4 141 111 212
5 100 61
6 100 90 102
Table 7.1 Cyclosporin does not precondition human hepatocytes.
HUH7 and primary cultures of isolated human hepatocytes were pretreated with
cyclosporin for 24 hours and then cytoprotection assessed in a model of oxidative
injury using an MTT assay. Results are displayed as a percentage of non-pretreated
cells, t p<0.05 vs Nil control. A. HUH7 cells. B. Primary cultures. C. Primary
cultures with additional heat shock (see text).
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7.3 Discussion
Initial experiments trialled three different vehicles for diluting cyclosporin.
Cremophor and DMSO had been used in other studies in the literature, however, the
use of cremophor led to toxicity in HUH7 cells at the required concentrations,
therefore ethanol was chosen as the vehicle for all subsequent experiments. It is
possible that a vehicle effect has contributed to some of the stress response inducing
effects of cyclosporin in published studies, as not all include appropriate vehicle
controls (for example Andres 2000).
Cyclosporin in ethanol was found to be toxic in doses greater than 10pM. It is known
that some of the deleterious effects of long-term cyclosporin treatment arise from
toxic effects, particularly in the kidney. In vitro studies have often used doses from
0.1 to 50pM, and so these were the doses chosen for further study in the preceding
experiments. Andres had found that in primary cultures of rat hepatocytes that
cyclosporin was toxic in doses of 10 to 50pM after 24 hours of treatment, consistent
with the findings in HUH7 cells (Andres 2000).
Confirmation of the actual tissue levels of cyclosporin obtained during treatment is
difficult. The original phase I and II trial data remains classified, and Novartis will
not release such information at present. Other studies have found that the
concentration in the liver in patients with a liver transplant on therapeutic doses of
cyclosporin is approximately 3.5pg/g of whole tissue (Sandborn 1992). It is difficult
to correlate this with the experiments performed here, as the cellular concentration of
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cyclosporin was not directly measured. One group has published that uptake of
cyclosporin into HepG2 cells (another human hepatocyte cell line) is approximately
50% of available cyclosporin when given in the presence of LDL, as would be the
case in the above experiments (Rifai 1996). If this were translatable to the HUH7
cells, this would mean an approximate cellular concentration of lOmg/g, thus far in
excess of the levels obtained in clinical practice. Other published studies show
plasma concentrations of cyclosporin of 100 to 38000pg/l in healthy volunteers
(Sgoutas 1986, Gurecki 1985), although levels of around 300 are more common
clinically (Sandborn 1992). This gives plasma levels in the range of 0.1 to 32pM.
Therefore the levels examined in this chapter are for the most part greater than would
be seen in clinical practice, although they may still be achievable by oral dosing.
Examination ofHsp expression after cyclosporin treatment yielded variable results.
Hsp70 was never induced, and HO-1 was induced on most, but not every occasion in
HUH7 cells, and was only minimally induced in primary cultures. The reason for
these differences is unclear. During the courses of the experiments several different
bottles of cyclosporin were used. Although these were bought from a reputable
dealer (Sigma) and of tissue culture grade, it is possible that there was some inter-
batch variation in their biological activity. The cyclosporin was always made fresh
from a stock stored at the recommended conditions (2-8°C). However the drug may
not have been as stable as described, and there may have been degradation of its
biological activity during storage. There is also the possibility of contaminants,
although the bottles were only opened with careful aseptic technique within tissue
culture hoods. There is, as described in earlier chapters, a degree of variation in the
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preparations of primary cultures. However, this would not explain the results from
the HUH7 cells which should have behaved in an identical fashion in each
experiment, thus suggesting that the problem did not lie with the cells themselves. As
mentioned above, LDL levels change the cellular uptake of cyclosporin (Rifai 1996),
and it may be that there was variation in the lipoprotein content of the fetal calf
serum used during the course of the experiments. No experiments were performed in
serum free culture.
Although HO-1 was induced to a variable degree, Hsp70 was not induced. This is in
contrast to other groups results in cardiomyocytes and in a kidney whole organ
model (Chen 2002, Yang 2001). In rat hepatocytes, Andres found an increase in
Hsp70 following treatment with 50pM cyclosporin for 24hours, which was
associated with significant toxicity, with 30% cell death (Andres 2000). This is the
same degree of cellular toxicity obtained in HUH7 cells with the same cyclosporin
treatment, and it is possible that the difference reflects differences in the cell types'
responses to cell death. This is analogous to previous findings ofHsp70 following
curcumin treatment, where even toxic doses of curcumin did not lead to Hsp70
induction (chapter 3).
HO-1 was induced by treatment with lOpM cyclosporin. This was variable in both
HUH7 cells and primary cultures as discussed above. This was reflected in the
results for the reporter activity, mRNA levels and HO enzymatic activity, which
show variation in the degree of response between the three methods. This likely
reflects the differential success in inducing HO-1 protein on different occasions. The
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liver slices did not demonstrate a large increase in HO-1 in hepatocytes. However,
this was performed using immunohistochemistry and was only used to provide
qualitative data on the localisation ofHO-1 within the treated liver, where HO-1 was
seen to be mostly concentrated within the Kupffer cells, and this was unchanged by
cyclosporin treatment.
In view of a previously published report that cyclosporin activates HSF-1 in kidney
cells (Paslaru 2000), this was examined in HUH7 cells. There was no activation of
HSF-1 in any of the methods tested. There is a concern that, with such apparent
variation in the biological effect of cyclosporin between experiments, activation of
HSF-1 may have been missed. However, there was at no point induction ofHsp70
with cyclosporin treatment, and when combination treatment of cyclosporin and heat
shock was performed, there was also no additional induction of Hsp70 over that seen
with heat shock alone. This appears to confirm that HSF-1 was not modified or
activated by cyclosporin.
Cyclosporin has been demonstrated by other groups to induce production of reactive
oxygen species (Chen 2002), and hypoxia inducible factor la (HIF-la) has been
shown to respond to chemical oxidative stress in the liver (Tacchini 2002). HIF-la is
a potent inducer ofHO-1, and it was for this reason that HIF-la activity was studied.
It appeared that cyclosporin treatment did increase HIF-la activation as measured by
EMSA. Whilst the human HO-1 promoter does contain a consensus binding
sequence for HIF-la, it has recently been established that hypoxia does not induce
HO-1 in human tissues, although it does in other species (Kitamuro 2003). Recent
213
evidence suggests that in human cells, hypoxia induces the inhibitory factor Bachl,
preventing the upregulation ofHO-1 by hypoxia. In the absence of hypoxia,
however, HIF-la could bind to the HRE and mediate HO-1 induction in response to
a chemical stimulus. Of note, however HIF-la activation did occur at higher
treatment doses (30pM), which would be consistent with the doses known to induce
ROS production (Chen 2002).
As noted earlier, HO-1 induction was seen following treatment with IOjxM
cyclosporin, the level at which toxicity was identified. The toxicity and HO-1
induction could both be related to ROS generation. At this concentration, however,
with increased generation of intracellular ROS, many non-HIF pathways could also
be activated (e.g. Nrf2 or AP-1). Whilst this was not directly explored because of the
inconsistent induction ofHO-1, it could have been tested by siRNA or Nrf2 and HIF-
la as performed in chapter 5. From the data obtained, it is not possible to conclude
whether HIF-la contributes significantly to HO-1 induction by cyclosporin.
Final experiments regarding cyclosporin involved examining it for a cytoprotective
effect. This was assessed in HUH7 cells and in primary cultures of isolated human
hepatocytes. Despite initial experiments in each cell type showing a possible
protective effect, this was not reproducible. It has to be concluded that there is no
preconditioning effect of cyclosporin treatment on human hepatocytes. This conflicts
with results from other groups where cyclosporin was able to protect cardiomyocytes
from oxidative injury (Chen 2002), and protect kidneys in an ischaemia reperfusion
model (Yang 2001). However, as discussed above, both of these studies found that
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there was induction ofHsp70, which may account for their cytoprotective phenotype,
whilst in contrast, human hepatocytes did not produce Hsp70 following cyclosporin
treatment.
7.4 Conclusion
Cyclosporin was not found to consistently induce the stress response in human
hepatocytes. It was able to induce HO-1 expression in a very variable manner, and it
is unclear why the results between experiments was inconsistent. Cyclosporin was
not able to induce preconditioning in in vitro models of oxidative injury, and would
not be a candidate preconditioning agent.
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Chapter 8




Earlier chapters have focussed on chemical induction of HO-1 and the mechanisms
through which this occurs. However, whilst there are numerous agents and stimuli
which induce HO-1, there has been little examination of the effect ofHO-1 induction
on other functions of the cell. The HO-1 pathway is of doubtless importance,
however it is often thought of as a single separate entity within a cell, and collateral
effects both of the various inducing agents and of the products of HO-1 activity are
generally not considered. The premise of this work is the development of a
preconditioning agent for therapeutic use. It is for this reason that this chapter
examines the effect of several different methods of HO-1 induction on differentiated
cell function within hepatocytes.
Hepatocytes are the synthetic powerhouse of the liver and the body, producing
important proteins such as albumin and fibrinogen. They are also involved in the
response of the body to infection or inflammation, producing large volumes of acute
phase proteins such as C reactive protein (CRP) and a1-antichymotrypsin. They are
involved in body iron metabolism by synthesis of transferrin, and are also critical in
the clearance of waste products such as urea. They have further roles including
detoxification of drugs and other agents by the action of various cytochrome
oxidases. It is a requirement for any therapeutic manipulation of HO-1 in the liver
that it does not impair the many other diverse activities of hepatocytes.
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8.2.1 HUH7 cell line
Initial experiments were performed to determine which acute phase proteins were
synthesised by HUH7 cells. They were found to produce undetectable amounts of
CRP, haptoglobin or a1-antichymotrypsin. However, they did generate measurable
amounts of transferrin and fibrinogen, and these were chosen for further study.
Curcumin (lOpM) and hemin (20pM) were chosen as chemical inducers of HO-1,
and the synthesis of fibrinogen and transferrin was then measured in the presence or
absence of these agents. Other cells were transfected with a rat HO-1 expression
vector (or a control vector) and fibrinogen and transferrin levels measured.
Curcumin suppressed fibrinogen synthesis in resting cells after treatment for 8 or 24
hours (figure 8.1 A). It was lowered to 55% of that seen in control cells following 24
hours of treatment (211±13 vs 382±18 in controls, p<0.05). This did not prevent the
induction of fibrinogen by the addition of IL-6, although levels in curcumin and
IL-6-treated cells were still lower than in cells treated with IL-6 alone (888±14 vs
1073±45, p=0.075).
Hemin treatment led to a minor reduction in fibrinogen levels to 94% of control
levels at 8 hours and 92% at 24 hours, with an identical effect on cells co-treated
with IL-6 (92% of controls, not significant). Transfection with the HO-1 expression
vector suppressed fibrinogen in resting cells, which was slightly lower than the level
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seen in control transfections (245±10 vs 288±24 at 24 hours, p<0.05, figure 8.1A).
Transfection with HO-1 also limited the response to IL-6 to a greater degree than the
control vector (607±34 vs 795±19, p<0.05).
Curcumin suppressed transferrin production in resting cells after treatment for 8 or
24 hours (figure 8.IB). It was lowered to 45% and 39% of that seen in control cells
following 8 or 24 hours of treatment (p<0.05). IL-6 treatment a minor effect on
transferrin levels, increasing it to 120% of control cells (385±25 vs 318±23). This
increase was not seen in curcumin treated cells.
Hemin treatment led to a reduction in transferrin levels to 86% of control levels at 8
hours and 72% at 24 hours. The addition of IL-6 increased transferrin levels to 120%
of that in cells receiving hemin alone, but this was still less than that seen in cells
treated with IL-6 alone (p<0.05). Transfection with the HO-1 expression vector
suppressed transferrin both in resting cells and in cells treated with IL-6. This






























Figure 8.1 Fibrinogen and Transferrin Levels in HUH7 cells following treatment
with various HO-1 inducers. A. Fibrinogen B. Transferrin.
HUH7 cells were treated with curcumin (10pM) or hemin (20p.M) or transfected with
a rat HO-1 expression vector (HO-1) or control vector (CAT), and the production of
fibrinogen and transferrin was measured. The concentration of fibrinogen was
measured after 24 hours of treatment, with or without concomitant administration of
IL-6. *=p<0.05 between indicated comparison groups.
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8.2.2 Isolated Primary Human Hepatocytes
8.2.2.1 Acute Phase Proteins
Fibrinogen, CRP and ocl-antichymotrypsin were chosen as positive acute phase
proteins, and transferrin was chosen as a negative acute phase protein. All of these
acute phase proteins are synthesised by isolated human hepatocytes. The level of
production was then measured after treatment for 24 hours with the HO-1 inducing
agents curcumin (lOpM), cobalt chloride (lOOpM) and hemin (20pM). In addition to
treatment with these agents, IL-6 and TNFa were used to modulate the acute phase
response where indicated.
8.2.2.1.1 Fibrinogen
Fibrinogen levels were unchanged following treatment with curcumin or hemin,
whilst cobalt chloride produced a significant reduction compared with that of
untreated controls (547 vs 1331 ng/ml, p<0.05, figure 8.2A). Fibrinogen was
significantly upregulated by IL-6 (1331 to 3091, p<0.05). There was still a marked
response to IL-6 in cells treated with curcumin and hemin, although this was slightly
less than that seen in controls (232% in controls, 195% and 162% respectively in
curcumin and hemin treated cells). Cobalt chloride completely prevented any
response to IL-6. TNFa treatment lowered fibrinogen levels in all groups. This was
unaffected by curcumin treatment, but hemin remained capable of inducing
fibrinogen in the presence of TNFa (798ng/ml in hemin and TNFa treated vs
588ng/ml in TNFa only controls, p<0.05, figure 8.2A).
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8.2.2.1.2 C Reactive Protein
As with fibrinogen, there was no effect of curcumin or hemin treatment on resting
CRP levels (figure 8.2B). Cobalt chloride treatment did slightly reduce CRP levels,
but this was not significant (125ng/ml vs 94ng/ml, p=0.173). In keeping with its
status as a positive acute phase protein, there was a marked increase in CRP levels
with IL-6 treatment and, as found with fibrinogen, curcumin and hemin treatment did
not prevent the response to IL-6, although it was slightly less than that seen in
controls (341 and 291ng/ml respectively, compared with 400ng/ml in controls). In
cells treated with cobalt chloride, CRP levels were completely unchanged with IL-6
treatment. TNFa had no significant effect on CRP levels.
8.2.2.1.3 al-Antichymotrypsin
The levels of al-antichymotrypsin (A1AT) were unchanged by treatment with
curcumin or hemin, although they were markedly reduced by treatment with cobalt
chloride (763 vs 382ng/ml p<0.05, figure 8.3A). There was a mild increase in A1AT
levels with IL-6, which was unaffected by curcumin treatment, but was prevented in
hemin treated cells. TNFa lowered A1AT levels in all groups tested, but there was no
difference with the response seen in control, curcumin or hemin treated cells. Cobalt
chloride impaired A1AT production, and this was unaffected by cytokine treatment.
8.2.2.1.4 Transferrin
Treatment with curcumin or hemin had no effect on transferrin levels, although
cobalt chloride did significantly reduce transferrin (128 vs 237ng/ml, p<0.05, figure
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Figure 8.2 Acute Phase Protein Synthesis in Isolated Human Hepatocytes.
A. Fibrinogen. B. CRP.
Isolated human hepatocytes were treated with curcumin (lOpM), hemin (20pM) or
cobalt chloride (100pM) for 24 hours in the presence or absence or IL-6 and TNFa.
Cobalt chloride significantly reduced the expression of fibrinogen and CRP. *=p<0.05
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Figure 8.3 Acute Phase Protein Synthesis in Isolated Human Hepatocytes.
A. al-Antichymotrypsin. B. Transferrin.
Isolated human hepatocytes were treated with curcumin (lOpM), hemin (20pM) or
cobalt chloride (lOOpM) for 24 hours in the presence or absence or IL-6 and TNFa.
Cobalt chloride significantly reduced the expression of al-antichymotrypsin and
transferrin. *=p<0.05 compared with appropriate nil controls.
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8.2.2.2 Cytochrome p450
The activities of three cytochrome p450 enzymes were measured: 1A2, 2C9, and
3A4 (figure 8.4). 1A2 activity was significantly increased by curcumin and cobalt
chloride treatment (171% and 670% percent of activity in untreated cells, both
p<0.05). Treatment with hemin or cobalt chloride increased 2C9 activity (202% and
167% of untreated cell, both p<0.05). Curcumin marginally increased 2C9 activity,
although this was not statistically significant (122%, p= 0.173). 3A4 activity was
unchanged by curcumin or hemin treatment, but significantly elevated after treatment
with cobalt chloride (228% of controls, p<0.05).
8.2.2.3 Urea synthesis and ATP levels
Urea production was increased in cells that had been treated with hemin (142% of
untreated controls, p<0.05) and cobalt chloride (120%, p<0.05, figure 8.5). In
contrast, curcumin reduced urea synthesis to 49% of untreated controls (p<0.05).
ATP levels were also measured in hepatocytes following treatment with the HO-1
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Figure 8.4 Cytochrome p450 activity following treatment with HO-1 inducers.
The activity of the 1A2, 2C9 and 3A4 isoforms of cytochrome p450 were measured
in isolated human hepatocytes following treatment with curcumin (lOpM), hemin
(20pM) or cobalt chloride (C0CI2, lOOpM). Results are expressed as % of untreated
controls. The induction of 1A2 activity following cobalt chloride treatment (670% of
untreated controls) is not plotted to prevent distortion of the scale. *=p<0.05





Figure 8.5 Urea synthesis following treatment with various HO-1 inducers.
Urea synthesis was measured in primary cultures of isolated human hepatocytes
following treatment with the HO-1 inducers curcumin (10pM), hemin (20pM) and
cobalt chloride (C0CI2, lOOpM). Results are shown as % of urea synthesis in nil
controls, and represent the mean of 6 repeats ± SEM. All treatment groups were
statistically different from untreated controls, with curcumin reducing ureagenesis
and cobalt chloride and hemin increasing it. *=p<0.05 compared with nil control.
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8.3 Discussion
There are many different ways to induce HO-1 in hepatocytes. Many of these involve
the administration of chemical agents, the full cellular effects of which are unknown.
If such strategies are to be used in the liver in clinical practice, it is important to
consider the effects of these agents on the various specialised functions of the
hepatocyte.
The hepatocyte has many different functions, of which only some were studied in
this chapter. The functions chosen were identified as representing clinically
important parameters. Acute phase protein synthesis is important in how the body
responds to stress and surgery. Cytochrome p450 is important in the metabolism of
many drugs, and urea synthesis is the main route of removal of ammonia from the
body.
HUH7 cells and primary cultures of isolated human hepatocytes were used in this
study. There are significant differences between the two cell types. HUH7s were
found not to produce measurable levels of CRP, haptoglobin or al-antichymotrypsin.
This is consistent with other reports (Nakabayashi 1982). This limited the amount of
information which could be obtained from HUH7 cells, and thus primary cultures of
hepatocytes were used for further experiments.
The methods of HO-1 induction were treatment with curcumin, hemin or cobalt
chloride, or transfection with a rat HO-1 expression vector. The different methods all
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induce HO-1 through slightly different mechanisms, and hence may result in
different effects on hepatocellular function, with curcumin acting through ROS
generation (chapter 5), hemin acting through inhibition of Bachl (Ogawa 2001) and
cobalt chloride stimulating HO-1 through HIF-la dependent and independent
pathways (Gong 2001). Use of the HO-1 expression vector should have allowed
examination of the effect of HO-1 induction in a pure form. However, it was only
used in HUH7 cells, as the transfection efficiency obtained in primary cultures was
insufficient to allow further study.
Each chemical inducer (hemin, curcumin and cobalt chloride) induces HO-1 at
different concentrations. Preliminary experiments confirmed that 20pM hemin,
lOpM curcumin and 100pM cobalt chloride produced similar levels of induction of
HO-1. Hence, although different treatment doses were used for each chemical agent,
they produced similar levels of HO-1. If these agents were to be used clinically for
preconditioning, they would each be given in a dose which reliably induced HO-1
and produced the desired cytoprotective effect. Thus, although the dose of each drug
used in this study was different, they were selected on the basis that these doses
produce comparable HO-1 levels, and their comparison is clinically relevant.
Fibrinogen is a positive acute phase protein, and in both primary hepatocytes and
HUH7 cells it was seen to respond appropriately to IL-6. Curcumin and hemin had
no effect on either basal or induced levels, whilst cobalt chloride reduced fibrinogen
levels. In contrast, in HUH7 cells, fibrinogen levels were suppressed by curcumin
treatment, although they still increased with concomitant IL-6 treatment. The reason
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for this conflicting result is unclear, but it may represent differences in the HUH7
cells. These are an immortalised cell line, and do not synthesise all acute phase
proteins. Hence it is possible that there is aberrant control of acute phase protein
synthesis. The primary cultured hepatocytes are much more likely to represent a
"normal" response. It is also important to note that there is significantly less
fibrinogen synthesised by HUH7 cells than by primary cultured hepatocytes
(approximately one third at resting and post IL-6 levels). This is unlikely to be due
simply to a difference in the synthetic potential of the two cell types, as the basal
level of transferrin in HUH7 cells is greater than that found in primary hepatocytes,
and it further implies differential regulation of acute phase protein expression in the
two different cell types.
In primary hepatocytes, neither curcumin nor hemin had a deleterious effect on acute
phase protein expression, with only slight differences being noted between treated
and control cells. Only four such proteins have been assessed here, and only their
response to IL-6 and TNFa. However, from the current study there is no evidence to
suggest that using these agents to induce HO-1 would significantly alter the synthesis
of acute phase proteins if they were used as preconditioning agents in the human
body. Cobalt chloride, given at lOOpM, was found to suppress the production of all
acute phase proteins studied.
The synthesis of urea was altered by the HO-1 inducing agents. Cobalt chloride
treatment increased ureagenesis, whilst curcumin suppressed it. Hence the
suppression of acute phase protein production by cobalt is not simply the result of
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generalised inhibition of cellular processes. This demonstrates that various potential
preconditioning agents may have different profiles across the different specialist
functions of the hepatocyte. For example, cobalt also increased the activity of all
cytochrome p450 enzymes studied. Thus cobalt chloride cannot necessarily be seen
as an inferior preconditioning agent, as there may potentially be occasions where it
would be preferred to have elevated cytochrome activity and a reduced acute phase
response. However, from the current results, it appears that hemin was the best agent
tested in terms ofmaintaining normal levels of cellular function.
The cytochrome p450 system is a large family of mixed function oxidases, and are
hemoproteins. They are important for the metabolism of a wide variety of drugs and
chemicals. One of the reasons for establishing the cytochrome activity following
HO-1 induction is that, as they are hemoproteins, they are a potential substrate for
HO-1 activity. Whilst some HO-1 inducers such as hemin provide a substrate for the
new HO-1 to metabolise, when HO-1 is induced by other agents, such as curcumin, it
is unclear which heme groups are degraded by the new formed enzyme. It has been
established that the protective effects of HO-1 induction require both substrate and
functional activity of the enzyme, and not merely its presence (Foresti 2001).
Therefore, in all models where HO-1 has been shown to be cytoprotective, there
must be degradation of heme groups. Because the cytochrome p450 system
constitutes a significant proportion of the heme groups in hepatocytes, it is of interest
to establish the effects of HO-1 induction on this family of enzymes. A study by
Yoshida in rat partial hepatectomy noted that there was an inverse relationship
between HO-1 and cytochrome p450 during liver regeneration (Yoshida 1984).
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However, as shown, with any of the chemical treatments used there was no
significant drop in the three cytochromes which were measured. It would have been
of interest to examine the effect of the HO-1 expression vector on cytochrome p450
activity. However this was precluded by the low transfection efficiency achieved in
primary human hepatocytes.
The cytochrome system is inducible by a variety of stimuli such as hormones,
alcohol and bioflavonoid (Waxman 1999). Each enzyme has its own peculiar
substrates. The 3A subfamily is one of the most important drug metabolising families
in humans. The 3A4 enzyme is important in metabolising a large number of
clinically useful drugs including paracetamol and warfarin. Among other substrates,
1A2 metabolises caffeine and 2C9 metabolises non-steroidal anti-inflammatory
agents. Thus, there is a significant potential for clinically important interactions if
preconditioning agents were to alter the expression of these enzymes.
Curcumin has been reported to inhibit 1A2 in rat hepatocytes (Oetari 1996). This was
not found in the current study. Whilst this might reflect species differences, the
reason may lie in the different assay methods used. In the method used in this study,
cells had been pretreated with curcumin for 24 hours. However, when the protein
was extracted from the cells, the actual reaction contained only cellular protein.
Curcumin is highly lipophilic, and whilst it may have saturated the cell, it is likely to
have been largely removed with the membrane during the protein extraction process.
In contrast, in Oetari's study, curcumin was added directly into the assay reaction,
and was found to be inhibitory. Thus, whilst Oetari has shown that curcumin can
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inhibit the activity of 1A2 when it is present in the chemical reaction, the results of
this chapter do not support this as being of relevance to the functional activity of 1A2
within the cellular environment.
It has been shown by another group that curcumin has no effect on the expression of
3A4 (Raucy 2003). This would be consistent with the findings of this study. Of
interest, endotoxin suppresses cytochrome p450 levels. Curcumin has been shown to
prevent the reduction in 2C11, 3A2 and 2E1 following endotoxin treatment (Cheng
2003). Such a dynamic response has not been studied in this work. However it
suggests that curcumin may be a good choice as a preconditioning agent because it
may be able to help maintain cytochrome p450 levels.
8.4 Conclusion
Heme oxygenase-1 induction does have an effect on the differentiated cell function
of hepatocytes, and this varies between the agents used. Greater understanding of the
wider effects of HO-1 inducing agents may enable establishment of scenarios in
which distinct agents are chosen in particular circumstances. From the results
obtained, hemin was the best agent at maintaining normal hepatocellular function.
Curcumin, which has been found in earlier chapters to have preconditioning potential





This work has examined the ability of curcumin and cyclosporin to induce the stress
response in human hepatocytes, and the mechanisms through which this may occur.
The principle underlying this work is that induction of the cell's natural defence
mechanisms in the form of the stress response could be used as a therapeutic strategy
to improve outcomes after liver surgery.
9.1 Isolated Human Hepatocytes
This research focused on the study of the stress response in human hepatocytes.
Primary cultures of isolated human hepatocytes were prepared from patients
undergoing elective liver surgery. There were some limitations on the project as a
result of using these cells. The cells were not always available on a regular basis,
depending on the scheduling of patients for resectional surgery. This meant that a
proportion of experiments were performed in the HUH7 cell line, which allowed
guaranteed supply.
There was some intrinsic variability of the primary human hepatocytes between
preparations. This is a result of the duration of surgery and other operative factors,
but also relates to the age of the patient. Significantly greater yields of cells were
obtained from younger patients than from older patients.
One of the other potential areas of criticism of this work is that it relates solely to
hepatocytes. In the liver there is a complex arrangement of Kupffer cells, Ito cells
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and endothelial cells, which all interact with the hepatocytes. This interaction was
not addressed in the current study. Kupffer cells and endothelial cells were
independently isolated several times during the preparation of hepatocytes, and the
method within the laboratory generated almost pure populations of these cells. Thus,
the effect of the interaction of different cell types could be studied using a variety of
co-culture models, although time did not allow for this to be performed in the current
study.
Slices of liver tissue were prepared and cultured, which could have been used to
address some of the effects of cell-cell interaction. However, there were some
intrinsic difficulties with this technique. A dedicated tissue slicing machine was not
available, and so the slices were cut by hand. This led to minute variations in the
thickness of the slices, and this had a profound effect on the viability of the thicker
slices. Even in thin slices, there was noted to be patchy cell death and loss of the liver
architecture. Thus the culture conditions were not perfect, and although there were
several attempts made to optimise conditions, these were unsuccessful. The slices
were used in a limited fashion to examine the pattern of HO-1 expression in the liver
following curcumin and cyclosporin treatment (chapters 3 and 7 respectively). If the
technical difficulties could be overcome, the ability to culture fresh slices of tissue
would be of great interest and a valuable laboratory tool.
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9.2 Curcumin
Initial experiments examined the bioflavonoid compound curcumin. This natural
extract from the plant curcuma longa has been used in as a traditional medicine in
Indian and Chinese cultures. In human hepatocytes it was found to increase
production of heme oxygenase-1, and this was found to be protective in in vitro
models of hepatocellular injury. Thus, it may have clinical potential as a
preconditioning agent.
As described in chapter 4, a considerable amount of time and effort was spent on
examining the effect of curcumin on HSF-1. Ultimately this was not rewarded by
positive results. The main stimulus for the continued examination ofHSF-1 was a
combination of the previously published reports that HSF-1 was activated by
curcumin in HeLa cells (Dunsmore 2001), and the finding of elevated Hsp70 mRNA
levels after curcumin treatment in HUH7 cells (chapter 3). Thus it was important to
be certain that an effect on HSF-1 by curcumin had not merely been undetected by
the experimental design. It was for this reason that each of the component parts of
the HSF-1 activation process was examined.
On reflection it would appear that there are a number of significant differences in
HUH7 and HeLa cells. It is apparent from their response to toxic doses of both
curcumin and cyclosporin A that HUH7 cells do not respond to such toxicity by
producing Hsp70. They do respond appropriately to heat, which does produce HSF-1
activation and Hsp70 as expected. This lack of Hsp70 induction in the face of drug
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toxicity is not unique to HUH7 cells, and similar differences in several types of
primary and immortalised cell lines in response to curcumin has been demonstrated
by other groups (Khar 2001).
Curcumin has many attractions as a preconditioning agent. It is a dietary constituent
and is well tolerated when given orally even in high doses, although at very high
doses mild gastro-intestinal upset may occur (Garcea 2004). However, as discussed
in chapter 6, its bioavailability following oral administration is poor, and may be
insufficient to induce HO-1 in vivo. Curcumin has been administered parenterally in
animal studies and this is a potential route for use in humans, however one of the
advantages of curcumin is that it is known to be safe after oral administration. There
are no studies in human subjects on parenteral administration of curcumin, and, if
this line of treatment were to be pursued, the phase I initial trials and would need to
be repeated and the full process of drug development would need to begin from
scratch just as for a newly developed agent. This is not insurmountable, but removes
some of the attractions of curcumin as a ready to use preconditioning agent.
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9.3 Cyclosporin
Cyclosporin was also examined for its preconditioning potential. This was based on
reports in the literature suggesting that it was capable of inducing Hsp70 and exerting
a preconditioning effect on the kidney (Andres 2000, Yang 2001). However,
cyclosporin did not consistently induce the stress response in human hepatocytes in
this study. Cyclosporin did induce HO-1 expression in a very variable manner, but it
remains unclear why the results between experiments was inconsistent. Cyclosporin
showed promise as a preconditioning agent on initial testing (chapter 7). However,
this result was not reproducible. A considerable amount of time was exerted in
attempting to reproduce the initial results. Ultimately these were not reproducible
and thus it has to be concluded that cyclosporin A is not a suitable preconditioning
agent.
9.4 Other Preconditioning Agents
Curcumin and cyclosporin A were not the only agents tested. Initial plans were to
examine tacrolimus (another calcineurin inhibitor) in addition to cyclosporin A, to
look for a class effect of these drugs on the stress response. Unfortunately, the
disappointing results with cyclosporin A suggested that tacrolimus may not be a
suitable preconditioning agent. A small number of experiments were performed
which showed that tacrolimus did induce HO-1. However, by this point the project
was fairly advanced and there was insufficient time to explore this agent in detail.
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Tacrolimus would be worthy of further study, particularly the mechanism through
which it induces HO-1. Indirectly, this work also confirmed that hemin is a good
agent to induce HO-1 in human hepatocytes, and that it has a strong preconditioning
effect.
9.5 The Ideal Preconditioning Agent
The ideal preconditioning agent would work as a "silver bullet", having its effect on
a specific molecular target, with a specific cellular effect. This would have no
unintended effect on other aspects of the cell's natural functioning. Current
understanding of cellular mechanisms and the interplay between different pathways
does not provide sufficient detail to be sure from the laboratory that any agent would
be entirely specific. There will always have to be a series of experiments to assess
the effects of the treatment on the cell as a whole, and then subsequently in whole
organ and whole organism treatment.
It is in some ways unlikely that any drug derived from plants or fungi will have a
unique effect within the human body. Thus, from a philosophical point of view, it
was unlikely that curcumin would work as a "clean" drug, on a specific cell
membrane receptor, with no unintentional side effects. The fact that it, in common
with several other agents, appears to trigger its induction ofHO-1 through generation
of ROS demonstrates that many structurally varied compounds can have the same
effect on the cell, but this is not the same as a targeted molecular approach. As our
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understanding of the interplay between different kinase pathways and transcription
factors increases, the goal of developing a single agent to produce a single cellular
effect seems in many ways more elusive than ever. However, as technology
continues to develop, other approaches and avenues open up. In light of the known
cytoprotective effects of HO-1, current understanding of the regulation ofHO-1
could be used to develop a novel way of inducing HO-1. The options range from
increased substrate delivery in an organ specific manner, through to molecular
delivery of transcription factors and ultimately to introducing extrinsic HO-1.
Recombinant viral transfer techniques may in time allow the delivery of synthetic
HO-1 to specific cells, in a manner that allows the HO-1 to be produced after a
certain trigger, and then for it to desist and remove itself after another such stimulus.
However, the lack of specificity of current methods should not prevent their use for
preconditioning. For example, ischaemic preconditioning is effective and likely
harnesses multiple cellular mechanisms.
The initial premise of this work was to assess the ability of the hepatocellular stress
response to be pharmacologically induction, thus producing a stress-tolerant
phenotype. Since its description over twenty years ago (Tanguay 1983), the stress
response has attracted a great deal of research. In this regard, Hsp70 and HO-1 have
been identified as potential components of the stress response which could be
manipulated for therapeutic use. As this work progressed, it became apparent that
curcumin had potent HO-1 inducing properties, with very little effect on HSF-
1/Hsp70. Similarly, cyclosporin, although very variable in its effect, also had its
main effect on HO-1. Thus, although this work began to examine the stress response
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in general, it became increasingly focused on HO-1. The ubiquitous nature ofHO-1
and its established ability to protect cells from a wide variety of damaging stimuli
mean that it is a good target to seek to modulate for clinical ends. Whilst many
agents can induce HO-1, the realistic development of a clinically useful HO-1
inducing agent requires that it be safe, non-toxic, and easily administered with no
deleterious effect on the human body. In many ways this work has demonstrated that
hemin is a good agent to induce HO-1 in human hepatocytes. It robustly and
reproducibly induces HO-1 and results in a tolerant preconditioned phenotype. When
compared with curcumin and cobalt chloride, it was the best agent at maintaining
normal cellular function whilst still inducing HO-1. Hemin is also physiological,
known to be well tolerated and available in a form that has a clinical license for
human treatment (as heme arginate for acute porphyria).
As this work progressed, it became apparent that curcumin had potent HO-1 inducing
properties, with very little effect on HSF-1/Hsp70. Similarly, cyclosporin, although
very variable in its effect, also had its main effect on HO-1. Thus, although this work
began to examine the stress response in general, it became increasingly focused on
HO-1. The ubiquitous nature ofHO-1 and its established ability to protect cells from
a wide variety of damaging stimuli mean that it is a good target to seek to modulate
for clinical ends. Whilst many agents can induce HO-1, the realistic development of
a clinically useful HO-1 inducing agent requires that it be safe, non-toxic, and easily
administered with no deleterious effect on the human body. In many ways this work
has demonstrated that hemin is a good agent to induce HO-1 in human hepatocytes.
It robustly and reproducibly induces HO-1 and results in a tolerant preconditioned
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phenotype. When compared with curcumin and cobalt chloride, it was the best agent
at maintaining normal cellular function whilst still inducing HO-1. Hemin is also
physiological, known to be well tolerated and available in a form that has a clinical
license for human treatment (as heme arginate for acute porphyria).
9.6 Practicalities of Therapeutic Preconditioning
The concept of preconditioning, as outlined in chapter one, requires the
foreknowledge of an injurious event. Despite this, there are many diverse areas
where it could be applied for clinical use. These range across several medical
disciplines, but the potential benefit is most apparent in elective surgical procedures
which interrupt the blood supply of an organ. It has particular potential for
resectional liver surgery and for solid organ transplantation.
9.6.1 Resectional Liver Surgery
In patients undergoing liver resection, there is often a need to clamp the blood inflow
to the liver to reduce bleeding during the operation. This is accomplished by the
"Pringle" manoeuvre. The vessels are clamped for as short a period as possible to
perform the surgery, and then the clamps are removed and the hepatic inflow is
restored. This results in an ischaemia-reperfusion injury as described in the
introduction. It is apparent that, in this controlled situation, preconditioning
treatments would be of benefit to limit the degree of damage sustained during the
244
ischaemia-reperfusion injury. There is adequate forewarning of the insult which
would allow treatment with a preconditioning agent, and an appropriate insult which
preconditioning may limit, allowing improved outcomes after liver surgery.
However, current practice is safe and effective, and it is unlikely that preconditioning
will be used in straightforward resections where the clamp time is minimal. Indeed,
anatomical resections where solely the right or left lobe of the liver is removed
require only interruption of the blood supply to that portion of the liver which is
being removed, leaving the remaining liver tissue undamped and unharmed during
the operation. Preconditioning is likely to be ofmost benefit where extended liver
resections are to be performed, removing one lobe and a portion the another, which
necessitates the use of the Pringle manoeuvre as described, to prevent haemorrhage
from the remaining section of liver. This also leaves a smaller amount of functional
liver volume postoperatively. One of the limiting factors in larger resections is
leaving sufficient working liver tissue, the function of which is often impaired by the
ischaemia-reperfusion injury. Preconditioning treatments, in reducing the severity of
the insult, will maintain hepatic function to a greater degree, possibly allowing
longer clamping periods or extended resections to be performed.
In a clinical trial of ischaemic preconditioning in human liver resection, Clavien
found that the improvement in outcomes varied between the population subgroups.
In particular, the greatest benefit was seen in fatty livers (Clavien 2003). Although
pharmacological therapy may have a different clinical profile, the implication is that
preconditioning treatments may be best implemented in selected groups.
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9.6.2 Solid Organ Transplantation
Organ transplantation has been one of the great medical successes of our times. It has
revolutionised the treatment of organ failure, often allowing the recipient to resume a
normal lifestyle (Lazzaretti 2004). Every advance has led to an increased demand for
organs for transplantation and despite major improvements in immunosuppression,
organ preservation and operative techniques, patients continue to die on waiting lists
due to the shortage of donors (UK Transplant 2004). The number of potential
recipients in the United Kingdom awaiting organ transplantation has increased
annually, reaching more than 7000 by March 2004. New sources of organs, such as
living-donors, split livers and non-heart beating donors, has increased available
organs to a degree, however, these developments have failed to keep pace with the
decline in the available number of cadaveric organs. Novel therapies such as stem
cell technology and bio-artificial livers hold promise for the future, but have not yet
met their potential. There remains, therefore, a requirement for solid organ
transplantation that is unlikely to recede in the near future.
Solid organ transplantation, with its attendant ischaemia-reperfusion injury,
represents an area where pre-conditioning of the donor or the donated organs could
make a great contribution (McLaren 2003, Kosieradzki 2002), potentially reducing
primary non-function and early graft failure, and thus the requirement for re-
transplantation. This may allow organs that would currently be discarded to be used,
thus expanding the organ pool. However, there are practical and ethical issues
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involved in implementing pre-conditioning strategies that are particular to solid
organ transplantation.
9.6.3 Administration
Pharmacological pre-conditioning requires administration of a drug. In the case of
elective, living donor transplantation, there is adequate planning and time to permit
treatment of almost unlimited duration prior to surgery. However, in the case of
cadaveric donors, there is a limited window of treatment between diagnosis of brain
stem death and the organ harvest. This is of necessity kept to a minimum to maintain
the viability of the transplanted organs. Thus, whilst practically the treatment would
be in addition to a range of infusions which the donor would already be receiving and
would make little difference to the medical management of the donor, the agent
would need to be effective within a limited time frame.
This does, however raise some ethical issues. The optimum management of heart-
beating organ donors currently involves the administration of a variety of drugs and
infusions to maintain the organs in a suitable condition for transplantation. Pre¬
conditioning agents would aim to improve the target organs, rather than merely
limiting the detrimental effects of brain death, thus crossing the boundary from
maintenance to treatment, a cause of ethical concern. There are several precedents
for this type of active treatment. Hormonal resuscitation with triiodothyronine,
vasopressin and methylprednisolone is administered to heart transplant donors
(Rosendale 2003), with the aim of correcting the endocrine imbalances that occur
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after brain death. These are active treatments, intended to increase the number of
organs suitable for transplantation. However, they differ from pre-conditioning in
that they represent maintenance rather than therapeutic measures. Thus the boundary
between donor maintenance, optimization and pre-conditioning can be considered
indistinct.
There is an alternative argument that pre-conditioning may represent part of the
normal process of organ harvesting as it has the intention of increasing the chances
of a successful outcome and therefore should not require further assent or lack of
objection beyond that associated with organ donation itself. In his treatise on the
ethics of organ donation, Price suggests that "where an individual has requested that
his/her organs be used for transplantation after death, it seems correct to infer that
permission is granted for procedures which form part of the routine preliminaries to
transplantation without seriously compromising the patient in any way" (Price 2000).
Even where there is no explicit authorisation of procedures for maintaining donors
and their organs, they are not necessarily unlawful. However, while explicit
legislative provision to cover organ-pre-conditioning techniques may be desirable, it
is far more important that society endorses the concept that pre-conditioning
strategies in donors to improve organ function and outcome are ethically acceptable
and clinically warranted. With regard to organ procurement for transplantation, the
UK Human Tissue Bill currently being considered by Parliament states that "it shall
be lawful.. ..to take steps for the purpose of preserving that part [part of a body] for
use in transplantation, and to retain the body for that purpose". However, this
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authorisation "shall only extend to the taking of the minimum steps necessary....and
to the use of the least invasive procedure" (UK Human Tissue Bill 2004). It is
unclear whether such authorisation would extend to pre-conditioning techniques.
It is conceivable that the relative importance ascribed to such considerations might
alter depending on the nature of the pre-conditioning strategy considered. For
example it seems unlikely that many relatives would object to the deceased donor
being given a drug to improve organ function but it is possible that they might raise
objection if it were necessary to keep the donor ventilated for a prolonged period of
time to allow the drug to take effect.
9.6.4 Multi-organ donors
The majority of organ donors in the UK donate more than one organ. This raises the
question that if a pre-conditioning strategy had been demonstrated to confer a
beneficial outcome for a particular organ, would it be acceptable to use such a
treatment in a multi-organ donor if the effects on other organs were not known? The
answer in this case would probably be negative and so research involved in the
development of such strategies should consider effects on other organs that might be
donated simultaneously in a clinical setting. If the effects of a treatment on other
organs were not adverse, the question then arises as to whether the potential
recipients of other organs should be consulted and requested to give their consent to
pre-conditioning being used. The issues of consent and collateral involvement
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become more prescient in the context of a clinical trial where the effect of a pre¬
conditioning strategy may be the subject of evaluation.
9.6.5 Recipients of pre-conditioned organs
In many circumstances where pre-conditioning is used it may be impractical to
obtain consent from the recipients in time to influence the application of the pre¬
conditioning intervention. There is concern therefore that if a recipient objects to
receiving an organ which has undergone pre-conditioning this may subvert the
normal informed consent process by placing coercion on the recipient. Thus the
desire to receive a transplant may outweigh the concerns or objections of the
recipient to receiving an organ from a research protocol. It could be argued that pre¬
conditioning has the potential to improve the outcomes of transplantation and that
society should support research which aims to advance science or outcome in
medicine. Following this argument to its practical conclusion, the occasional refusal
to receive a pre-conditioned organ would be offset by the perceived benefit to society
as a whole. In practice perhaps the easiest way to deal with this issue would be to
inform patients, at the time of addition to the waiting list, that they may be offered
organs derived from trials of pre-conditioning protocols and that they should
consider whether they would accept such an organ. They would also be informed that
such protocols would have received approval from local regional ethics committees
and that such approval would not normally have been granted if there were issues
over either safety or perceived benefit.
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9.6.6 Pre-conditioning in a research setting
In common with other medical research, trials of pre-conditioning should abide by
the principles enshrined within the Declaration of Helsinki (World Medical
Organisation 1996). Specifically there should be an adequate laboratory and animal
research base to support human studies and these studies should have clear potential
for benefit counterbalanced against the inherent risk of the intervention. The design
of studies should be clearly set out and be undertaken by competent individuals.
Studies should have been reviewed and approved by an independent committee - in
the UK this would be the local or multi-centre research ethics committee as
appropriate.
Of importance is also the data from Azoulay's study on ischaemic preconditioning in
human liver transplantation from cadaveric donors (Azoulay 2005). This found that,
although biochemical markers of hepatocellular damage (i.e. serum transaminase
levels) were lower following transplantation of a preconditioned graft, initial poor
function was more common in these livers. This suggests that although the cells were
protected from the transplant-associated injury, the preconditioning technique
impaired hepatocellular function. This underlines the importance of understanding
the manifold unintended effects which may be seen with such a non-specific
treatment. In regard of the pharmacological agents tested in this work, this was
explored in chapter 8. All preconditioning agents will need to pass through a rigorous
testing procedure before they can be adopted as routine clinical tools. This is of
particular importance in the setting of organ transplantation where many parties are
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involved and there is a requirement to make the best use of a limited resource. This
may therefore limit the testing of preconditioning strategies in the transplantation
setting, despite its tremendous potential.
9.7 Future Work
Building on this work, future directions include further development of curcumin and
hemin as preconditioning treatments, and exploration of the role that HO-1 plays in
the survival of cancer cells.
Due to its aforementioned low bioavailability, curcumin may have limited use as an
oral agent for hepatic preconditioning. However, this has yet to be tested, and the
attractions of a ready to use, well tolerated agent with few side effects mandates that
this be assessed. This could be accomplished simply and easily in a limited study as
performed by Garcea, using a small number of patients due for elective liver
resection, and measuring HO-1 levels in the resected specimen (Garcea 2004).
It is possible that curcumin will not be suitable as an oral agent. It has been used
parenterally in animals, and this requires further study. None of the studies published
using curcumin in this way have yet looked at HO-1 expression and its
preconditioning potential. Furthermore, derivatives of curcumin such as
tetrahydrocurcumin may have greater biological activity than curcumin itself (Okada
2001). This has yet to be assessed in terms of its HO-1 inducing potential. Also, the
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interplay between different cell types may be important, and there may be an
amplification of HO-1 induction by hepatocytes in the presence of Kupffer cells.
This could be studied simply in vitro using co-culture models.
One of the outcomes of this work was that hemin was found to be a very clean
inducer ofHO-1, with minimal effects on the other functions of the hepatocyte. The
availability of hemin in a form for parenteral administration (heme arginate -
licensed for use in porphyria), makes this a attractive prospect for further study.
Heme arginate should be tested in vitro to confirm that this form is effective as a
preconditioning treatment, and then appropriate animal and human studies could be
performed depending on results.
In a different direction, the findings of chapter 9 demonstrated the contribution that
HO-1 genotype makes to outcomes of two malignancies. It would be of interest to
pursue this along several different avenues. Confirmation that tumours with the SS
genotype actually do manufacture greater levels of HO-1 than LL genotype cancers
would add to current knowledge. If this was confirmed, it raises the possibility of
developing anti-HO-1 therapies to help treat cancer, the premise for which has
already been established (Fang 2003). Ofmore relevance to liver surgery, now that




This work has added to the understanding of HO-1 induction and the cellular
mechanisms through which curcumin is effective. It has demonstrated that curcumin
induces HO-1 in human hepatocytes and that this occurs through oxidant pathways.
It also established that curcumin is a candidate preconditioning agent for human
hepatocytes. It does, however, have an effect on other important functions of the
hepatocyte. It merits further study, and clinical phase I/II trials are warranted.
Cyclosporin was not found to be a useful preconditioning agent, and it was extremely
inconsistent in its effect. Hemin, however, as a reliable agent to induce HO-1 which
has minimal other effects on the cell, may in due course be established as a clinically
useful agent for pharmacological preconditioning.
Preconditioning as a concept is now established. It holds great potential for a wide
sphere of clinical scenarios, and heme oxygenase-1 appears to be an ideal molecule
to exploit to achieve preconditioning. It only remains for the ideal therapeutic agent
to be established to permit preconditioning to be used as a clinical tool which may in





Analysis of the Effects ofDifferent Concentrations
ofHeme on Apparent Heme Oxygenase Activity
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The end products of heme oxygenase are carbon monoxide, biliverdin and free iron,
all of which can be measured. Monitoring carbon monoxide production requires
specialist equipment (Marks 2002). For this reason, many researchers use a
combination paired enzyme reaction with biliverdin reductase, first described by
Tenhunen in 1968 (Tenhunen 1968):
Heme Oxygenase Biliverdin Reductase
Hemin > Biliverdin > Bilirubin
NADPH NADPH
Bilirubin levels are then measured by a standard spectrophotometric method using
the difference in absorption at 454 and 530nm (s = 40mM~'cm~l). This technique has
been performed in several different ways over the past 30 years (Tenhunen 1968 and
1972, Motterlini 1996, Cuturi 1999 and Chauveau 2002) and appears to be robust.
There is a degree of variation in the way the assay as performed by different
laboratories. For this reason, the methods were compared in detail, and the effect of
different protein concentrations and heme concentrations were compared.
The basic reaction components do not vary between methods described in the
literature. All contain: hemin as a substrate for the reaction; an NADPH generating
system; a source of biliverdin reductase; and the experimental tissue sample or cell
lysate. The reaction is performed at 37°C and pH 7.4. Whilst the method for
purifying biliverdin reductase from fresh rat or human liver is well established (Kutty
1981, Yamaguchi 1994), the use of an unprocessed 105,000g supernatant from
homogenised liver obviates the requirement for prolonged purification steps which
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remove over 60% of biliverdin reductase activity. Attempts within this laboratory to
purify biliverdin reductase from human liver lysates resulted only in the production
of a very dilute extract with no discernable enzymatic activity. This loss of activity
was noted during the precipitation stage. Thenceforth, unprocessed 105,000g
supernatant was used.
The bilirubin concentration can be measured either directly in the aqueous reaction,
or following chloroform extraction. The peak absorbance of hemin and bilirubin is
385nm and 454nm respectively. However, the absorption spectra overlap particularly
at the concentrations present in the assay (figure B.l). This results in increasing
concentrations of hemin reducing the sensitivity of bilirubin measurement when
measured in the aqueous phase (figure B.2).
Chloroform extraction ameliorates the reduction in sensitivity seen with increasing
hemin concentration. Bilirubin has a low solubility in phosphate buffer at pH 7.4,
with a tendency to exist as a colloidal sol or form large flocculants and its true
solubility is reportedly less than 0.1 pM (Lee 1976). The solubility of bilirubin in
chloroform is much greater. It is reportedly up to 1 Omg/ml however, at this
concentration, it exists as a particulate suspension. Chloroform can extract bilirubin
from an aqueous solution to a maximum of 35pM. Whilst hemin is also soluble in
chloroform, the extraction from an aqueous phase is much less efficient than with
bilirubin. Hence chloroform extraction has the two-fold benefit of solubilising all
bilirubin within the reaction, and partially reducing the dampening effect seen with
the presence of hemin (figure B.2).
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Lower concentrations ofhemin will ensure more accurate measurement of bilirubin.
However, reducing the substrate concentration affects the efficiency of the enzymatic
reaction, resulting in a limitation of bilirubin (figure B.3). Furthermore, large
amounts of protein in the reaction inhibit the function of both heme oxygenase and
biliverdin reductase (Tenhunen 1972). This was seen with the use of greater than
lmg of protein.
The final method used was as follows: Tissue samples were prepared by
homogenisation in buffer (50mM Tris, 20mM NaCl, lOmM KC1, O.lmM DTT, ImM
EDTA, 1% SDS, pH 7.4), and cultured cells were prepared by collecting in
phosphate buffer (0.1M potassium phosphate, 2mM MgCl2,pH 7.4), followed by
three freeze-thaw cycles using liquid nitrogen. The coupled enzyme reaction method
was performed in a 400pl mixture containing: 500pg of sample protein; 50pM
hemin; 0.8mM NADPH; 2mM G6P; 0.2 units G6P dehydrogenase; and lmg of liver
cytosol (105,000g supernatant). Liver supernatant was prepared fresh, from liver that
had been snap frozen in liquid nitrogen, by homogenisation in 0.1M sodium citrate
buffer, pH5, containing 10% glycerol. Large volumes of liver cytosol were prepared
to minimise variation due to differences in biliverdin reductase activity within
preparations from different liver samples. The reaction was prepared in 0.1 M
potassium phosphate buffer with 2mM MgCf, pH 7.4, and a mastermix is used to
minimise pippetting error. Following a 1 hour incubation in the dark at 37°C, the
reaction is terminated with the addition of 400pl chloroform and the bilirubin
generated is measured in a spectrophotometer at A460-A530 (e = dOmlVF'cm"1). A
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control reaction containing all components except the test protein extract is used
the spectrophotometric blank. Results are expressed as pmoles bilirubin/mg
protein/hour. 50p,M hemin and 500pg of protein. The inter and the intra assay
coefficient of variation at the concentrations used are both 8%.
Figure B.l. The absorbance spectra of hemin and bilirubin overlap.
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A. Absorbance spectra of hemin in an aqueous solution pH7.4 and bilirubin in
chloroform. B. Absorbance spectra of 20pM hemin and lOpM bilirubin in 0.1M
phosphate buffer pH 7.4, concentrations commonly seen with the HO assay, showing















Figure B.2. Hemin reduces the sensitivity of bilirubin measurement.
An aqueous solution of lOpM bilirubin was prepared and increasing
concentrations of hemin added. There is a stepwise reduction in the
apparent bilirubin content with increasing hemin beyond 25pM.
Chloroform extraction was performed and the extracted bilirubin
measured, demonstrating that chloroform extraction lessens the
desensitising effect of hemin when present at greater than 50pM. Results





Figure B.3. Hemin concentration affects apparent HO activity. Protein prepared
from HUH7 hepatoma cells was used for assaying HO activity. 250 to lOOOpg of
protein was incubated in reactions with varying hemin concentrations. Low hemin
concentrations (25pM) reduced the apparent HO activity as measured by bilirubin
production. A linear relationship ofHO activity to protein content was seen when








Buffer B lx HBSS
0.5mM EGTA
Buffer C lx HBSS







1 Ox HBSS lOmls
Phosphate Buffer 2mls
pH 7.4




HBSS (10X) Gibco/Invitrogen Cat no 14185-045
MTT Assay
MTT solution 5mg/ml in PBS

















Protease inhibitors (Protease cocktail inhibitor tablets, Roche)
One tablet/ lOmls RIPA
Nuclear and Cytoplasmic Extracts








Protease inhibitors one tablet/lOmls
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40x TAE (for 1 litre)
lOx TBE (for 1 litre)
lx TBS (immunostaining)






pH 7.2 (with acetic acid)
Tris Base
Disodiumdihydrate EDTA







9.1mM dibasic sodium phosphate








lml 0.05% bromophenol blue







Running Buffer 0.025mM Tris
0.2M Glycine
0.0035M SDS
Transfer Buffer (for 5 litres) 15.15g Tris
72g Glycine
10% Polyacrylamide Gel (Western)
Water 4.05ml
1.5M TrisHCl, pH 8.8 2.5ml
10% SDS lOOgtl
Acrylamide/Bisacrylamide (30% stock, 29:1 ratio) 3.3ml




0.5M TrisHCl, pH 6.8 2.5ml
10% SDS lOOpl
Acrylamide/Bisacrylamide (30% stock, 29:1 ratio) 1.3ml
10% ammonium persulphate 1 OOpl
TEMED 20pl
12% Polyacrylamide Gel (GT Repeats)
Water 4.9ml
lOxTBE 1ml
Acrylamide/Bisacrylamide (30% stock, 29:1 ratio) 4ml
10% ammonium persulphate 100pi
TEMED lOpl
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Reverse Transcription Master Mix
Mg2+ 4pl





Heme Oxygenase Activity Assay Buffers
Buffer G lOOmM potassium phosphate
2mM MgCl2
pH 7.4




Phosphatase Activity Assay Buffers











Protease inhibitors 1 tablet/lOmls
pH 7.5
























Coating buffer 0.01M Phosphate Buffer
0.15M NaCl
pH 7.2




Chromogenic Substrate 4x 2mg OPD tablets
12mls H2O
5pi of 30% H202
0.01M Phosphate Buffer NaH2P04.H20 0.35g
Na2HP04.2H20 1.34g
In 1 litre of distilled water, pH 7.2
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Antibodies for ELISAs
All antibodies purchased from DAKO. All conjugated antibodies with a PE code
were custom made for the laboratory by DAKO and are not in the general catalog.
a1-antichymotrypsin Coating A0022
Detection (HRP conj) PE870
CRP Coating A0073,
Detection (HRP conj) P0227
Fibrinogen Coating A0245
Detection (HRP conj) P0246
Transferrin Coating A0061
Detection (HRP conj) PE563
Standard curve made with Human Serum Protein Calibrator (HSPC) X0908 for al-
antichymotrypsin, fibrinogen and transferrin. CRP standard curve made with human
serum CRP calibrator X0923.
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P450 Assay Buffers and Conditions
1M KP04 (forlOOmls) Potassium phosphate, dibasic, anhydrous 13.94g
Potassium phosphate, monobasic, anhydrous2.72g
pH7.4 with KOH or H3PO4
2x NADPH Generating System






4x Substrate Reaction Mixture
1A2 2C9 3A4
1M KPO4 30pl 0 0
Luciferin Substrate 8pi ME 8pl H 4pi BE
Water 62pi 92pi 96pl
Reaction Conditions
1A2 40 mins room temperature
2C9 60mins 37°C


















HO-1 (GT)„ polymorphism primers
F 5' - GAGCCTGCAGCTTCTCAGA - 3'
F 5' - TCTGGCCATAGGACTTT - 3'
Cytochrome B Primers
F 5' - GGTTCTGCAATAAGAATATAGG - 3'
R 5' - GACAACACAGTAAGAACCAGG - 3'
275
Gel Shift Oligonucleotide Sequences
HIF-la (Santa Cruz - sc2625 and 2626)
Consensus Binding Sequence
F 5' - TCTGTACGTGACCACACTCACCTC - 3'
R 5' - GAGGTGAGTGTGGTCACGTACAGA - 3'
Mutant Oligonucleotide
F 5' - TCTGTAAAAGACCACACTCACCTG - 3'
R 5' - GAGGTGAGTGTGGTCTTTTACAGA - 3'
Nrf2 (Santa Cruz -sc-2527 and 2528)
Consensus Binding Sequence
F 5' - TGGGGAACCTGTGCTGAGTCACTGGAG - 3'
R 5' - CTCCAGTGACTCAGCACAGGTTCCCCA - 3'
Mutant Oligonucleotide
F 5' - TGGGGAACCTGTGCTAGGTCACTGGAG - 3'
R 5' - CTCCAGTGACCTAGCACAGGTTCCCCA - 3'
HSF-1
Consensus Binding Sequence
F 5' - GATCTCGGCTGGAATATTCCCGACCTGGCAGCCGA -
R 5' - TCGGCTGCCAGGTCGGGAATATTCCAGCCGAGATC -
Mutant Oligonucleotide
F 5' - GATCTCGGCTTCAATATTGTCCACCTGGCAGCCGA -







































Actinomycin D (A9415) Sigma
Bilirubin (B4126) Sigma
Catalase (C9322) Sigma
CoC12 (232696) Aldrich (Sigma)
Collagenase (LS004196) Worthington
CCCP (21855) Fluka (Sigma)
Curcumin (CI386) Sigma
Cyclohexamide (CI988) Sigma
Cyclosporine A (CI832) Sigma
Dichloromethane (D7566) Sigma
Dihydroethidium (D7008) Sigma
DAB (diamino benzidine) Sigma
DPX mountant (44581) Fluka (Sigma)
ECL (RPN2108) Amersham Biosciences
Fugene Roche
GF109203X (B6292) Sigma
Glucose -6-Phsophate (G7879) Sigma
G6P dehydrogenase (G4134) Sigma
Glucose oxidase (G7141) Sigma





Mitotracker Red (M7513) Molecular Probes
Mitotracker Green (M7514) Molecular Probes
MTT (M2003) Sigma




NAD oxidised form Fluka (Sigma)
Penicillin G (P3032) Sigma
Phenazine Methosulphate (P9625) Sigma





Staurosporine (S 5921) Sigma
Sodium arsenite (35000) Sigma
streptavidin biotin-HRP complex DAKO




ZnPPIX (282820) Aldrich (Sigma)
Where not otherwise specified, all chemicals were purchased from Sigma and were
of cell culture or molecular biology grade.
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Kits
Annexin V-FITC Apoptosis Detection Kit (556570) BD Pharmingen
Apo-ONE Homogenous Caspase 3/7 Assay (G7790) Promega
ATP Assay Kit (119107) Calbiochem
P-Galactosidase Enzyme Assay System (E2000) Promega
BioRad DC Protein Assay Kit (500-0122) BioRad
DIG Gel Shift Kit (1 635 352) Roche
Luciferase Assay System (E4030) Promega
P450-Glo Assays (V8771, V8791, V8801) Promega
Serine/Threonine Phosphatase Assay System (V2460) Promega
Tyrosine Phosphatase Assay System (V2471) Promega
Urea Nitrogen Kit (no longer available) Sigma
Wizard Genomic DNA extraction Kit (A1125) Promega
siRNA Reagents HIFla (sc-35661) Santa Cruz
Nrf2 (sc-37030) Santa Cruz
Control sequence (sc-37007) Santa Cruz
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Molecular weight markers
Low Molecular Weight Markers Amersham
High Molecular Weight Markers Amersham
Non-denatured Protein Molecular Weight Marker Kit (MW-ND-500) Sigma
Media and Plastics
Cell Culture Plates Corning
William's E medium (22551) Gibco
DMEM (41966) Gibco
University ofWisconsin Solution - Belzer UW solution
Dupont Pharmaceuticals
Fetal Calf Serum Gibco
DNA/RNA Reagents and Enzymes
RNAse free water (P1193) Promega
RQ1 DNAse (M6101) Promega
AMV reverse transcriptase (M5101) Promega
Taq polymerase (Ml665) Promega
dNTPs(U1420) Promega
25bp, PCR markers, lkb markers Promega
1 Obp DNA Ladder (10821-015) Invitrogen
Taqman universal PCR mastermix (4304437) Applied Biosystems
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Suppliers and Stockists
Amersham and Pharmacia products ordered from Amersham:
Amersham pic, Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK.
Applied Biosystems, Division Headquarters, 850 Lincoln Centre Drive, Foster City,
CA 94404, USA.
BD Biosciences (BD Pharmingen): BD, 21 Between Towns Road, Cowley, Oxford,
0X4 3LY, UK
Cell Signaling Technology, Inc., 3 Trask Lane, Danvers, MA 01923, USA.
Corning Ltd., Quantum House, Marylands Avenue, Hemel Hempstead HP2 7DE,
United Kingdom.
Dako UK Ltd., Denmark House, Angel Drove, Ely, Cambridgeshire CB7 4ET, UK.
Dupont Pharmaceuticals Ltd, Hertfordshire, UK
Invitrogen, Gibco and Molecular Probes products all ordered from Invitrogen:
Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley, UK, PA4 9RF
Promega UK, Delta House, Chilworth Science Park, Southampton, SO 16 7NS, UK.
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Roche Diagnostics Ltd, Bell Lane, Lewes, East Sussex BN7 1LG, UK.
Santa Cruz products ordered through Insight Biotechnology:
Insight Biotechnology Ltd, PO Box 520, Wembley, Middlesex, HA9 7YN, UK.
Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham, Dorset,
SP8 4XT.
Stressgen Products ordered through Bioquote:
Bioquote Limited, TheRaylor Centre, James Street, York, North Yorkshire, YO10
3DW, UK.







ANP Atrial Natriuretic Peptide
CO Carbon Monoxide
CoCl2 Cobalt Chloride
CRP C Reactive Protein
CsA Cyclosporin A
DAB Diaminobenzidine
DCM Dichloromethane (Methylene Chloride)
DMSO Dimethylsulfoxide
Grp Glucose Regulated Protein
HO-1 Heme Oxygenase-1
HIF-la Hypoxia Inducible Factor-la
HRE Hypoxia Response Element
HSBP1 HSF-1 Binding Protein 1
HSE Heat Shock Element
HSF-1 Heat Shock Factor-1
Hsp Heat Shock Protein
IL6 Interleukin-6
iNOS Inducible Nitric Oxide Synthase
IP Ischaemic Preconditioning
IRI Ischaemia Reperfusion Injury
MAPK Mitogen Activated Protein Kinase
MTT Methyltetrazolium
NAC N-Acetylcysteine
NFkB Nuclear Factor kB
NO Nitric Oxide
Nrf2 NF-E2 Related Factor 2
p38 p38 MAPK
PCR Polymerase Chain Reaction
PKC Protein Kinase C
PP2A Protein Phosphatase 2A
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PP2C Protein Phosphatase 2C
ROS Reactive Oxygen Species
SA Sodium Arsenite
siRNA Small Interfering RNA
StRE Stress Response Element
TNFa Tumour Necrosis Factor a
UVC Ultraviolet C
UW University ofWisconsin Solution







Presentations and Published Papers
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Publications
The following publications have arisen from this work.
Curcumin Induces Heme Oxygenase 1 through Generation of Reactive Oxygen
Species, p38 Activation and Phosphatase Inhibition.
McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ.
International Journal of Molecular Medicine 19 (1): 165-72, January 2007.
Curcumin Induces Heme Oxygenase-1 in Hepatocytes and is Protective in Simulated
Cold Preservation and Warm Reperfusion Injury.
McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ.
Transplantation. 81 (4): 623-6, February 2006.
Ethical Considerations in the Application ofPreconditioning to Solid Organ
Transplantation.
McNally SJ, Harrison EM, Wigmore SJ.
Journal ofMedical Ethics, 31 (11): 631-4, November 2005.
Optimisation of the Paired Enzyme Assay for Heme Oxygenase Activity.
McNally SJ, Ross JA, Garden OJ, Wigmore SJ.
Analytical Biochemistry, 332(2):398-400, September 2004
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Presentations
Presentations arising from this work have been presented to the following learned
societies.
Heme Oxygenase-1 Preconditioning Agents Differentially Modulate Hepatocyte
Function. Oral Presentation at the Association of Surgeons in Training Conference,
Edinburgh, March 2006.
Curcumin Induces Heme Oxygenase 1 in Hepatocytes via Nrf2, and is
Cytoprotective in In Vitro Models of Reperfusion and Cold Storage Injury.
Oral presentation at the Quincentenary Congress, Royal College of Surgeons of
Edinburgh, Edinburgh 2005.
Curcumin Protects Hepatocytes via Heme Oxygenase 1 From Simulated Warm
Reperfusion Injury and Following Cold Storage. Poster Presentation at the Society
of Academic and Research Surgery (SARS), Newcastle, January 2005.
British Journal of Surgery 92(10): 1320, October 2005 (abstract)
Curcumin Preconditions Hepatocytes In Models ofWarm Reperfusion Injury And
Cold Storage. Oral presentation at the Scottish Society for Experimental Medicine
(SSEM), Edinburgh, November 2004.
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Determination of the Mechanism of Stress Protein Preconditioning by Calcineurin
Inhibitors. Oral presentation at the Scottish Hospital Endowments Research Trust
Open Day, Royal Society of Edinburgh, Edinburgh, June 2004.
Curcumin Induces an Atypical Stress Response in Hepatoma Cells.
Poster presentation at the Biochemistry Society Focused Meeting, London March
2004.
Curcumin modifies Heat Shock Transcription Factor-1 and induces Heme Oxygenase
1 but not inducible hsp70 in human hepatocytes Poster presentation at the British
Transplantation Society Annual Congress, London, April 2003
Curcumin and the Stress Response in Human Hepatocytes.
Oral presentation at the Chiene Medal Surgical Research Meeting November 2002
Curcumin Modifies Heat Shock Factor 1 and Induces Heme Oxygenase 1 but not
Hsp70 in Human Hepatocytes. Oral presentation at the Scottish Society for
Experimental Medicine (SSEM), Edinburgh, October 2002.
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